<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------
SCHEDULE 13D
(RULE 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1 AND
AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)
(AMENDMENT NO. ___________)
ONCORMED, INC.
- --------------------------------------------------------------------------------
(NAME OF THE ISSUER)
COMMON STOCK
- --------------------------------------------------------------------------------
(TITLE OF CLASS OF SECURITIES)
68231 D 109
- --------------------------------------------------------------------------------
(CUSIP NUMBER)
DR. TIMOTHY TRICHE
205 PERRY PARKWAY
GAITHERSBURG, MARYLAND 20877
(301) 208-1888
- --------------------------------------------------------------------------------
(NAME, ADDRESS AND TELEPHONE NUMBER OF PERSON
AUTHORIZED TO RECEIVE NOTICES AND COMMUNICATIONS)
JULY 6, 1998
- --------------------------------------------------------------------------------
(DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)
If the filing person has previously filed a statement on
Schedule 13G to report the acquisition which is the subject of this Schedule
13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check
the following box / /.
NOTE: Schedules filed in paper format shall include a signed
original and five copies of the schedule, including all exhibits. SEE Rule
13d-1(a) for other parties to whom copies are to be sent.
The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect to the subject
class of securities, and for any subsequent amendment containing information
which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page
shall not be deemed to be "filed" for the purpose of Section 18 of the
Securities Exchange Act of 1934 ("Act") or otherwise subject to the
liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, SEE the NOTES).
(Continued on following pages)
(Page 1 of 16 Pages)
<PAGE>
CUSIP NO. 368689 10 5 13D Page 2 of 16 Pages
- --------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
GENE LOGIC INC.
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) / /
(b) / /
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS
N/A
- --------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS
2(d) OR 2(e) / /
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
- --------------------------------------------------------------------------------
NUMBER 7 SOLE VOTING POWER
OF -0-
SHARES
BENEFICIALLY
OWNED BY
REPORTING
PERSON
WITH
--------------------------------------------------------------
8 SHARED VOTING POWER
5,695,968 (1)
--------------------------------------------------------------
9 SOLE DISPOSITIVE POWER
-0-
--------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
-0-
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
5,695,968 (1)
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES CERTAIN SHARES
/ /
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
53.8% (1)(2)
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON CO
- --------------------------------------------------------------------------------
(1) Calculated pursuant to Rule 13d-3 of the Securities Exchange Act of 1934,
as amended.
(2) Percent based upon (i) 7,887,300 shares of Common Stock issued and
outstanding as of July 6, 1998, (ii) the conversion of 333 shares of Series
A Preferred Stock into 1,574,915 shares of Common Stock, (iii) the
conversion of a promissory note into 35,787 shares of Common Stock, (iv)
the exercise of warrants to purchase 166,666 shares of Common Stock and (v)
the exercise of options to purchase 922,833 shares of Common Stock, all on
an fully-diluted basis.
(Page 2 of 16 Pages)
<PAGE>
ITEM 1. SECURITY AND ISSUER
(a) TITLE OF SECURITY:
Common Stock, $.01 par value per share (the "Common Stock").
Series A Preferred Stock, $.01 par value per share (the "Preferred
Stock").
(b) NAME OF THE ISSUER:
Oncormed, Inc., a Delaware corporation.
(c) THE ISSUER'S PRINCIPAL EXECUTIVE OFFICE:
205 Perry Parkway
Gaithersburg, MD 20877
ITEM 2. IDENTITY AND BACKGROUND
(a) This statement is filed by Gene Logic Inc., a Delaware
corporation ("Gene Logic"). Gene Logic is principally in the business
of developing genomics technologies, bioinformatics systems and
database products used to identify the expression of genes, drug
targets and drug leads.
(b) The address of the principal business offices of Gene Logic
is 708 Quince Orchard Road, Gaithersburg, Maryland 20878.
(c) Set forth in Schedule I to this Schedule 13D is the name and
present principal occupation or employment of each of Gene Logic's
executive officers and directors and the name, principal business and
address of any corporation or other organization in which employment
is conducted.
(d) During the last five years, there have been no criminal
proceedings against Gene Logic, or, to the best knowledge of Gene
Logic, any of the other persons with respect to whom information is
given in response to this Item 2.
(e) During the last five years, neither Gene Logic nor, to the
best knowledge of Gene Logic, any of the other persons with respect to
whom information is given in response to this Item 2, has been a party
to any civil proceeding of a judicial or administrative body of
competent jurisdiction resulting in a judgment, decree or final order
enjoining future violations of, or prohibiting or mandating activities
subject to, federal or state securities laws or finding any violation
with respect to such laws.
(f) Michael J. Brennan, M.D., Ph.D. is a permanent resident of
the United States. To the best knowledge of Gene Logic, all other
directors and
(Page 3 of 16 Pages)
<PAGE>
executive officers of Gene Logic named in Schedule I to
this Schedule 13D are citizens of the United States.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
To facilitate the Merger (as defined in Item 4 below), certain
stockholders of the Issuer have agreed to vote shares of Issuer's
capital stock in favor of the Merger and have entered into voting
agreements with Gene Logic to that effect as more fully described
in Item 4. Such voting agreements do not contemplate a purchase of
the Common Stock or Preferred Stock of the Issuer by Gene Logic.
ITEM 4. PURPOSE OF THE TRANSACTION
(a) - (b) Pursuant to that certain Agreement and Plan of Merger
and Reorganization dated as of July 6, 1998 (the "Merger Agreement"),
among Gene Logic, Gene Logic Acquisition Corp., a Delaware corporation
and wholly-owned subsidiary of Gene Logic ("Merger Sub"), and the
Issuer and subject to the conditions set forth therein (including the
approval of the respective stockholders of the Issuer and Gene Logic),
Issuer will be merged with and into Merger Sub (the "Merger") and
Issuer will cease to exist. Merger Sub will remain a wholly owned
subsidiary of Gene Logic. The holders of the outstanding shares of
Preferred Stock of Issuer have agreed to convert such shares of
Preferred Stock into Common Stock of Issuer prior to the consummation
of the Merger. All of the shares of Common Stock (including the
shares of Common Stock issuable upon conversion of the Preferred
Stock) of Issuer outstanding immediately prior to the effective time
of the Merger will be converted into a number of fully paid and
non-assessable shares of Common Stock of Gene Logic (the "Merger
Shares") such that immediately following the Merger, the former
holders of Issuer Common Stock and Preferred Stock will, in the
aggregate, own approximately 24.8% of the outstanding Common Stock
of Gene Logic. Gene Logic will assume outstanding warrants to
purchase Issuer Common Stock on the terms set forth in Section 1.9
of the Merger Agreement.
The foregoing summary of the Merger is qualified in its entirety
by reference to the copy of the Merger Agreement included as
Exhibit 99.1 to this Schedule 13D and incorporated herein in its
entirety by reference.
Each of the directors and executive officers of the Issuer which
include Dr. Timothy J. Triche, Dr. Douglas Dolginow, L. Robert
Johnston, Jr., John Pappajohn, Dr. Leslie Alexandre, John W. Colloton,
Stephen Turner and Dr. Wayne Patterson (the "Affiliates") has entered
into a Voting Agreement dated as of July 6, 1998
(Page 4 of 16 Pages)
<PAGE>
in the form included as Exhibit 99.2 to this Schedule 13D (the
"Executive's Voting Agreement"). Oncor, Inc. ("Oncor") has entered
into that certain Voting Agreement dated as of July 6, 1998
included as Exhibit 99.3 to this Schedule 13D (the "Oncor Voting
Agreement"). Incyte Pharmaceuticals, Inc. ("Incyte") has entered
into that certain Voting Agreement dated as of July 6, 1998
included as Exhibit 99.4 to this Schedule 13D (the "Incyte Voting
Agreement"). Each of Southbrook International Investments, Ltd.,
Westover Investments L.P., Montrose Investments, Ltd., Brown
Simpson Strategic Growth Fund, L.P., Brown Simpson Strategic Growth
Fund, Ltd. and Incyte (collectively, the "Preferred Holders") have
entered into that certain letter agreement dated as of July 6, 1998
containing provisions as to the voting of securities of Issuer held
by such entities included as Exhibit 99.5 to this Schedule 13D (the
"Preferred Holder Voting Agreement"). Individually, each of the
Affiliates, Oncor, Incyte and each of the Preferred Holders are
referred to herein as a "Voting Agreement Stockholder" and
collectively as the "Voting Agreement Stockholders." Individually,
the Executive's Voting Agreement, the Oncor Voting Agreement, the
Incyte Voting Agreement and the Preferred Holder Voting Agreement
are referred to herein as a "Voting Agreement" and collectively as
the "Voting Agreements."
The number of shares of Common Stock and Preferred Stock of the
Issuer beneficially owned by each of the Voting Agreement Stockholders
is set forth on Schedule II to this Schedule 13D. Pursuant to the
Voting Agreements, the Voting Agreement Stockholders have agreed to
vote or direct the vote of all shares of Common Stock and Preferred
Stock of the Issuer over which such person has voting power or control
(the "Subject Shares") as follows: (i) in favor of the issuance of
shares of Gene Logic Common Stock to the Issuer stockholders in the
Merger, the Merger, the execution, delivery and performance by the
Issuer of the Merger Agreement and the adoption and approval of the
terms thereof and in favor of each of the other actions contemplated
by the Merger Agreement and any action required in furtherance
thereof; (ii) against any action or agreement that would result in a
breach of any representation, warranty, covenant or obligation of the
Issuer in the Merger Agreement; and (ii) against the following actions
(other than the Merger and the transactions contemplated by the Merger
Agreement): (A) any extraordinary corporate transaction, such as a
merger, consolidation or other business combination involving the
Issuer; (B) any sale, lease or transfer of substantially all of the
assets of the Issuer; (C) any reorganization, recapitalization,
dissolution or liquidation of the Issuer; (D) any change in a majority
of the board of directors of the Issuer; (E) any amendment to the
Issuer's Certificate of Incorporation or Bylaws; (F) any material
change in the capitalization of the Issuer or the Issuer's corporate
structure; or (G) any other action which is intended to, or would,
impede, interfere with, delay, postpone, discourage or adversely
affect the Merger or any of the other transactions contemplated by the
Merger Agreement or the Voting Agreement.
In addition, pursuant to Section 3.3 of the Voting Agreements
(excluding the Preferred Holder Voting Agreements), in the event of
termination of the Merger Agreement upon the occurrence of certain
specified events, for a period of 180 days following the date on which
the Merger Agreement is terminated, the Voting Agreement Stockholders
(other than the Preferred Holders as to the shares of Preferred Stock
covered by the Preferred Holder Voting Agreements) have agreed to vote
the Subject Shares (i) against any acquisition proposals other than
(Page 5 of 16 Pages)
<PAGE>
the Merger and any related transaction or agreement, and (ii) against
any action which is intended, or could reasonably be expected, to
facilitate the consummation of any acquisition transaction other than
the Merger.
Pursuant to the Voting Agreements, the Voting Agreement
Stockholders (other than the Preferred Holders as to the shares of
Preferred Stock covered by the Preferred Holder Voting Agreements)
have also agreed not to, directly or indirectly, (i) offer, sell,
offer to sell, contract to sell, pledge, grant any option to purchase
or otherwise dispose of or transfer (or announce any offer, sale,
offer of sale, contract of sale or grant of any option to purchase or
other disposition or transfer of) any of the Subject Shares to any
person other than Gene Logic or Gene Logic's designee; (ii) create or
permit to exist any encumbrance with respect to any of the Subject
Shares; (iii) reduce such Voting Agreement Stockholder's beneficial
ownership of, interest in or risk relating to any of the Subject
Shares; (iv) commit or agree to do any of the foregoing; or (v)
deposit any of the Subject Shares into a voting trust or grant a proxy
(except as provided in the Voting Agreements) or enter into a voting
agreement with respect to any of the Subject Shares.
Pursuant to the Voting Agreements, the Voting Agreement
Stockholders also executed and delivered to Gene Logic irrevocable
proxies to vote the Subject Shares in favor of the Merger Agreement
and Merger and each of the other actions contemplated by the Merger
Agreement and against any action or agreement that would result in a
breach of any representation, warranty, covenant or obligation of the
Issuer in the Merger Agreement.
The foregoing summary of the Voting Agreements is qualified in
its entirety by reference to the form of the Executive's Voting
Agreement, the Oncor Voting Agreement, the Incyte Voting Agreement and
the Preferred Holder Voting Agreement included as Exhibits 99.2, 99.3,
99.4 and 99.5, respectively and incorporated herein in their entirety
by reference.
(c) Not applicable.
(d) As a result of the Merger, the Issuer will cease to exist
and each member of the board of directors of Issuer will resign. In
addition, the executive officers of Issuer will be terminated,
provided, however, that certain executive officers of Issuer may serve
as employees of Gene Logic.
(e) As a result of the Merger, all of the shares of Common Stock
(including the shares of Common Stock issuable upon conversion of the
Preferred Stock) of Issuer outstanding immediately prior to the
effective time of the Merger will be converted into a number of fully
paid and non-assessable shares of Common Stock of Gene Logic such that
immediately following the Merger, the former holders of Issuer Common
Stock and Preferred Stock will, in the aggregate, own approximately
24.8% of the outstanding Common Stock of Gene
(Page 6 of 16 Pages)
<PAGE>
Logic. Gene Logic will also assume outstanding warrants to purchase
Issuer Common Stock on the terms set forth in Section 1.9 of the
Merger Agreement.
(f) - (g) Upon consummation of the Merger, Issuer will merge
with and into Merger Sub and Issuer will cease to exist.
(h) Upon consummation of the Merger, Issuer Common Stock, which
is currently traded on the American Stock Exchange ("AMEX") under the
symbol "ONM," will cease to be traded on AMEX.
(i) Not applicable.
(j) Other than as described above, Gene Logic has no plan or
proposal which relates to, or may result in, any of the matters listed
in Items 4(a) - (i) of this Schedule 13D (although Gene Logic reserves
the right to develop such plans).
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER
(a) - (b) As a result of the Voting Agreements, Gene Logic has
shared power to vote an aggregate of 5,695,968 shares of Common Stock
(which includes 1,574,915 shares of Common Stock issuable upon
conversion of the Preferred Stock, 35,787 shares of Common Stock
issuable upon conversion of a promissory note, the exercise of
warrants to purchase 166,666 shares of Common Stock, and the exercise
of options to purchase 922,833 shares of Common Stock) of the Issuer
for the limited purposes described in Item 4 above. Such shares
constitute approximately 53.8% of the issued and outstanding shares of
capital stock of the Issuer as of July 6, 1998. Under the Voting
Agreements, as of July 6, 1998, Gene Logic has shared voting power
with respect to approximately 48.3% of the total shares of Common
Stock of Issuer outstanding on such date (after giving effect to the
conversion of all outstanding shares of Preferred Stock of Issuer into
Common Stock of Issuer).
To Gene Logic's knowledge, no shares of Common Stock or Preferred
Stock of the Issuer are beneficially owned by any of the persons named
in Schedule I, except for such beneficial ownership, if any, arising
solely from the Voting Agreements.
Set forth in Schedule III to this Schedule 13D is the name of and
certain information regarding each person or entity with whom Gene
Logic shares the power to vote or to direct the vote of Common Stock
and Preferred Stock of the Issuer.
During the past five years, to the best knowledge of Gene Logic,
no person named in Schedule III to this Schedule 13D, has been
convicted in a criminal proceeding.
(Page 7 of 16 Pages)
<PAGE>
During the past five years, to the best knowledge of Gene Logic,
no person named in Schedule III to this Schedule 13D was a party to a
civil proceeding of a judicial or administrative body of competent
jurisdiction as a result of which such person was or is subject to a
judgment, decree or final order enjoining future violations of or
prohibiting or mandating activity subject to federal or state
securities laws or finding any violation with respect to such laws.
To the best knowledge of Gene Logic, all persons named in
Schedule III to this Schedule 13D are citizens of the United States.
(c) Neither Gene Logic nor, to Gene Logic's knowledge, any
person named in Schedule I, has effected any transaction in Common
Stock or Preferred Stock of the Issuer during the past 60 days, except
as disclosed herein.
(d) Not applicable.
(e) Not applicable.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT
TO SECURITIES OF THE ISSUER.
In connection with the Merger Agreement, the Affiliates
entered into an Affiliate Agreement with the Issuer, dated as of
July 6, 1998. Pursuant to Section 2(d) thereof, each Affiliate has
agreed that such Affiliate shall not dispose of the shares of the
Issuer's Common Stock received by such Affiliate as a result of the
Merger unless at the time of such transfer either (i) such transfer
shall be in conformity with the provisions of Rule 145(d) under the
Securities Act of 1933, as amended (the "Act") (or any successor
rule then in effect), (ii) such Affiliate shall have furnished to
Gene Logic an opinion of counsel reasonably satisfactory to Gene
Logic, or a no action letter from the Securities and Exchange
Commission, to the effect that no registration under the Act would
be required in connection with the proposed offer, sale, pledge,
transfer or other disposition or (iii) a registration statement
under the Act covering the proposed offer, sale, pledge, transfer
or other disposition shall be effective under the Act.
Other than as described in the foregoing paragraph and in Item 4
above, to the best knowledge of Gene Logic there are no contracts,
arrangements, understandings or relationships (legal or otherwise)
among the persons named in Item 2 and between such persons and any
person with respect to any securities of the Issuer, including but not
limited to transfer or voting of any securities, finder's fees, joint
ventures, loan or option arrangements, puts or calls, guarantees of
profits, division of profits or loss, or the giving or withholding of
proxies.
(Page 8 of 16 Pages)
<PAGE>
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS
99.1 Agreement and Plan of Merger and Reorganization dated as of
July 6, 1998, by and among Gene Logic Inc., Gene Logic
Acquisition Corp. and Oncormed, Inc.
99.2 Form of Voting Agreement dated as of July 6, 1998 entered into
by and between Gene Logic Inc., and each of the Affiliates.
99.3 Voting Agreement dated as of July 6, 1998 by and between Gene
Logic Inc. and Oncor, Inc.
99.4 Voting Agreement dated as of July 6, 1998 by and between Gene
Logic Inc. and Inctye Pharmaceuticals, Inc.
99.5 Voting Agreement dated as of July 6, 1998 by and between Gene
Logic Inc. and each of Southbrook International Investments,
Ltd., Westover Investments L.P., Montrose Investments, Ltd.,
Brown Simpson Strategic Growth Fund, L.P., Brown Simpson
Strategic Growth Fund, Ltd. and Incyte Pharmaceuticals, Inc.
(Page 9 of 16 Pages)
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
July 10, 1998
------------------------------------
(Date)
GENE LOGIC INC.,
a Delaware corporation
By: /s/ MICHAEL J. BRENNAN
-------------------------------
Michael J. Brennan, M.D., Ph.D.
President and Chief Executive
Officer
(Page 10 of 16 Pages)
<PAGE>
SCHEDULE I
EXECUTIVE OFFICERS AND DIRECTORS OF GENE LOGIC INC.
Michael J. Brennan, M.D., Ph.D. is the President, Chief Executive Officer and
Director of Gene Logic.
Mark D. Gessler is the Senior Vice President, Corporate Development and Chief
Financial Officer of Gene Logic.
Daniel R. Passeri, J.D. is the Senior Vice President, Technology and Program
Management of Gene Logic.
Gregory G. Lennon, Ph.D. is the Senior Vice President, Research and
Development and Chief Scientific Officer of Gene Logic.
Alan G. Walton, Ph.D., D.Sc. is the Chairman of the Board of Directors of
Gene Logic. Dr. Walton is also a General Partner of Oxford Bioscience
Partners with its principal place of business at 315 Post Road West,
Westpart, Connecticut 06880, and a member of the Board of Directors of
Collaborative Clinical Research.
Jules Blake, Ph.D. is a Director of Gene Logic and a member of Board of
Directors of Martek Biosciences Corporation and ProCyte Corporation.
Charles L. Dimmler, III is a Director of Gene Logic. Mr. Dimmler is also a
General Partner of Hambro International Equity Partners with its principal
place of business at 650 Madison Avenue, 21st Floor, New York, New York
10022, a principal investment officer of Cross Atlantic Partners Funds, an
operating officer of Hambro Health International, Inc. and a member of the
Board of Directors of SunPharm, Inc.
G. Anthony Gorry, Ph.D. is a Director of Gene Logic, Vice President for
Information Technology and Professor of Computer Science at Rice University
and Chairman of the Board of Directors of The Forefront Group, Inc.
Jeffrey D. Sollender is a Director of Gene Logic, Chairman and Chief
Executive Officer of AriZeke Pharmaceuticals and a general partner of Forward
Ventures.
All individuals described in this Schedule I are employed at, or retained as
directors by, Gene Logic Inc., 708 Quince Orchard Road, Gaithersburg,
Maryland 20878.
(Page 11 of 16 Pages)
<PAGE>
SCHEDULE II
<TABLE>
<CAPTION>
NUMBER
NUMBER NUMBER OF SHARES PERCENT OF
OF SHARES OF SHARES OF ISSUER OUTSTANDING
OF ISSUER OF ISSUER COMMON STOCK SHARES
COMMON STOCK PREFERRED STOCK ISSUABLE UPON OF ISSUER
BENEFICIALLY BENEFICIALLY CONVERSION OF COMMON
VOTING AGREEMENT STOCKHOLDER OWNED OWNED PREFERRED STOCK STOCK 1
- ---------------------------- ------------ -------------- --------------- -----------
<S> <C> <C> <C> <C>
Dr. Timothy J. Triche 236,100(2) 0 -- 2.4%
Dr. Douglas Dolginow 243,750(3) 0 -- 2.5%
L. Robert Johnston, Jr. 75,135(4) 0 -- *
John Pappajohn 292,167(5) 0 -- 3.0%
Dr. Leslie Alexandre 61,825(6) 0 -- *
John W. Colloton 10,000 0 -- *
Stephen Turner 174,000(7) 0 -- 1.8%
Dr. Wayne Patterson 45,833(8) 0 -- *
Oncor, Inc. 2,035,787(9) 0 -- 21.4%
Incyte Pharmaceuticals, Inc. 796,456(10) 33 156,073 10.0%
Southbrook International
Investments, Ltd. 62,500(11) 125 591,184 6.9%
Westover Investments L.P. 21,875(12) 44 208,097 2.4%
Montrose Investments, Ltd. 40,625(13) 81 383,087 4.5%
Brown Simpson Strategic Growth
Fund, L.P. 6,000(14) 12 56,754 *
Brown Simpson Strategic Growth
Fund, Ltd. 19,000(15) 38 179,720 2.1%
------------ ---- --------- -----
4,121,053 333 1,574,915 53.8%
</TABLE>
- -------------
* Less than one percent.
1 Calculated in accordance with Rule 13(d)-1 and based upon (i) 7,887,300
shares of Common Stock issued and outstanding as of July 6, 1998, and (ii)
the conversion of 333 shares of Series A Preferred Stock into 1,574,915
shares of Common Stock. Under the Voting Agreements, as of July 6, 1998,
Gene Logic has shared voting power with respect to approximately 48.3% of
the total shares of Common Stock of Issuer outstanding on such date (after
giving effect to the conversion of all outstanding shares of Preferred
Stock of Issuer into Common Stock of Issuer).
2 Includes 225,000 shares of Common Stock issuable pursuant to options
exercisable within 60 days of July 6, 1998.
3 Includes 243,000 shares of Common Stock issuable pursuant to options
exercisable within 60 days of July 6, 1998.
4 Includes 75,000 shares of Common Stock issuable pursuant to options
exercisable within 60 days of July 6, 1998.
(Page 12 of 16 pages)
<PAGE>
5 Includes (i) 100,000 shares of Common Stock issuable pursuant to options
exercisable within 60 days of July 6, 1998 and (ii) 50,000 shares of Issuer
Common Stock owned by Halkis Ltd., as to which Mr. Pappajohn has sole
voting and investment power.
6 Includes 60,000 shares of Common Stock issuable pursuant to options
exercisable within 60 days of July 6, 1998.
7 Includes 174,000 shares of Common Stock issuable pursuant to options
exercisable within 60 days of July 6, 1998.
8 Includes 45,833 shares of Common Stock issuable pursuant to options
exercisable within 60 days of July 6, 1998.
9 Includes 35,787 shares of Common Stock issuable pursuant to a convertible
promissory note convertible within 60 days of July 6, 1998.
10 Includes 16,666 shares of Common Stock issuable pursuant to a warrant
exercisable within 60 days of July 6, 1998. In addition, Issuer has issued
to Incyte a warrant to purchase up to an aggregate of ten percent (10%) of
Issuer's Common Stock issued and outstanding on the date of such warrant's
exercise.
11 Includes 62,500 shares of Common Stock issuable pursuant to a warrant
exercisable within 60 days of July 6, 1998.
12 Includes 21,875 shares of Common Stock issuable pursuant to a warrant
exercisable within 60 days of July 6, 1998.
13 Includes 40,625 shares of Common Stock issuable pursuant to a warrant
exercisable within 60 days of July 6, 1998.
14 Includes 6,000 shares of Common Stock issuable pursuant to a warrant
exercisable within 60 days of July 6, 1998.
15 Includes 19,000 shares of Common Stock issuable pursuant to a warrant
exercisable within 60 days of July 6, 1998.
(Page 13 of 16 pages)
<PAGE>
SCHEDULE III
Dr. Timothy J. Triche is the Chief Executive Officer and Chairman of the
Board of Directors of the Issuer and a member of the Board of Directors of
Oncor, Inc.
Dr. Douglas Dolginow is the President, Chief Operating Officer, and a
Director of the Issuer.
L. Robert Johnston, Jr. is the Chief Financial Officer, Secretary, Treasurer
and Senior Vice President of the Issuer.
John Pappajohn, a Director of the Issuer, is the sole owner of Pappajohn
Capital Resources, a venture capital firm, and President of Equity Dynamics,
Inc., a financial consulting firm with a business address of 2116 Financial
Center, Des Moines, Iowa 50309.
Dr. Leslie Alexandre is the Vice President, Corporate Affairs of Issuer.
John W. Colloton, a Director of the Issuer, is the Vice President for
Statewide Health Services for the University of Iowa.
Stephen Turner, a Director of the Issuer, is a Director of Oncor, Inc., and
the Chief Executive Officer and Chairman of the Board of Directors of Codon
Pharmaceuticals, Inc., a Delaware corporation with a business address of 200
Perry Parkway, Gaithersburg, Maryland 20877.
Dr. Wayne Patterson, a Director of the Issuer, is the President of Green
Mountain Associates, Inc., a consulting firm.
Oncor, Inc. is a Maryland corporation with its principal place of business
and principal offices at 209 Perry Parkway, Gaithersburg, Maryland 20877.
The principal business of Oncor, Inc. is the development, production and
marketing of cancer-oriented genetic probes, related reagents, molecular
biology products, and diagnostic products.
Incyte Pharmaceuticals, Inc. is a Delaware corporation with its principal
place of business and principal offices at 3174 Porter Drive, Palo Alto,
California 94304. The principal business of Incyte Pharmaceuticals, Inc. is
providing genomic information and services to the biotechnology,
pharmaceutical and agricultural industries, and the design, development and
marketing of genomic database products, genomic data management software
tools and related reagents and services.
Southbrook International Investments, Ltd. is a private equity investment
firm located at 630 Fifth Avenue, Suite 2000, New York, NY 10111.
Westover Investments L.P. is a private equity investment firm located at 777
Main Street, Suite 2750, Fort Worth, Texas 76102.
Montrose Investments, Ltd. is a private equity investment firm located at
777 Main Street, Suite 2750, Fort Worth, Texas 76102
(Page 14 of 16 pages)
<PAGE>
Brown Simpson Strategic Growth Fund, L.P. is a private equity investment firm
located at 152 West 57th Street, 40th Floor, New York, NY 10019.
Brown Simpson Strategic Growth Fund, Ltd. is a private equity investment firm
located at 152 West 57th Street, 40th Floor, New York, NY 10019.
(Page 15 of 16 pages)
<PAGE>
EXHIBIT INDEX
<TABLE>
<CAPTION>
EXHIBIT DESCRIPTION OF DOCUMENT
- ------- -----------------------
<S> <C>
99.1 Agreement and Plan of Merger and Reorganization dated as of July 6,
1998, by and among Gene Logic Inc., Gene Logic Acquisition Corp. and
Oncormed, Inc.
99.2 Form of Voting Agreement dated as of July 6, 1998 by and between Gene
Logic Inc., and each of Dr. Timothy J. Triche, Dr. Douglas Dolginow,
L. Robert Johnston, Jr., John Pappajohn, Dr. Leslie Alexandre, John W.
Colloton, Stephen Turner and Dr. Wayne Patterson.
99.3 Voting Agreement dated as of July 6, 1998 by and between Gene Logic
Inc. and Oncor, Inc.
99.4 Voting Agreement dated as of July 6, 1998 by and between Gene Logic
Inc. and Inctye Pharmaceuticals, Inc.
99.5 Voting Agreement dated as of July 6, 1998 by and between Gene Logic
Inc. and each of Southbrook International Investments, Ltd., Westover
Investments L.P., Montrose Investments, Ltd., Brown Simpson Strategic
Growth Fund, L.P., Brown Simpson Strategic Growth Fund, Ltd. and
Incyte Pharmaceuticals, Inc.
</TABLE>
(Page 16 of 16 pages)
<PAGE>
AGREEMENT
AND PLAN OF MERGER AND REORGANIZATION
AMONG
GENE LOGIC INC.,
GENE LOGIC ACQUISITION CORP.
AND
ONCORMED, INC.
----------------------
JULY 6, 1998
----------------------
<PAGE>
TABLE OF CONTENTS
<TABLE>
<CAPTION>
PAGE
<S> <C>
ARTICLE 1 DESCRIPTION OF TRANSACTION . . . . . . . . . . . . . . . . . . 1
1.1 Merger of the Company into Merger Sub . . . . . . . . . . . . . . . 1
1.2 Effect of the Merger. . . . . . . . . . . . . . . . . . . . . . . . 1
1.3 Closing; Effective Time . . . . . . . . . . . . . . . . . . . . . . 1
1.4 Certificate of Incorporation and Bylaws; Directors and Officers . . 2
1.5 Conversion of Shares. . . . . . . . . . . . . . . . . . . . . . . . 2
1.6 Closing of the Company's Transfer Books . . . . . . . . . . . . . . 3
1.7 Exchange of Company Stock Certificates. . . . . . . . . . . . . . . 4
1.8 Stock Options . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.9 Warrants. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.10 Stock Subject to Conditions . . . . . . . . . . . . . . . . . . . . 6
1.11 Tax Consequences. . . . . . . . . . . . . . . . . . . . . . . . . . 6
1.12 Accounting Consequences . . . . . . . . . . . . . . . . . . . . . . 6
1.13 Further Action. . . . . . . . . . . . . . . . . . . . . . . . . . . 6
ARTICLE 2 REPRESENTATIONS AND WARRANTIES OF THE COMPANY . . . . . . . . 6
2.1 Organization; Subsidiaries; Capitalization. . . . . . . . . . . . . 6
2.2 SEC Filings; Financial Statements . . . . . . . . . . . . . . . . . 8
2.3 Absence of Certain Changes or Events. . . . . . . . . . . . . . . . 9
2.4 Tax Matters . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
2.5 Proprietary Assets. . . . . . . . . . . . . . . . . . . . . . . . .10
2.6 Contracts . . . . . . . . . . . . . . . . . . . . . . . . . . . . .11
2.7 Employees; Benefit Plans. . . . . . . . . . . . . . . . . . . . . .13
2.8 Litigation. . . . . . . . . . . . . . . . . . . . . . . . . . . . .14
2.9 Properties. . . . . . . . . . . . . . . . . . . . . . . . . . . . .14
2.10 Environmental Matters . . . . . . . . . . . . . . . . . . . . . . .14
2.11 Compliance with Legal Requirements. . . . . . . . . . . . . . . . .15
2.12 Transactions with Affiliates. . . . . . . . . . . . . . . . . . . .15
2.13 Vote Required . . . . . . . . . . . . . . . . . . . . . . . . . . .15
2.14 Company Action. . . . . . . . . . . . . . . . . . . . . . . . . . .15
2.15 Fairness Opinion. . . . . . . . . . . . . . . . . . . . . . . . . .16
i
<PAGE>
TABLE OF CONTENTS
(CONTINUED)
PAGE
<S> <C>
2.16 Financial Advisor . . . . . . . . . . . . . . . . . . . . . . . . .16
2.17 Enforceability. . . . . . . . . . . . . . . . . . . . . . . . . . .16
2.18 Governmental Consents; No Conflicts . . . . . . . . . . . . . . . .16
2.19 Title to Assets . . . . . . . . . . . . . . . . . . . . . . . . . .17
2.20 Company Preferred Stock Conversion. . . . . . . . . . . . . . . . .17
2.21 No Existing Discussions . . . . . . . . . . . . . . . . . . . . . .17
2.22 Stock Options . . . . . . . . . . . . . . . . . . . . . . . . . . .17
2.23 Waiver. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .17
2.24 Disclosure. . . . . . . . . . . . . . . . . . . . . . . . . . . . .17
ARTICLE 3 REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB . . .18
3.1 Organization. . . . . . . . . . . . . . . . . . . . . . . . . . . .18
3.2 SEC Filings; Financial Statements . . . . . . . . . . . . . . . . .20
3.3 Absence of Certain Changes or Events. . . . . . . . . . . . . . . .20
3.4 Tax Matters . . . . . . . . . . . . . . . . . . . . . . . . . . . .21
3.5 Litigation. . . . . . . . . . . . . . . . . . . . . . . . . . . . .21
3.6 Compliance with Legal Requirements. . . . . . . . . . . . . . . . .22
3.7 Valid Issuance. . . . . . . . . . . . . . . . . . . . . . . . . . .22
3.8 Vote Required . . . . . . . . . . . . . . . . . . . . . . . . . . .22
3.9 Parent Action.. . . . . . . . . . . . . . . . . . . . . . . . . . .22
3.10 Fairness Opinion. . . . . . . . . . . . . . . . . . . . . . . . . .22
3.11 Financial Advisor . . . . . . . . . . . . . . . . . . . . . . . . .22
3.12 Enforceability. . . . . . . . . . . . . . . . . . . . . . . . . . .22
3.13 Governmental Consent; No Conflicts. . . . . . . . . . . . . . . . .23
3.14 Disclosure. . . . . . . . . . . . . . . . . . . . . . . . . . . . .23
3.15 Interim Operations of Merger Sub. . . . . . . . . . . . . . . . . .24
3.16 Parent Contracts. . . . . . . . . . . . . . . . . . . . . . . . . .24
ARTICLE 4 COVENANTS; ADDITIONAL AGREEMENTS. . . . . . . . . . . . . . .25
4.1 Parent Access and Investigation . . . . . . . . . . . . . . . . . .25
4.2 Company Access and Investigation. . . . . . . . . . . . . . . . . .25
ii
<PAGE>
TABLE OF CONTENTS
(CONTINUED)
PAGE
<S> <C>
4.3 Confidentiality.. . . . . . . . . . . . . . . . . . . . . . . . . .25
4.4 Conduct of the Company's Business . . . . . . . . . . . . . . . . .25
4.5 Conduct by Parent.. . . . . . . . . . . . . . . . . . . . . . . . .28
4.6 Notification. . . . . . . . . . . . . . . . . . . . . . . . . . . .28
4.7 No Shop . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .28
4.8 Registration Statement; Prospectus/Joint Proxy Statement. . . . . .29
4.9 Company Stockholders' Meeting . . . . . . . . . . . . . . . . . . .30
4.10 Parent Stockholders' Meeting. . . . . . . . . . . . . . . . . . . .31
4.11 Regulatory Approvals. . . . . . . . . . . . . . . . . . . . . . . .32
4.12 Additional Agreements . . . . . . . . . . . . . . . . . . . . . . .32
4.13 Disclosure. . . . . . . . . . . . . . . . . . . . . . . . . . . . .33
4.14 Letter of the Company's Accountants.. . . . . . . . . . . . . . . .33
4.15 Company Affiliate Agreements. . . . . . . . . . . . . . . . . . . .33
4.16 Tax Matters . . . . . . . . . . . . . . . . . . . . . . . . . . . .33
4.17 Employment or Consulting Agreement and Noncompetition Agreement . .33
4.18 Employee Benefits.. . . . . . . . . . . . . . . . . . . . . . . . .33
4.19 Indemnification.. . . . . . . . . . . . . . . . . . . . . . . . . .34
4.20 Nasdaq Listing. . . . . . . . . . . . . . . . . . . . . . . . . . .35
4.21 Blue Sky Laws.. . . . . . . . . . . . . . . . . . . . . . . . . . .35
4.22 Resignation of Officers and Directors . . . . . . . . . . . . . . .35
ARTICLE 5 CONDITIONS PRECEDENT TO OBLIGATIONS OF PARENT
AND MERGER SUB. . . . . . . . . . . . . . . . . . . . . . . .35
5.1 Representations and Warranties Accurate . . . . . . . . . . . . . .35
5.2 Compliance With Covenants . . . . . . . . . . . . . . . . . . . . .36
5.3 No Material Adverse Effect. . . . . . . . . . . . . . . . . . . . .36
5.4 Effectiveness of Registration Statement . . . . . . . . . . . . . .36
5.5 Company Stockholder Approval. . . . . . . . . . . . . . . . . . . .36
5.6 Parent Stockholder Approval . . . . . . . . . . . . . . . . . . . .36
5.7 Agreements and Documents. . . . . . . . . . . . . . . . . . . . . .36
5.8 Absence of Restraint. . . . . . . . . . . . . . . . . . . . . . . .37
iii
<PAGE>
TABLE OF CONTENTS
(CONTINUED)
PAGE
<S> <C>
5.9 No Governmental Litigation. . . . . . . . . . . . . . . . . . . . .37
5.10 Other Required Consents and Approvals . . . . . . . . . . . . . . .37
5.11 Stock Options . . . . . . . . . . . . . . . . . . . . . . . . . . .37
ARTICLE 6 CONDITIONS PRECEDENT TO THE COMPANY'S OBLIGATIONS . . . . . .37
6.1 Representations and Warranties Accurate . . . . . . . . . . . . . .38
6.2 Compliance With Covenants . . . . . . . . . . . . . . . . . . . . .38
6.3 No Material Adverse Effect. . . . . . . . . . . . . . . . . . . . .38
6.4 Effectiveness of Registration Statement . . . . . . . . . . . . . .38
6.5 Company Stockholder Approval. . . . . . . . . . . . . . . . . . . .38
6.6 Parent Stockholder Approval . . . . . . . . . . . . . . . . . . . .38
6.7 Agreements and Documents. . . . . . . . . . . . . . . . . . . . . .38
6.8 Absence of Restraint. . . . . . . . . . . . . . . . . . . . . . . .39
6.9 Listing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .39
6.10 Closing Price . . . . . . . . . . . . . . . . . . . . . . . . . . .39
6.11 No Governmental Litigation. . . . . . . . . . . . . . . . . . . . .39
ARTICLE 7 TERMINATION OF AGREEMENT. . . . . . . . . . . . . . . . . . .39
7.1 Termination . . . . . . . . . . . . . . . . . . . . . . . . . . . .39
7.2 Effect of Termination . . . . . . . . . . . . . . . . . . . . . . .41
7.3 Fees and Expenses . . . . . . . . . . . . . . . . . . . . . . . . .41
ARTICLE 8 MISCELLANEOUS . . . . . . . . . . . . . . . . . . . . . . . .41
8.1 Amendment . . . . . . . . . . . . . . . . . . . . . . . . . . . . .41
8.2 Waiver. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .41
8.3 No Survival of Representations and Warranties . . . . . . . . . . .42
8.4 Entire Agreement; Counterparts. . . . . . . . . . . . . . . . . . .42
8.5 Applicable Law; Jurisdiction. . . . . . . . . . . . . . . . . . . .42
8.6 Assignability . . . . . . . . . . . . . . . . . . . . . . . . . . .42
8.7 Notices . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .42
8.8 Cooperation . . . . . . . . . . . . . . . . . . . . . . . . . . . .43
8.9 Construction. . . . . . . . . . . . . . . . . . . . . . . . . . . .44
</TABLE>
iv
<PAGE>
EXHIBITS
Exhibit A Certain Definitions
Exhibit B [reserved]
Exhibit C Directors and Officers of Surviving Corporation
Exhibit D Form of Stock Option Agreement
Exhibit E Form of Company Proprietary Information and Assignment Agreement
Exhibit F Form of Company Affiliate Agreement
Exhibit G List of Persons to Enter into Employment or Consulting and
Noncompetition Agreement
<PAGE>
AGREEMENT AND PLAN OF MERGER AND REORGANIZATION
THIS AGREEMENT AND PLAN OF MERGER AND REORGANIZATION ("Agreement") is made
and entered into as of July 6, 1998, by and among GENE LOGIC INC., a Delaware
corporation ("Parent"); GENE LOGIC ACQUISITION CORP., a Delaware corporation and
a wholly-owned subsidiary of Parent ("Merger Sub"); and ONCORMED, INC., a
Delaware corporation (the "Company"). Certain capitalized terms used in this
Agreement are defined in Exhibit A.
RECITALS
A. Parent, Merger Sub and the Company intend to effect a merger of the
Company with and into Merger Sub (the "Merger") in accordance with this
Agreement and the Delaware General Corporation Law (the "DGCL"). Upon
consummation of the Merger, the Company will cease to exist, and Merger Sub will
remain a wholly-owned subsidiary of Parent.
B. This Agreement and the Merger have been unanimously approved by the
respective Boards of Directors of Parent, Merger Sub and the Company.
C. Pursuant to the Merger, among other things, the outstanding shares of
Common Stock of the Company will be converted into shares of Common Stock of the
Parent at the rate provided herein.
D. It is intended that the Merger qualify as a tax-free reorganization
within the meaning of Section 368(a) of the Internal Revenue Code of 1986, as
amended (the "Code"). For financial reporting purposes, it is intended that the
Merger be accounted for as a "purchase."
AGREEMENT
Parent, Merger Sub and the Company, in consideration of the foregoing and
the mutual covenants and agreements herein contained, and intending to be
legally bound, agree as follows:
ARTICLE 1
DESCRIPTION OF TRANSACTION
1.1 MERGER OF THE COMPANY INTO MERGER SUB. Upon the terms and subject to
the conditions set forth in this Agreement, at the Effective Time (as defined in
Section 1.3), the Company shall be merged with and into Merger Sub and the
separate existence of the Company shall cease. Merger Sub will be the surviving
corporation in the Merger (the "Surviving Corporation") and a wholly-owned
subsidiary of Parent.
1.2 EFFECT OF THE MERGER. The Merger shall have the effects set forth in
this Agreement and in the applicable provisions of the DGCL.
1.3 CLOSING; EFFECTIVE TIME. The consummation of the transactions
contemplated by this Agreement (the "Closing") shall take place at the offices
of Cooley Godward LLP, 4365 Executive Drive, Suite 1100, San Diego, California
92121, on the second business day following
1.
<PAGE>
the date as of which each of the conditions set forth in Articles 5 and 6 has
been fulfilled or waived or on such other date as may be mutually agreed upon by
Parent and the Company (the "Closing Date"). Contemporaneously with or as soon
as practicable after the Closing, a properly executed certificate of merger
conforming to the requirements of the DGCL (the "Certificate of Merger") shall
be filed with the office of the Secretary of State of the State of Delaware.
The Merger shall become effective at the time the Certificate of Merger is filed
with the office of the Secretary of State of the State of Delaware or at such
later time as may be specified in the Certificate of Merger (the "Effective
Time"), which shall be no later than the second business day following the date
on which each of the conditions set forth in Articles 5 and 6 has been fulfilled
or waived or on such other date as may be mutually agreed upon by Parent and the
Company.
1.4 CERTIFICATE OF INCORPORATION AND BYLAWS; DIRECTORS AND OFFICERS. The
Certificate of Incorporation of Merger Sub shall be the Certificate of
Incorporation of the Surviving Corporation as of the Effective Time. The Bylaws
of Merger Sub as in effect immediately prior to the Effective Time shall be the
Bylaws of the Surviving Corporation as of the Effective Time. The directors and
officers of the Surviving Corporation immediately after the Effective Time shall
be the respective individuals set forth on Exhibit C.
1.5 CONVERSION OF SHARES.
(a) At the Effective Time, by virtue of the Merger (and without any
action on the part of Parent, Merger Sub, the Company or any stockholder of the
Company (the "Company Stockholders")):
(i) each share of the common stock, $.01 par value per share,
of the Company ("Company Common Stock") and each share of the 6% Series A
Convertible Preferred Stock, $.01 par value per share, of the Company ("Company
Preferred Stock") then held by the Company or any subsidiary of the Company (or
held in the Company's treasury) shall be canceled and retired and shall cease to
exist, and no consideration shall be delivered in exchange therefor;
(ii) each share of Company Common Stock and Company Preferred
Stock then held by Parent or Merger Sub shall be canceled and retired and shall
cease to exist, and no consideration shall be delivered in exchange therefor;
(iii) except as provided in clauses (i) and (ii) above and
subject to Sections 1.5(c) and 1.5(d), each share of Company Common Stock then
outstanding shall be converted into the right to receive (A) one share of the
common stock, $.01 par value per share, of Parent ("Parent Common Stock"),
multiplied by (B) the Exchange Ratio (as defined in Section 1.5(b)(ii)); and
(iv) each share of the common stock, par value $.01 per share,
of Merger Sub then outstanding shall remain outstanding.
2.
<PAGE>
(b) For purposes of this Agreement:
(i) The term "Total Merger Shares" shall mean the whole number
of shares of Parent Common Stock equal to (A) $33,221,235, divided by (B) $6.85,
which shall initially equal 4,849,815; PROVIDED, HOWEVER, that in the event the
average closing price of the Parent's Common Stock as reported on the Nasdaq
National Market System (the "Nasdaq NMS") for the fifteen (15) trading days
ending the second day prior to the day of the Parent Stockholders' Meeting (as
defined in Section 4.10(a)) called for the purpose of approving the Merger (the
"Closing Price") is more than $7.88, then Total Merger Shares shall equal
(x) $38,204,420, divided by (y) the Closing Price.
(ii) The term "Exchange Ratio" shall mean a fraction (as may be
adjusted in accordance with Section 1.5(c)) equal to (A) the Total Merger Shares
divided by (B) the number of Outstanding Shares (as defined in
Section 1.5(b)(iii)) outstanding immediately prior to the Effective Time.
(iii) The term "Outstanding Shares" shall mean, at the Effective
Time, the sum of (A) the total number of outstanding shares of Company Common
Stock, and (B) the total number of shares of Company Common Stock into which all
outstanding Company Preferred Stock is then convertible in accordance with the
Company Certificate of Incorporation.
(c) If, between the date of this Agreement and the Effective Time,
the outstanding shares of Company Common Stock, Company Preferred Stock or
Parent Common Stock are changed into a different number or class of shares by
reason of any stock, cash or property dividend or distribution, stock split,
reverse stock split, reclassification, recapitalization, or similar transaction,
then the Exchange Ratio shall be appropriately adjusted.
(d) No fractional shares of Parent Common Stock shall be issued in
connection with the Merger, and no certificates or scrip for any such fractional
shares shall be issued. In lieu of such fractional shares, any holder of
Company Common Stock or Company Preferred Stock who would otherwise be entitled
to receive a fraction of a share of Parent Common Stock (after aggregating all
fractional shares of Parent Common Stock issuable to such holder) shall, upon
surrender of such holder's Company Stock Certificate(s) (as defined in Section
1.6), be paid in cash the dollar amount (rounded to the nearest whole cent),
without interest, determined by multiplying such fraction by the closing sales
price of a share of Parent Common Stock as quoted on the Nasdaq NMS on the
Closing Date (and if such day is not a trading day, then the trading day
immediately preceding the Closing Date).
1.6 CLOSING OF THE COMPANY'S TRANSFER BOOKS. At the Effective Time (a)
all shares of Company Common Stock and Company Preferred Stock outstanding
immediately prior to the Effective Time shall automatically be canceled and
retired and shall cease to exist, and holders of certificates representing
shares of Company Common Stock or Company Preferred Stock shall cease to have
any rights as stockholders of the Company; and (b) the stock transfer books
of the Company shall be closed with respect to all shares of Company Common
Stock and Company Preferred Stock outstanding immediately prior to the
Effective Time. No further transfer of any such shares of Company Common
Stock or Company Preferred Stock shall be made on such stock transfer books
after the Effective Time. If, after the Effective Time, a valid certificate
3.
<PAGE>
previously representing any of such shares of Company Common Stock or Company
Preferred Stock (a "Company Stock Certificate") is presented to the Exchange
Agent (as defined in 1.7(a)) or to the Surviving Corporation or Parent, such
Company Stock Certificate shall be canceled and exchanged as provided in Section
1.7.
1.7 EXCHANGE OF COMPANY STOCK CERTIFICATES.
(a) Prior to the Closing Date, Parent shall select ChaseMellon
Shareholder Services or another reputable bank or trust company to act as
exchange agent in the Merger (the "Exchange Agent"). Promptly after the
Effective Time, Parent shall deposit with the Exchange Agent (i) certificates
representing the number of shares of Parent Common Stock to be issued to the
Company Stockholders in the Merger and (ii) cash sufficient to make payments in
lieu of fractional shares in accordance with Section 1.5(d). The shares of
Parent Common Stock and cash amounts so deposited with the Exchange Agent,
together with any dividends or distributions received by the Exchange Agent with
respect to such shares, are referred to collectively herein as the "Exchange
Fund."
(b) As soon as practicable after the Effective Time, the Exchange
Agent will mail to the registered holders of Company Stock Certificates (i) a
letter of transmittal in customary form and containing such provisions as Parent
may reasonably specify (including a provision confirming that delivery of
Company Stock Certificates shall be effected, and risk of loss and title to
Company Stock Certificates shall pass, only upon delivery of such Company Stock
Certificates to the Exchange Agent), and (ii) instructions for use in effecting
the surrender of Company Stock Certificates in exchange for certificates
representing Parent Common Stock. Subject to Section 1.5(d), upon surrender of
a Company Stock Certificate to the Exchange Agent for exchange, together with a
duly executed letter of transmittal and such other documents as may be
reasonably required by the Exchange Agent, (i) the holder of such Company Stock
Certificate shall be entitled to receive in exchange therefor a certificate
representing the number of whole shares of Parent Common Stock that such holder
has the right to receive pursuant to the provisions of this Article 1, and
(ii) the Company Stock Certificate so surrendered shall be canceled. Until
surrendered as contemplated by this Section 1.7, each Company Stock Certificate
shall be deemed, from and after the Effective Time, to represent only the right
to receive upon such surrender a certificate representing shares of Parent
Common Stock (and cash in lieu of any fractional share of Parent Common Stock)
as contemplated by this Article 1. If any Company Stock Certificate shall have
been lost, stolen or destroyed, Parent may, in its discretion and as a condition
precedent to the issuance of any certificate representing Parent Common Stock,
require the owner of such lost, stolen or destroyed Company Stock Certificate to
provide an appropriate affidavit and to deliver a bond (in such sum as Parent
may reasonably direct) as indemnity against any claim that may be made against
the Exchange Agent, Parent or the Surviving Corporation with respect to such
Company Stock Certificate.
(c) No dividends or other distributions declared or made with respect
to Parent Common Stock with a record date after the Effective Time shall be paid
to the holder of any unsurrendered Company Stock Certificate with respect to the
shares of Parent Common Stock represented thereby, and no cash payment in lieu
of any fractional share shall be paid to any such holder, until such holder
surrenders such Company Stock Certificate in accordance with
4.
<PAGE>
this Section 1.7 (at which time such holder shall be entitled to receive all
such dividends and distributions and such cash payment).
(d) Any portion of the Exchange Fund that remains undistributed to
former stockholders of the Company as of the date 270 days after the Effective
Time shall be delivered to Parent upon demand, and any holders of Company
Common Stock who have not theretofore surrendered their Company Stock
Certificates in accordance with this Section 1.7 shall thereafter look only to
Parent for payment of their claims for Parent Common Stock, cash in lieu of
fractional shares of Parent Common Stock and any dividends or distributions with
respect to Parent Common Stock.
(e) Neither Parent nor the Surviving Corporation shall be liable to
any holder or former holder of shares of Company Common Stock, Company Preferred
Stock or Parent Common Stock with respect to any shares (or dividends or
distributions with respect thereto) or cash amounts comprising the Exchange Fund
which are delivered to a public official pursuant to any applicable abandoned
property, escheat or similar law.
1.8 STOCK OPTIONS. Parent shall not assume any option to purchase capital
stock of the Company outstanding at the Effective Time under any stock option
plan or agreement of the Company. The Company has delivered to Parent a list of
all options to purchase capital stock of the Company outstanding under stock
option plans and agreements of the Company (the "Company Options"). Under the
terms (as in effect as of the date hereof) of each stock option plan under which
any Company Option was issued and each stock option agreement by which any
Company Option is evidenced, as applicable, in connection with the Merger, all
outstanding Company Options shall automatically accelerate and become fully
exercisable for all of the shares of Company Common Stock subject to such
Company Options and, to the extent such Company Options are not exercised prior
to the Effective Time, shall terminate and cease to remain outstanding
immediately after the Effective Time. The Company shall take all action that
may reasonably be necessary (under the stock option plans pursuant to which
Company Options are outstanding and otherwise) to effectuate the provisions of
this Section 1.8.
1.9 WARRANTS. At the Effective Time, Parent shall assume each warrant to
purchase Company Common Stock then outstanding as set forth on a list delivered
to Parent (the "Company Warrants") in accordance with the terms (as in effect as
of the date hereof) of such Company Warrants. From and after the Effective
Time, (a) each Company Warrant assumed by Parent may be exercised solely for
shares of Parent Common Stock, (b) the number of shares of Parent Common Stock
subject to each Company Warrant shall be equal to the number of shares of
Company Common Stock subject to such Company Warrant immediately prior to the
Effective Time multiplied by the Exchange Ratio, rounding down to the nearest
whole share (with cash, less the applicable exercise price, being payable for
any fraction of a share), (c) the per share exercise price under each such
Company Warrant shall be equal to the per share exercise price under such
Company Warrant divided by the Exchange Ratio, rounding up to the nearest cent
and (d) any restriction on the exercise of any Company Warrant shall continue in
full force and effect and the term, exercisability and other provisions of such
Company Warrant shall otherwise remain unchanged. The Company shall take all
action that may be necessary (under the Company Warrants and otherwise) to
effectuate the provisions of this Section 1.9 and
5.
<PAGE>
to ensure that, from and after the Effective Time, holders of Company Warrants
have no rights with respect thereto other than those specifically provided
herein.
1.10 STOCK SUBJECT TO CONDITIONS. If any shares of Company Common Stock or
Company Preferred Stock outstanding immediately prior to the Effective Time are
unvested or are subject to a repurchase option, risk of forfeiture or other
condition under any applicable stock purchase agreement, restriction agreement
or other agreement with the Company, then (unless such condition terminates by
virtue of the Merger pursuant to the express terms of such agreement) the shares
of Parent Common Stock issued in exchange for such shares of Company Common
Stock or Company Preferred Stock will also be unvested or subject to the same
repurchase option, risk of forfeiture or other condition, and the certificates
evidencing such shares of Parent Common Stock may accordingly be marked with
appropriate legends.
1.11 TAX CONSEQUENCES. For federal income tax purposes, the Merger is
intended to constitute a tax-free reorganization within the meaning of Section
368(a) of the Code. The parties to this Agreement intend this Agreement to be
treated as a "plan of reorganization" within the meaning of Sections 1.368-2(g)
and 1.368-3(a) of the United States Treasury Regulations.
1.12 ACCOUNTING CONSEQUENCES. For financial reporting purposes, the Merger
is intended to be accounted for as a "purchase."
1.13 FURTHER ACTION. If at any time after the Effective Time any further
action is determined by Parent to be reasonably necessary or desirable to carry
out the purposes of this Agreement or to vest the Surviving Corporation with the
full right, title and possession of and to all assets, property, rights,
privileges, immunities, powers and franchises of Merger Sub and the Company, the
officers and directors of the Surviving Corporation shall be fully authorized
(in the name of Merger Sub, in the name of the Company and otherwise) to take
such action.
ARTICLE 2
REPRESENTATIONS AND WARRANTIES OF THE COMPANY
The Company represents and warrants to Parent and Merger Sub that, except
as set forth in the disclosure schedule delivered by the Company to Parent dated
and signed as of the date of this Agreement by the President of the Company (the
"Company Disclosure Schedule"):
2.1 ORGANIZATION; SUBSIDIARIES; CAPITALIZATION.
(a) The Company is a corporation duly organized, validly existing and
in good standing under the laws of the State of Delaware. The Company has all
requisite corporate power and authority to (i) own and use its assets in the
manner in which its assets are currently owned and used, (ii) to carry on its
business as presently conducted, and (iii) to perform all of its obligations
under all Company Contracts. The Company does not own or hold, directly or
indirectly, any debt or equity securities of, or have any other interest in, any
Entity, and the Company has not entered into any Contract or otherwise become
obligated to acquire any such interest.
6.
<PAGE>
(b) The Company is qualified to do business as a foreign corporation
and is in good standing under the laws of all jurisdictions where the nature of
its business requires such qualification and where the failure to be so
qualified would have a Material Adverse Effect on the Company.
(c) As of the date of this Agreement, the authorized capital stock of
the Company consists of: 40,000,000 shares of Company Common Stock, par value
$.01 per share, of which, 7,887,300 shares are issued and outstanding; and
2,000,000 shares of preferred stock, par value $.01 per share, of which 333
shares have been designated as 6% Series A Convertible Preferred Stock, 333 of
which are issued and outstanding. All the issued and outstanding shares of
Company Common Stock and Company Preferred Stock are validly issued, fully paid
and nonassessable and were issued in compliance with all state and federal
securities laws and all requirements set forth in applicable Contracts. None of
the outstanding shares of Company Common Stock or Company Preferred Stock is
entitled or subject to (i) any preemptive right, right of participation, right
of maintenance or any similar right, or (ii) any right of first refusal in favor
of any Person. There is no Company Contract relating to the voting or
registration of, or restricting any Person from purchasing, selling, pledging or
otherwise disposing of (or granting any option or similar right with respect
to), any shares of Company Common Stock or Company Preferred Stock.
(d) As of the date of this Agreement, the Company has outstanding
Company Options to purchase a total of 1,581,042 shares of Company Common Stock
(minus any Company Options exercised on the date hereof), and outstanding
Company Warrants to purchase a total of 1,088,896 shares of Company Common Stock
(minus any Company Warrants exercised on the date hereof). Part 2.1(d) of the
Company Disclosure Schedule sets forth, as of the date of this Agreement, with
respect to the Company Options: (i) the name of each optionee; (ii) the number
of shares of Company Common Stock subject to each Company Option; (iii) the date
of grant; (iv) the exercise price; (v) the applicable vesting schedule(s); and
(vi) the particular plan, if any, pursuant to which such Company Option was
granted. Part 2.1(d) of the Company Disclosure Schedule sets forth, as of the
date of this Agreement, each option plan and agreement under which the Company
Options have been granted, and the Company has delivered to Parent complete and
accurate copies of all such plans. Part 2.1(d) of the Company Disclosure
Schedule sets forth, as of the date of this Agreement, with respect to the
Company Warrants: (i) the number of shares of Company Common Stock issuable
upon exercise; (ii) the exercise price per share; and (iii) the expiration date
of each Company Warrant. All outstanding Company Options have been issued under
and are evidenced by a stock option agreement identical to that form of stock
option agreement attached hereto as Exhibit D, except with respect solely to the
name of the optionee, the grant date, the number of shares subject to the
Company Option, the vesting schedule and the exercise price.
(e) Except as set forth above, as of the date of this Agreement, (i)
there are no shares of capital stock of the Company authorized, issued or
outstanding, (ii) there are no outstanding subscriptions, options, warrants,
stock appreciation right plans, calls, rights, convertible securities,
stockholder rights plans (or similar plans commonly referred to as "poison
pills") or other agreements or commitments of any character relating to issued
or unissued capital stock or other securities of the Company, or obligating the
Company or, to the Company's knowledge, any other Person, to issue, transfer or
sell any shares of the capital stock or other securities of the
7.
<PAGE>
Company, (iii) there are no other outstanding securities convertible into,
exchangeable for or evidencing the right to subscribe for any shares of the
capital stock or other securities of the Company, and (iv) there is no condition
or circumstance that may give rise to or provide a basis for the assertion of a
claim by any Person to the effect that such Person is entitled to acquire or
receive any shares of capital stock or other securities of the Company.
(f) The Company does not own any Parent Common Stock.
(g) Complete and accurate copies of the Certificate of Incorporation,
including any Certificate of Designation (collectively the "Company Certificate
of Incorporation") and Bylaws (or comparable charter documents), each as amended
to date, of the Company are filed as exhibits to the Company SEC Documents (as
defined in Section 2.2(a)) and have been delivered to Parent.
2.2 SEC FILINGS; FINANCIAL STATEMENTS.
(a) The Company has delivered to Parent a complete and accurate copy
of each report, schedule, registration statement and definitive proxy statement
filed by the Company with the Securities and Exchange Commission ("SEC") on or
after December 31, 1995 (the "Company SEC Documents"), which are all the forms,
reports and documents required to be filed by the Company with the SEC since
December 31, 1995. As of the time it was filed with the SEC (or, if amended or
superseded by a filing prior to the date of this Agreement, then on the date of
such filing): (i) each of the Company SEC Documents complied in all material
respects with the published requirements of the Securities Act or the Exchange
Act, as the case may be, and (ii) none of the Company SEC Documents contained
any untrue statement of a material fact or omitted to state a material fact
required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made, not
misleading.
(b) Each of the financial statements (including, in each case, any
related notes thereto) contained in the Company SEC Documents and the set of the
Company's unaudited interim financial statements as of and for the three-month
period ended March 31, 1998 including the Company's unaudited balance sheet as
of March 31, 1998 (the "March 1998 Balance Sheet") that are attached to the
Company Disclosure Schedule (collectively, the "Company Financial Statements")
(i) complied as to form in all material respects with the published rules and
regulations of the SEC applicable thereto, (ii) was prepared in accordance with
GAAP applied on a consistent basis throughout the periods involved (except as
may be indicated in the notes thereto and except that the unaudited interim
financial statements included in the Company Financial Statements are subject to
normal year-end audit adjustments which were not or are not expected to be
material in amount and do not contain footnotes), and (iii) fairly presented the
financial position of the Company as at the respective dates thereof and the
results of its operations and cash flows for the periods indicated.
(c) The unaudited bi-weekly financial statements to be delivered to
Parent pursuant to Section 4.4(a)(v) will be prepared in a manner consistent
with the basis on which the Company Financial Statements were prepared and will
fairly present the financial position of the Company as at the respective dates
thereof and the results of operations and cash flows of the
8.
<PAGE>
Company for the periods indicated, except that the unaudited bi-weekly financial
statements will be subject to normal year-end audit adjustments and will not
contain footnotes.
(d) The Company has previously furnished to Parent a complete and
accurate copy of any amendments or modifications that have not yet been filed
with the SEC to agreements, documents or other instruments that have been filed
by the Company with the SEC pursuant to the Securities Act or the Exchange Act.
(e) The Company has no Liabilities, except for (i) any Liabilities
which are set forth in the March 1998 Balance Sheet or disclosed in the notes
included in the Company Financial Statements, (ii) any Liabilities which were
incurred after March 31, 1998 in the ordinary course of business consistent with
past practice and do not exceed in the aggregate $50,000, or (iii) other
Liabilities which, individually or in the aggregate, have not had and would not
reasonably be expected to have a Material Adverse Effect on the Company.
2.3 ABSENCE OF CERTAIN CHANGES OR EVENTS. Since December 31, 1997, there
has not been (a) any change, or any development or combination of changes or
developments that has had or would reasonably be expected to have a Material
Adverse Effect on the Company, (b) any damage, destruction or loss of any of the
assets of the Company, whether or not covered by insurance, that has had or
would reasonably be expected to have a Material Adverse Effect on the Company,
(c) any transaction, commitment, dispute or other event or condition (financial
or otherwise) of any character (whether or not in the ordinary course of
business) which would be prohibited by Section 4.4(b)(ii), (vi), (viii), (ix),
(x), (xi), (xii) or (xvi) if it were to occur or be effected between the date of
this Agreement and the Effective Time or (d) any declaration, accrual, set aside
or payment of any dividend or distribution by the Company.
2.4 TAX MATTERS.
(a) All Tax Returns required to be filed by or on behalf of the
Company with any Governmental Authority on or before the Closing Date (i) have
been or will be filed on or before the applicable due date (including any
extensions of such due date that expire prior to the Closing Date), and
(ii) have been, or will be when filed, prepared in all material respects in
compliance with all applicable Legal Requirements. All amounts shown on the
Company's Tax Returns to be due on or before the Closing Date have been or will
be paid on or before the Closing Date except for amounts which, individually or
in the aggregate, could not reasonably be expected to have a Material Adverse
Effect on the Company.
(b) To the knowledge of the Company, the Company Financial Statements
and the financial statements to be delivered to the Company pursuant to Section
4.4(a)(v) fully accrue all Taxes with respect to all periods through the dates
thereof in accordance with generally accepted accounting principles. The
Company will establish, in the ordinary course of business and consistent with
its past practices, reserves reasonably adequate for the payment of all Taxes
through the Closing Date, except for amounts which, individually or in the
aggregate, could not reasonably be expected to have a Material Adverse Effect on
the Company.
(c) No claim or Legal Proceeding is pending or, to the knowledge of
the Company, has been threatened against or with respect to the Company in
respect of any Tax.
9.
<PAGE>
There are no unsatisfied liabilities for material Taxes (including liabilities
for interest, additions to tax and penalties thereon and related expenses) with
respect to any notice of deficiency or similar document received by the Company
with respect to any material Tax (other than liabilities for Taxes asserted
under any such notice of deficiency or similar document which are being
contested in good faith by the Company and with respect to which adequate
reserves for payment have been established). There are no liens for material
Taxes upon any of the assets of the Company except liens for current Taxes not
yet due and payable. The Company has not entered into or become bound by any
agreement or consent pursuant to Section 341(f) of the Code. The Company has
not been, and will not be, required to include any adjustment in taxable income
for any tax period (or portion thereof) pursuant to Section 481 or 263A of the
Code or any comparable provision under state or foreign Tax laws as a result of
transactions or events occurring, or accounting methods employed, prior to the
Closing.
(d) To the knowledge of the Company, there is no agreement, plan,
arrangement or other Contract covering any employee or independent contractor or
former employee or independent contractor of the Company that, considered
individually or considered collectively with any other such Contracts, will, or
could reasonably be expected to, give rise directly or indirectly to the payment
of any amount that would not be deductible pursuant to Section 280G or
Section 162 of the Code. The Company is not a party to or bound by any tax
indemnity agreement, tax sharing agreement, tax allocation agreement or similar
Contract.
2.5 PROPRIETARY ASSETS.
(a) The Company owns, or licenses or otherwise possess legally
enforceable rights to use, all Proprietary Assets that are owned by the Company,
or licensed to or otherwise used in the Company's business as currently
conducted (the "Company Proprietary Assets"), except to the extent that the
failure to have such rights has not had, and would not reasonably be expected to
have, a Material Adverse Effect on the Company.
(b) Part 2.5(b) of the Company Disclosure Schedule lists (i) all
patents and patent applications and all registered and unregistered trademarks,
trade names, service marks and copyrights, and all applications with respect
therefor, included in the Company Proprietary Assets, including the
jurisdictions in which each such Company Proprietary Asset has been issued or
registered or in which any application for such issuance and registration has
been filed, (ii) all licenses, sublicenses and other agreements to which the
Company is a party and pursuant to which any Person is authorized to use any
Company Proprietary Asset, (iii) all licenses, sublicenses and other agreements
to which the Company is a party and pursuant to which it is authorized to use
any Proprietary Asset held or used by a third party (other than "shrink wrap"
licenses with respect to commercially available software programs costing less
than $10,000) ("Third Party Proprietary Assets"), and (iv) a description of any
Company Proprietary Asset not disclosed under clauses (i), (ii) and (iii) above.
(c) To the Company's knowledge, there is no unauthorized use,
disclosure, infringement or misappropriation of any Company Proprietary Asset,
or any Third Party Proprietary Asset to the extent licensed by or through the
Company by any third party, including any employee or former employee of the
Company, except such as would not have a Material
10.
<PAGE>
Adverse Effect on the Company. The Company has not entered into any agreement
to indemnify any other Person against any charge of infringement of any Company
Proprietary Asset.
(d) The Company is not, and will not be as a result of the execution
and delivery of this Agreement or the performance of its obligations under this
Agreement, in breach of any license, sublicense or other agreement relating to
any Company Proprietary Asset or Third Party Proprietary Asset, except for such
breaches that would not have a Material Adverse Effect on the Company.
(e) All patents, registered trademarks, registered service marks or
copyright registrations owned by the Company are valid and subsisting. Except
for actions which would not reasonably be expected to have a Material Adverse
Effect on the Company, the Company (i) is not a party to any Legal Proceeding
which involves a claim of infringement of any Third Party Proprietary Asset and
(ii) has not brought any Legal Proceeding for infringement of any Company
Proprietary Asset or breach of any license or agreement involving a Company
Proprietary Asset against any third party, which action is continuing. To the
Company's knowledge, the manufacture, marketing, licensing or sale of any
Company Proprietary Asset or products does not infringe any Third Party
Proprietary Asset.
(f) The Company has secured agreements with all consultants and
employees who prior to the date of this Agreement contributed to the creation or
development of any Company Proprietary Asset of the rights to such contributions
that the Company does not already own by operation of law in the form attached
hereto as Exhibit E.
(g) The Company has taken all reasonable and appropriate steps to
protect and preserve the confidentiality of all Company Proprietary Assets not
otherwise protected by patents, patent applications or copyrights ("Confidential
Information"). All use, disclosure or appropriation of Confidential Information
owned by the Company by or to any third party has been pursuant to the terms of
a written agreement between the Company and such third party, and all use,
disclosure or appropriation of Confidential Information not owned by the Company
has been pursuant to the terms of a written agreement between the Company and
the owner of such Confidential Information, or is otherwise lawful.
2.6 CONTRACTS.
(a) Except as identified as an exhibit to the Company's Annual Report
on Form 10-K for the year ended December 31, 1997 or as an exhibit to the
Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 1998,
the Company is not a party to, or bound by, any Material Company Contract. For
purposes of this Agreement, a "Material Company Contract" shall be deemed to be
any Contract filed as an exhibit to the Company's Annual Report on Form 10-K for
the year ended December 31, 1997 or as an exhibit to the Company's Quarterly
Report on Form 10-Q for the quarter ended March 31, 1998, and any Contract:
(i) relating to the employment or engagement of, or the
performance of services by, any employee, consultant or independent contractor
in excess of $75,000 per year;
11.
<PAGE>
(ii) restricting in any manner the Company's right or ability
to (A) compete with any other Person, (B) acquire or transfer any product,
technology or other asset from or to any other Person, or (C) develop or
distribute any Company Proprietary Asset;
(iii) that (A) provides for the receipt or expenditure by the
Company of cash or other consideration in excess of $25,000; (B) relates to the
performance of services by or on behalf of the Company having a value in excess
of $25,000; (C) was entered into outside the ordinary course of business; or
(D) is material and cannot be terminated by the Company without penalty with 30
days notice or less;
(iv) relating to the acquisition, issuance or transfer of any
securities;
(v) creating or relating to the creation of any Encumbrance
with respect to any of the Company Proprietary Assets or other assets having a
value in excess of $25,000;
(vi) involving or incorporating any guaranty, pledge,
performance, completion bond, indemnity or contribution or surety arrangement;
or
(vii) creating or relating to any partnership, joint venture,
research or development collaboration, license agreement, or any other Contract
by which the Company is obligated or has the right to share any revenues,
profits, losses, costs or Liabilities.
(b) Except as would not, individually or in the aggregate, have a
Material Adverse Effect on the Company, all Material Company Contracts are in
full force and effect and are enforceable against the Company and, to the
Company's knowledge, are enforceable against the other parties thereto, except
as enforcement thereof may be limited by bankruptcy, insolvency, reorganization,
moratorium and other laws of general application affecting enforcement of
creditors' rights generally, as limited by laws relating to the availability of
specific performance, injunctive relief, or by general equitable principles, and
to the extent any indemnification or contribution provisions thereof may be
limited by applicable federal or state securities laws. The Company has not
breached, nor has the Company received in writing any claim or threat that it
has breached, in any material respect, and no default has occurred under any of
the Material Company Contracts and, to the Company's knowledge, (i) none of the
other contracting parties has violated or breached, and no default has occurred
under any of the Material Company Contracts, and (ii) other than the
transactions contemplated hereby, no event has occurred, and no circumstance or
condition exists which with the giving of notice or the lapse of time, or both,
will, or could reasonably be expected to, result in a violation, breach or
default under any Material Company Contract or give any Person the right to
cancel, terminate or modify any Material Company Contract. To the Company's
knowledge, the Company's relationship with each other party under a Material
Company Contract, including, without limitation, Rhone-Poulenc Rorer,
Schering-Plough, Merck and Onyx Pharmaceuticals, Inc., is good. To the
Company's knowledge, no party to a Material Company Contract currently in effect
has given notice to the Company of intent to terminate such Material Company
Contract in a way that would have a Material Adverse Effect on the Company. The
Company has provided to Parent or Parent's counsel true and complete copies of
each of the Material Company Contracts. Consummation of the transactions
contemplated by this Agreement and each other
12.
<PAGE>
agreement to be entered into by the Company in connection herewith will not (and
will not give any Person a right to) cancel, terminate or modify any material
rights of, or accelerate or increase any material obligation of, the Company
under any Material Company Contract.
(c) The Company possesses all material Governmental Authorizations
which are required in order to operate its business as presently conducted, and
the Company is in compliance in all material respects with all such Governmental
Authorizations. Each such Governmental Authorization is identified in Part
2.6(c) of the Company Disclosure Schedule. Each such Governmental Authorization
is valid and in full force and effect and will remain so until consummation of
the transactions contemplated by this Agreement, except where the failure to
comply would not have a Material Adverse Effect on the Company.
(d) Part 2.6(d) of the Company Disclosure Schedule sets forth a list
of all claims made or, to the Company's knowledge, threatened against the
Company under each Material Company Contract presently or heretofore in effect
to the extent such claims, individually or in the aggregate, have had or would
reasonably be expected to have a Material Adverse Effect on the Company.
2.7 EMPLOYEES; BENEFIT PLANS.
(a) Part 2.7(a) of the Company Disclosure Schedule identifies each
bonus, deferred compensation, incentive compensation, stock purchase, stock
option, severance or termination pay, medical, life, disability or other
insurance, supplemental unemployment benefits, profit-sharing, pension or
retirement plan, program or agreement sponsored, maintained, contributed to or
required to be contributed to by the Company for the benefit of any current or
former employee, consultant, officer or director of the Company (other than
those plans, programs and agreements disclosed in the Company SEC Documents and
other than the Company's 401(k) profit sharing plan).
(b) Except as set forth in Part 2.7(a) of the Company Disclosure
Schedule (and except for the Company's 401(k) profit sharing plan), the Company
does not maintain, sponsor or contribute to, and has not at any time in the past
maintained, sponsored or contributed to, any employee pension benefit plan (as
defined in Section 3(2) of the Employee Retirement Income Security Act of 1974,
as amended ("ERISA"), whether or not excluded from coverage under specific
Titles or Merger Subtitles of ERISA) for the benefit of employees or former
employees of the Company.
(c) Each of the plans intended to be qualified under Section 401(a)
of the Code has received a favorable determination from the Internal Revenue
Service, and the Company is not aware of any reason why any such determination
letter should be revoked.
(d) Except as disclosed in the Company SEC Documents, neither the
execution, delivery or performance of this Agreement, nor the consummation of
the Merger or any of the other transactions contemplated by this Agreement, will
result in any payment (including any bonus, golden parachute or severance
payment) to any current or former employee or director of the Company (whether
or not under any plan), or materially increase the
13.
<PAGE>
benefits payable under any plan, or result in any acceleration of the time of
payment or vesting of any such benefits.
(e) The Company is in compliance with all applicable Legal
Requirements and Contracts relating to employment, employment practices, wages,
bonuses and terms and conditions of employment, including employee compensation
matters, except where the failure to be in compliance would not have a Material
Adverse Effect on the Company.
2.8 LITIGATION. There is no Legal Proceeding pending or, to the Company's
knowledge, threatened by or before any court or Governmental Authority that
involves the Company or any of the assets owned or used by the Company. The
Company is not a party to any decree, order, writ, injunction, judgment or
arbitration award (or agreement entered into in any Legal Proceeding) with
respect to its properties, assets, personnel or business activities.
2.9 PROPERTIES.
(a) Part 2.9(a) of the Company Disclosure Schedule sets forth each
lease of real and personal property to which the Company is a party (the
"Leases"). The Company has previously delivered to Parent complete and accurate
copies of all the Leases. Each of the Leases is valid, binding and enforceable
in accordance with its terms, except as enforcement thereof may be limited by
bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors' rights generally, as limited by
laws relating to the availability of specific performance, injunctive relief, or
by general equitable principles, and to the extent any indemnification or
contribution provisions thereof may be limited by applicable federal or state
securities laws. The Company has not breached, nor has the Company received in
writing any claim or threat that it has breached, in any material respect, and
no default has occurred under any of the Leases and, to the Company's knowledge,
(i) none of the other contracting parties has violated or breached, and no
default has occurred under any of the Leases, and (ii) other than the
transactions contemplated hereby, no event has occurred, and no circumstance or
condition exists which with the giving of notice or the lapse of time, or both,
will, or could reasonably be expected to, result in a violation, breach or
default under any of the Leases or give any Person the right to cancel,
terminate or modify any of the Leases. The Company does not own any real
property.
(b) The Company has, and at all times since June 1, 1995, has
continuously had, in effect fire, casualty, property, comprehensive general
liability including product/completed operations and contractual liability
coverage, and directors and officers insurance policies, with extended coverage
(subject to deductibles), sufficient to allow the Company to replace any of its
properties that might be damaged or destroyed, and reasonably adequate to
protect it and its financial condition against the risks involved in the
business conducted by it. Part 2.9(b) of the Company Disclosure Schedule lists
all such policies. The Company has not done anything by way of action or
inaction which might invalidate any of such policies in whole or in part and the
Company has not received any notice or other indication that any such policies
would be cancelled or that any such policies were no longer in full force or
effect or that the issuer of any policy is not willing or able to perform its
obligations thereunder.
14.
<PAGE>
2.10 ENVIRONMENTAL MATTERS. To the knowledge of the Company, no current or
prior owner of any property leased or controlled by the Company has received any
notice (in writing or otherwise), whether from a Governmental Authority,
citizens group, employee or otherwise, that alleges that such current or prior
owner or the Company is not in compliance with any Environmental Law. To the
knowledge of the Company, all property that is leased to, controlled by or used
by the Company, and all surface water, groundwater and soil associated with or
adjacent to such property is in clean and healthful condition and is free of any
material environmental contamination of any nature. For purposes of this
Section 2.10: (i) "Environmental Law" means any federal, state, local or foreign
Legal Requirement relating to pollution or protection of human health or the
environment (including ambient air, surface water, ground water, land surface or
subsurface strata), including any law or regulation relating to emissions,
discharges, releases or threatened releases of Materials of Environmental
Concern, or otherwise relating to the manufacture, processing, distribution,
use, treatment, storage, disposal, transport or handling of Materials of
Environmental Concern; and (ii) "Materials of Environmental Concern" include
chemicals, pollutants, contaminants, wastes, toxic substances, petroleum and
petroleum products and any other substance that is now or hereafter regulated by
any Environmental Law or that is otherwise a danger to health, reproduction or
the environment.
2.11 COMPLIANCE WITH LEGAL REQUIREMENTS. The Company is, and has at all
times since December 31, 1995 been, in compliance with all applicable Legal
Requirements, except where the failure to comply with such Legal Requirements
has not had and would not reasonably be expected to have a Material Adverse
Effect on the Company.
2.12 TRANSACTIONS WITH AFFILIATES. Except as set forth in the Company SEC
Documents, since the date of the Company's last proxy statement filed with the
SEC, no event has occurred that would be required to be reported by the Company
pursuant to Item 404 of Regulation S-K promulgated by the SEC. Part 2.12 of the
Company Disclosure Schedule identifies each person who is an "affiliate," as
that term is used in paragraphs (c) and (d) of Rule 145 under the Securities
Act, of the Company ("Company Affiliates"), as of the date of this Agreement.
2.13 VOTE REQUIRED. The affirmative vote of the holders of a majority of
the shares of Company Common Stock and the affirmative vote of the holders of
shares of the Company Preferred Stock (calculated on an as-converted basis),
voting as separate classes, outstanding on the record date for the Company
Stockholders' Meeting (the "Required Company Stockholder Vote") are the only
votes of the holders of any class or series of the Company's capital stock
necessary to adopt and approve this Agreement, the Merger and the other
transactions contemplated by this Agreement.
2.14 COMPANY ACTION. The Board of Directors of the Company (at a meeting
duly called and held) has (a) unanimously determined that the Merger is in the
best interests of the Company and its stockholders, (b) unanimously approved
this Agreement and the Merger in accordance with the provisions of Section 251
of the DGCL, (c) unanimously recommended the adoption and approval of this
Agreement and the Merger by the stockholders of the Company and directed that
the Merger be submitted for consideration by the Company's stockholders at the
Company Stockholders' Meeting, (d) taken all necessary steps to render
Section 203 of the DGCL inapplicable to the Merger and the other transactions
contemplated by this Agreement
15.
<PAGE>
and (e) adopted a resolution having the effect of causing the Company not to be
subject, to the extent permitted by applicable law, to any state takeover law
that may purport to be applicable to the Merger and the other transactions
contemplated by this Agreement.
2.15 FAIRNESS OPINION. The Company's Board of Directors has received the
written opinion of Hambrecht & Quist, financial advisor to the Company, dated
the date of this Agreement, to the effect that the consideration to be received
by the Company Stockholders is fair to the Company Stockholders from a financial
point of view and such written opinion has not been withdrawn or otherwise
modified by Hambrecht & Quist. The Company has furnished an accurate and
complete copy of said written opinion to Parent.
2.16 FINANCIAL ADVISOR. The Company represents and warrants that, except
for Hambrecht & Quist, no broker, finder or investment banker is entitled to any
brokerage, finder's or other fee or commission in connection with the Merger or
any of the other transactions contemplated by this Agreement based on
arrangements made by or on behalf of the Company. A copy of the Company's
agreement with Hambrecht & Quist has been delivered to Parent.
2.17 ENFORCEABILITY. The Company has all requisite corporate power and
authority to execute, deliver and, subject to obtaining requisite stockholder
approval, to perform its obligations under this Agreement and all other
agreements, documents and instruments contemplated hereby to which it is or will
become a party. The execution and delivery of this Agreement and the other
agreements, documents and instruments contemplated hereby have been duly and
validly authorized by the Board of Directors of the Company, and no other
corporate proceedings on the part of the Company are necessary for the Company
to authorize any of such agreements, documents or instruments and no such
corporate proceedings (other than the approval of the Company Stockholders) are
necessary to enable the Company to consummate the Merger or any of the other
transactions contemplated by this Agreement. All agreements, documents and
instruments to be executed in connection with the Merger (a) have been (or will
be) duly executed and delivered by duly authorized officers of the Company and
(b) constitute (or, when executed by the Company, will constitute) legal, valid
and binding obligations of the Company enforceable against it in accordance with
their terms, except as enforcement may be limited by bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting
enforcement of creditors' rights generally, as limited by laws relating to the
availability of specific performance, injunctive relief, or by general equitable
principles, and to the extent any indemnification or contribution provisions
thereof may be limited by applicable federal or state securities laws.
2.18 GOVERNMENTAL CONSENTS; NO CONFLICTS. Except as may be required by the
Exchange Act, the Securities Act, state securities or blue sky laws, the DGCL,
and the NASD bylaws and the rules and regulations of the American Stock Exchange
(as they relate to the S-4 Registration Statement and the Prospectus/Joint Proxy
Statement), there is no requirement applicable to the Company to make any filing
with, or to obtain any permit, authorization, or Consent of, any Governmental
Authority as a condition to the consummation of the Merger or any of the other
transactions contemplated by this Agreement. Neither the execution and delivery
of this Agreement and the other agreements, documents and instruments
contemplated hereby by the Company nor the consummation by the Company of the
Merger or any of the other transactions contemplated by this Agreement will
(a) violate the Certificate of
16.
<PAGE>
Incorporation or Bylaws of the Company, (b) result in a default (or with notice
or lapse of time or both would result in a default) under, or materially impair
the rights of the Company or materially alter the rights or obligations of any
third party under, or require the Company to make any material payment or become
subject to any material liability to any third party under, or give rise to any
right of termination, amendment, cancellation, acceleration, repurchase, put or
call under, any of the terms, conditions or provisions of any Material Company
Contract, (c) result in the creation of any material (individually or in the
aggregate) Encumbrance on any of the assets of the Company or (d) conflict with
or violate any law, statute, rule, regulation, judgment, order, writ,
injunction, decree or arbitration award applicable to the Company or any of its
assets, which conflict or violation has had or would reasonably be expected to
have a Material Adverse Effect on the Company.
2.19 TITLE TO ASSETS. The Company owns, and has good, valid and marketable
title to, or, in the case of leased assets, valid leasehold interests in, all
assets reflected on the March 1998 Balance Sheet. All of said assets are owned
or leased by the Company free and clear of any Encumbrances, except for (a) any
lien for current taxes not yet due and payable, (b) minor liens that have arisen
in the ordinary course of business and that do not (individually or in the
aggregate) materially detract from the value of the assets subject thereto or
would not have a Material Adverse Effect on the Company, (c) liens described in
Part 2.19 of the Company Disclosure Schedule, and (d) Liabilities reflected in
the March 1998 Balance Sheet.
2.20 COMPANY PREFERRED STOCK CONVERSION. Each share of the Company
Preferred Stock is convertible in accordance with the Company Certificate of
Incorporation and each of the holders of Company Preferred Stock has entered
into an agreement with the Company confirming such conversion.
2.21 NO EXISTING DISCUSSIONS. On the date hereof, neither the Company, nor
any Representative of the Company, is engaged, directly or indirectly, in any
discussions or negotiations with any other Person relating to any Acquisition
Proposal.
2.22 STOCK OPTIONS. Under the terms (as in effect as of the date hereof)
of each stock option agreement by which any Company Option is evidenced, in
connection with the Merger, all outstanding Company Options shall automatically
accelerate and become fully exercisable for all of the shares of Company Common
Stock subject to such Company Options and, to the extent such Company Options
are not exercised prior to the Effective Time, shall terminate and cease to
remain outstanding immediately after the Effective Time.
2.23 WAIVER. The holders of the Company Preferred Stock have waived their
right to purchase shares of 6% Series B Convertible Preferred Stock of the
Company and their right to require the Company to redeem any of the outstanding
shares of Company Preferred Stock.
2.24 DISCLOSURE.
(a) The copies of all documents furnished by the Company pursuant to
the terms of this Agreement are complete and accurate copies of the original, as
such documents may have been amended to date.
17.
<PAGE>
(b) The Company has timely filed all required forms, reports and
documents required to be filed with the SEC and the American Stock Exchange.
(c) None of the representations and warranties of the Company
contained in Article 2 of this Agreement or in any other Article of this
Agreement or the information disclosed in the Company Disclosure Schedule
contains any untrue statement of a material fact or omits to state any material
fact required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they are made, not
misleading.
(d) None of the information supplied or to be supplied by the Company
for inclusion or incorporation by reference in the Form S-4 registration
statement to be filed with the SEC by Parent in connection with the issuance of
the Merger Shares (the "S-4 Registration Statement") will, at the time the S-4
Registration Statement is filed with the SEC or at the time the S-4 Registration
Statement becomes effective under the Securities Act, contain any untrue
statement of a material fact or omit to state any material fact required to be
stated therein or necessary in order to make the statements therein, in light of
the circumstances under which they are made, not misleading. None of the
information supplied or to be supplied by the Company for inclusion or
incorporation by reference in the Prospectus/Joint Proxy Statement, will, at the
time the Prospectus/Joint Proxy Statement is mailed to the stockholders of the
Company or the stockholders of Parent, at the time of the Company Stockholders'
Meeting or the Parent Stockholders' Meeting and as of the Effective Time,
contain any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they are made, not
misleading. Notwithstanding the foregoing, no representation or warranty is
made by the Company with respect to statements made about the Parent or Merger
Sub or based on information supplied by Parent or Merger Sub or any of their
representatives which is contained in the S-4 Registration Statement or the
Prospectus/Joint Proxy Statement. The Prospectus/Joint Proxy Statement will
comply as to form in all material respects with the provisions of the Exchange
Act and the rules and regulations promulgated by the SEC thereunder.
ARTICLE 3
REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB
Parent and Merger Sub represent and warrant to the Company that, except as
set forth in the Parent SEC Documents filed prior to the date of this Agreement
or in the disclosure schedules delivered by Parent to the Company dated and
signed as of that date of this Agreement by an executive officer of Parent
(collectively, the "Parent Disclosure Schedule"):
3.1 ORGANIZATION.
(a) Each of Parent and Merger Sub is a corporation duly organized,
validly existing and in good standing under the laws of the State of Delaware.
Each of Parent and Merger Sub has all requisite corporate power and authority to
(i) own and use its assets in the manner in which its assets are currently owned
and used, and (ii) to carry on its business as presently conducted. Except for
Merger Sub, Parent has no subsidiaries.
18.
<PAGE>
(b) Each of Parent and Merger Sub is qualified to do business as a
foreign corporation and is in good standing under the laws of all jurisdictions
where the nature of its business requires such qualification and where the
failure to be so qualified would have a Material Adverse Effect on Parent or
Merger Sub.
(c) As of the date of this Agreement, the authorized capital stock of
Parent consists of: 60,000,000 shares of Parent Common Stock, $.01 par value,
14,669,844 shares of which are issued and outstanding; and 10,000,000 shares of
Preferred Stock, par value $.01 per share, none of which are issued and
outstanding. As of the date of this Agreement, Parent had outstanding options to
purchase a total of 2,135,821 shares of Parent Common Stock (minus any Parent
Options exercised on the date hereof) under the 1997 Equity Incentive Plan and
2,840,642 shares of Parent Common Stock are reserved for future grant under the
1997 Equity Incentive Plan. As of the date of this Agreement, warrants to
purchase 93,687 shares of Parent Common Stock (minus any Parent Warrants
exercised on the date hereof) were outstanding. Except as set forth above and
except for 125,000 shares of Parent Common Stock reserved for issuance pursuant
to Parent's Non-employee Directors' Stock Option Plan, 7,500 of which are issued
and outstanding, and 250,000 shares of Parent Common Stock reserved for issuance
pursuant to Parent's Employee Stock Purchase Plan, no shares of which have been
issued and are outstanding and 250,000 shares of which remain available for
purchase, there are no shares of capital stock of Parent authorized, issued or
outstanding or any outstanding subscriptions, options, warrants, stock
appreciation rights, calls, rights, convertible securities or other securities
convertible into, exchangeable for, or evidencing the right to subscriber for,
any shares of capital stock of Parent. All the issued and outstanding shares of
Parent Common Stock are validly issued, fully paid and nonassessable. None of
the outstanding shares of Parent Common Stock is entitled or subject to (i) any
preemptive right, right of participation, right of maintenance or any similar
right, or (ii) any right of first refusal in favor of any Person.
(d) As of the date of this Agreement, the authorized capital stock of
Merger Sub consists of 10,000 shares of Common Stock, par value $.01 per share,
100 of which are issued and outstanding and are held beneficially and of record
by Parent.
(e) Except as set forth above, as of the date of this Agreement, (i)
there are no shares of capital stock of Parent authorized, issued or
outstanding, (ii) there are no outstanding subscriptions, options, warrants,
stock appreciation right plans, calls, rights, convertible securities,
stockholder rights plans (or similar plans commonly referred to as "poison
pills") or other agreements or commitments of any character relating to issued
or unissued capital stock or other securities of Parent, or obligating Parent
or, to Parent's knowledge, any other Person, to issue, transfer or sell any
shares of the capital stock or other securities of Parent, (iii) there are no
other outstanding securities convertible into, exchangeable for or evidencing
the right to subscribe for any shares of the capital stock or other securities
of Parent, and (iv) there is no condition or circumstance that may give rise to
or provide a basis for the assertion of a claim by any Person to the effect that
such Person is entitled to acquire or receive any shares of capital stock or
other securities of Parent.
(f) Complete and accurate copies of the Certificate of Incorporation
and Bylaws of Parent, and Parent's 1997 Equity Incentive Plan, 1997 Non-employee
Directors' Stock Option Plan and Employee Stock Purchase Plan, each as amended
to date, are filed as
19.
<PAGE>
exhibits to the Parent SEC Documents (as defined in Section 3.2(a)) and have
been delivered to the Company. Complete and accurate copies of the Certificate
of Incorporation and Bylaws of Merger Sub have been delivered to the Company.
3.2 SEC FILINGS; FINANCIAL STATEMENTS.
(a) Parent has made available to the Company a complete and accurate
copy of each report, schedule, registration statement and definitive proxy
statement filed by Parent with the SEC on or after November 21, 1997 (the
"Parent SEC Documents"), which are all the forms, reports and documents required
to be filed by Parent with the SEC since November 21, 1997, the date of Parent's
initial public offering of its Common Stock. As of the time it was filed with
the SEC (or if amended or superseded by a filing prior to the date of this
Agreement, then on the date of such filing): (i) each of the Parent SEC
Documents complied in all material respects with the published requirements of
the Securities Act or the Exchange Act, as the case may be; and (ii) none of the
Parent SEC Documents contained any untrue statement of a material fact or
omitted to state a material fact required to be stated therein or necessary in
order to make the statements therein, in light of the circumstances under which
they were made, not misleading.
(b) Each of the financial statements (including, in each case, any
related notes thereto) contained in the Parent SEC Documents (i) complied as
to form in all material respects with the published rules and regulations of
the SEC applicable thereto, (ii) was prepared in accordance with GAAP applied
on a consistent basis throughout the periods involved (except as may be
indicated in the notes thereto and except that the unaudited interim
financial statements are subject to normal year-end audit adjustments which
were not, or are not, expected to be material in amount and do not contain
footnotes), and (iii) fairly presented the financial position of Parent as at
the respective dates thereof and the results of operations and cash flows for
the periods indicated.
(c) Parent has previously furnished to the Company a complete and
correct copy of any amendments or modifications that have not yet been filed
with the SEC but that are required to be filed to agreements, documents or other
instruments which previously had been filed by Parent with the SEC pursuant to
the Securities Act or the Exchange Act.
(d) Parent has no Liabilities, except for (i) any Liabilities set
forth in Parent's unaudited financial statements (including the notes thereto)
filed with the SEC as part of Parent's quarterly report on Form 10-Q for the
quarter ended March 31, 1998, (ii) any Liabilities which were incurred after
March 31, 1998 in the ordinary course of business consistent with past practice,
or (iii) other Liabilities which, individually or in the aggregate, have not had
and would not reasonably be expected to have a Material Adverse Effect on
Parent.
3.3 ABSENCE OF CERTAIN CHANGES OR EVENTS. Since December 31, 1997, there
has not been (a) any change, or any development or combination of developments
that has had or would reasonably be expected to have a Material Adverse Effect
on Parent, (b) any damage, destruction or loss, whether or not covered by
insurance which has had or would reasonably be expected to have a Material
Adverse Effect on Parent and (c) any declaration, accrual, set aside or payments
of any dividend or distribution by Parent.
20.
<PAGE>
3.4 TAX MATTERS.
(a) All Tax Returns required to be filed by or on behalf of Parent
with any Governmental Authority on or before the Closing Date (i) have been or
will be filed on or before the applicable due date (including any extensions of
such due date that expire prior to the Closing Date), and (ii) have been, or
will be when filed, prepared in all material respects in compliance with all
applicable Legal Requirements. All amounts shown on Parent's Tax Returns to be
due on or before the Closing Date have been or will be paid on or before the
Closing Date except for amounts which, individually or in the aggregate, could
not reasonably be expected to have a Material Adverse Effect on Parent.
(b) To the knowledge of Parent, the Parent Financial Statements fully
accrue all Taxes with respect to all periods through the dates thereof in
accordance with generally accepted accounting principles. Parent will
establish, in the ordinary course of business and consistent with its past
practices, reserves reasonably adequate for the payment of all Taxes through the
Closing Date, except for amounts which, individually or in the aggregate, could
not reasonably be expected to have a Material Adverse Effect on Parent.
(c) No claim or Legal Proceeding is pending or, to the knowledge of
Parent, has been threatened against or with respect to Parent in respect of any
Tax. There are no unsatisfied liabilities for material Taxes (including
liabilities for interest, additions to tax and penalties thereon and related
expenses) with respect to any notice of deficiency or similar document received
by Parent with respect to any material Tax (other than liabilities for Taxes
asserted under any such notice of deficiency or similar document which are being
contested in good faith by Parent and with respect to which adequate reserves
for payment have been established). There are no liens for material Taxes upon
any of the assets of Parent except liens for current Taxes not yet due and
payable. Parent has not entered into or become bound by any agreement or
consent pursuant to Section 341(f) of the Code. Parent has not been, and will
not be, required to include any adjustment in taxable income for any tax period
(or portion thereof) pursuant to Section 481 or 263A of the Code or any
comparable provision under state or foreign Tax laws as a result of transactions
or events occurring, or accounting methods employed, prior to the Closing.
(d) To the knowledge of Parent, there is no agreement, plan,
arrangement or other Contract covering any employee or independent contractor or
former employee or independent contractor of Parent that, considered
individually or considered collectively with any other such Contracts, will, or
could reasonably be expected to, give rise directly or indirectly to the payment
of any amount that would not be deductible pursuant to Section 280G or
Section 162 of the Code. Parent is not a party to or bound by any tax indemnity
agreement, tax sharing agreement, tax allocation agreement or similar Contract.
3.5 LITIGATION. There is no Legal Proceeding pending or threatened by or
before any court or Governmental Authority that involves Parent or any of the
assets owned or used by Parent. Parent is not a party, as of the date of this
Agreement, to any decree, order or arbitration award (or agreement entered into
in any Legal Proceeding with any Governmental Authority) with respect to its
property, assets, personnel or business activities.
21.
<PAGE>
3.6 COMPLIANCE WITH LEGAL REQUIREMENTS. Parent is, and has at all times
since December 31, 1995 been, in compliance with all applicable Legal
Requirements, except where the failure to comply with such Legal Requirements
has not had and would not reasonably be expected to have a Material Adverse
Effect on Parent.
3.7 VALID ISSUANCE. The shares of Parent Common Stock to be issued to the
Company Stockholders in the Merger, when issued by Parent pursuant to the terms
of this Agreement, will be duly authorized, validly issued, fully paid and
nonassessable, will be issued in compliance with applicable federal and state
securities laws and will be issued free and clear of any lien, pledge, security
interest, encumbrance, claim or equitable interest, and no preemptive right,
right of first refusal, registration right or other similar right of
stockholders exists with respect to such shares or the issuance thereof or the
inclusion thereof in the S-4 Registration Statement.
3.8 VOTE REQUIRED. The affirmative vote of the holders of a majority of
the shares of Parent Common Stock outstanding on the record date for the Parent
Stockholders' Meeting (the "Required Parent Stockholder Vote") is the only vote
of the holders of any class or series of Parent's capital stock necessary to
adopt and approve this Agreement, the Merger and the transactions contemplated
by this Agreement.
3.9 PARENT ACTION. The Board of Directors of Parent (at a meeting duly
called and held) has (a) unanimously determined that the Merger is in the best
interests of Parent and its stockholders, (b) unanimously approved this
Agreement and the Merger in accordance with the provisions of Section 251 of the
DGCL, (c) unanimously recommended the adoption and approval of this Agreement
and the Merger by the stockholders of Parent and directed that the Merger be
submitted for consideration by Parent's stockholders at the Parent Stockholders'
Meeting, and (d) taken all necessary steps to render Section 203 of the DGCL
inapplicable to the Merger and the other transactions contemplated by this
Agreement.
3.10 FAIRNESS OPINION. Parent's Board of Directors has received the
written opinion of Furman Selz LLC, financial advisor to Parent, dated the date
of this Agreement, to the effect that the Merger is fair to Parent from a
financial point of view and such written opinion has not been withdrawn or
otherwise modified by Furman Selz LLC. Parent has furnished an accurate and
complete copy of said written opinion to the Company.
3.11 FINANCIAL ADVISOR. Parent represents and warrants that, except for
Furman Selz LLC, no broker, finder or investment banker is entitled to any
brokerage, finder's or other fee or commission in connection with the Merger or
any of the other transactions contemplated by this Agreement.
3.12 ENFORCEABILITY. Each of Parent and Merger Sub has all requisite
corporate power and authority to execute, deliver and, subject to obtaining
requisite stockholder approval, to perform its obligations under this Agreement
and all other agreements, documents and instruments contemplated hereby to which
it is or will become a party. The execution and delivery of this Agreement and
the other agreements, documents and instruments contemplated hereby have been
duly and validly authorized by the Board of Directors of Parent and Merger Sub
and no other corporate proceedings on the part of Parent or Merger Sub are
necessary for
22.
<PAGE>
Parent or Merger Sub to authorize any of such agreements, documents or
instruments and no such corporate proceedings (other than the approval of
Parent's stockholders) are necessary to enable Parent or Merger Sub to
consummate the Merger or any of the other transactions contemplated by this
Agreement. All agreements, documents and instruments to be executed in
connection with the Merger (a) have been (or will be) duly executed and
delivered by duly authorized officers of Parent and Merger Sub and (b)
constitute (or, when executed by Parent and Merger Sub, will constitute) legal,
valid and binding obligations of Parent and Merger Sub enforceable against it in
accordance with their terms, except as enforcement thereof may be limited by
bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors' rights generally, as limited by
laws relating to the availability of specific performance, injunctive relief, or
by general equitable principles, and to the extent any indemnification or
contribution provisions thereof may be limited by applicable federal or state
securities laws.
3.13 GOVERNMENTAL CONSENT; NO CONFLICTS. Except as may be required by the
Exchange Act, the Securities Act, state securities or blue sky laws, the DGCL,
and the NASD bylaws (as they relate to the S-4 Registration Statement and the
Prospectus/Joint Proxy Statement), there is no requirement applicable to Parent
or Merger Sub to make any filing with, or to obtain any permit, authorization,
or Consent of, any Governmental Authority as a condition to the consummation by
Parent and Merger Sub of the Merger. Neither the execution and delivery of this
Agreement and the other agreements, documents and instruments contemplated
hereby by Parent or Merger Sub nor the consummation by Parent or Merger Sub of
the Merger or any of the other transactions contemplated by this Agreement will
(a) violate the Certificate of Incorporation or Bylaws of Parent or the
Certificate of Incorporation or Bylaws of Merger Sub, (b) result in a default
(or with notice or lapse of time would result in a default) under, or materially
impair the rights of Parent or Merger Sub or materially alter the rights or
obligations of any third party under, or require Parent or Merger Sub to make
any material payment or become subject to any material liability to any third
party under, or give rise to any right of termination, amendment, cancellation,
acceleration, repurchase, put or call under, any of the terms, conditions or
provisions of any material note, bond, mortgage, indenture, license agreement,
lease or other contract, instrument or obligation to which Parent or Merger Sub
is a party or by which Parent or Merger Sub or any of their respective assets
may be bound, (c) result in the creation of any material (individually or in the
aggregate) Encumbrance on any of the assets of Parent or Merger Sub or (d)
conflict with or violate any law, statute, rule, regulation, judgment, order,
writ, injunction, decree or arbitration award applicable to Parent or Merger Sub
or any of their respective assets, which conflict or violation has had or would
reasonably be expected to have a Material Adverse Effect on Parent or Merger
Sub.
3.14 DISCLOSURE.
(a) The copies of all documents furnished by Parent pursuant to the
terms of this Agreement are complete and accurate copies of the original, as
such documents may have been amended to date.
(b) Parent has timely filed all required forms, reports and documents
required to be filed with the SEC and the NASD.
23.
<PAGE>
(c) None of the representations and warranties of Parent or Merger
Sub contained in Article 3 of this Agreement or in any other Article of this
Agreement or the information disclosed in the Parent Disclosure Schedule
contains any untrue statement of a material fact or omits to state any material
fact required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they are made, not
misleading.
(d) None of the information supplied or to be supplied by Parent for
inclusion or incorporation by reference in the S-4 Registration Statement will,
at the time the S-4 Registration Statement is filed with the SEC or at the time
the S-4 Registration Statement becomes effective under the Securities Act,
contain any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they are made, not
misleading. None of the information supplied or to be supplied by Parent for
inclusion or incorporation by reference in the Prospectus/Joint Proxy Statement
will, at the dates mailed to the stockholders of Parent or the stockholders of
the Company, at the time of the Parent Stockholders' Meeting or the Company
Stockholders' Meeting and as of the Effective Time, contain any untrue statement
of a material fact or omit to state any material fact required to be stated
therein or necessary in order to make the statements therein, in light of the
circumstances under which they are made, not misleading. Notwithstanding the
foregoing, no representation or warranty is made by Parent or Merger Sub with
respect to statements made about the Company or based on information supplied by
the Company or any of its Representatives which is contained in the S-4
Registration Statement or the Prospectus/Joint Proxy Statement. The
Prospectus/Joint Proxy Statement will comply as to form in all material respects
with the provisions of the Exchange Act and the rules and regulations
promulgated by the SEC thereunder.
3.15 INTERIM OPERATIONS OF MERGER SUB. Merger Sub has been formed solely
for the purpose of engaging in the transactions contemplated by this Agreement
and has not engaged in any business activities or conducted any operations other
than in connection with the transactions contemplated hereby.
3.16 PARENT CONTRACTS. Except as would not, individually or in the
aggregate, have a Material Adverse Effect on Parent, the contracts between
Parent and each of Japan Tobacco Inc., Procter & Gamble Pharmaceuticals, Inc.
and N.V. Organon (collectively, the "Material Parent Contracts") are each in
full force and effect and are enforceable against Parent and, to Parent's
knowledge, are enforceable against the other parties thereto, except as
enforcement thereof may be limited by bankruptcy, insolvency, reorganization,
moratorium and other laws of general application affecting enforcement of
creditors' rights generally, as limited by laws relating to the availability of
specific performance, injunctive relief, or by general equitable principles, and
to the extent any indemnification or contribution provisions thereof may be
limited by applicable federal or state securities laws. Parent has not
breached, nor has Parent received in writing any claim or threat that it has
breached, in any material respect, and no default has occurred under any of the
Material Parent Contracts and, to Parent's knowledge, (i) none of the other
contracting parties has violated or breached, and no default has occurred under
any of the Material Parent Contracts, and (ii) other than the transactions
contemplated hereby, no event has occurred, and no circumstance or condition
exists which with the giving of notice or the lapse of time, or both, will, or
could reasonably be expected to, result in a violation, breach or default under
any
24.
<PAGE>
Material Parent Contract or give any Person the right to cancel, terminate or
modify any Material Parent Contract. To Parent's knowledge, Parent's
relationship with each other party under a Material Parent Contract is good.
To Parent's knowledge, no party to a Material Parent Contract currently in
effect has given notice to Parent of intent to terminate such Material Parent
Contract in a way that would have a Material Adverse Effect on Parent.
ARTICLE 4
COVENANTS; ADDITIONAL AGREEMENTS
4.1 PARENT ACCESS AND INVESTIGATION. During the period from the date of
this Agreement through the Effective Time (the "Pre-Closing Period"), the
Company shall, and shall cause its Representatives to: (a) provide Parent and
Parent's Representatives with reasonable access during normal business hours to
the Company's Representatives, personnel and assets and to all existing books,
records, Tax Returns, work papers and other documents and information relating
to the Company; and (b) provide Parent and Parent's Representatives with such
copies of the existing books, records, Tax Returns, work papers and other
documents and information relating to the Company, and with such additional
financial, operating and other data and information regarding the Company as
Parent may reasonably request.
4.2 COMPANY ACCESS AND INVESTIGATION. During the Pre-Closing Period,
Parent shall, and shall cause its Representatives to: (a) provide the Company
and the Company's Representatives with reasonable access during normal business
hours to Parent's and its Representatives', personnel and assets and to all
existing books, records, Tax Returns, work papers and other documents and
information relating to Parent; and (b) provide the Company and the Company's
Representatives with such copies of the existing books, records, Tax Returns,
work papers and other documents and information relating to Parent, and with
such additional financial, operating and other data and information regarding
Parent, as the Company may reasonably request.
4.3 CONFIDENTIALITY. The parties acknowledge that Parent and the Company
have previously executed Confidentiality Agreements (the "Confidentiality
Agreements"), which Confidentiality Agreements shall continue in full force and
effect in accordance with their respective terms and which Confidentiality
Agreements shall be applicable to any information obtained pursuant to this
Article 4.
4.4 CONDUCT OF THE COMPANY'S BUSINESS.
(a) During the Pre-Closing Period, the Company shall: (i) conduct
its business and operations (A) in the ordinary course and consistent with past
practices and (B) in compliance in all material respects with all applicable
Legal Requirements and the requirements of all Material Company Contracts,
except to the extent that the failure to be in compliance would not have a
Material Adverse Effect on the Company; (ii) use reasonable efforts to preserve
intact its current business organization, keep available the services of its
current officers and employees and maintain its relations and goodwill with all
suppliers, landlords, creditors, collaborators, joint venture partners,
licensors, licensees, employees and other Persons having business relationships
with the Company; (iii) keep in full force all insurance policies to which it
25.
<PAGE>
is a party as of the date of this Agreement; (iv) use reasonable efforts to
provide all notices, assurances and support required by any Company Contract
relating to any material Company Proprietary Asset in order to ensure that no
condition under such Company Contract occurs which could result in, or could
increase the likelihood of any transfer or disclosure of any material Company
Proprietary Asset; (v) provide to Parent bi-weekly updates of the Company's
financial position in an amount of detail reasonably satisfactory to Parent, and
(vi) to the extent requested by Parent, cause its officers to report regularly
to Parent concerning the status of the Company's business including any
corporate partnership discussions or other discussions with respect to any
collaborations between the Company and third parties, and will provide regular
status reports of such discussions.
(b) During the Pre-Closing Period, the Company shall not, without
Parent's prior written consent:
(i) declare, accrue, set aside or pay any dividend or
make any other distribution in respect of any capital stock (other than any
dividend required to be paid pursuant to the terms of the Company Certificate
of Incorporation on the Company Preferred Stock);
(ii) repurchase, redeem or otherwise acquire any capital
stock or other securities of the Company (other than any redemption of
Company Preferred Stock in accordance with the Company Certificate of
Incorporation);
(iii) sell, issue, grant or authorize the grant of any
shares of capital stock of the Company or any securities convertible into, or
rights, warrants or options to acquire, any such shares of capital stock or
other convertible securities (except that the Company may issue Company
Common Stock upon the exercise of Company Options and Company Warrants
outstanding on the date of this Agreement in accordance with their present
terms);
(iv) amend or waive any of its rights under, or
accelerate the vesting under, any provision of any of the Company's stock
option plans, any provision of any agreement evidencing any outstanding stock
option or any restricted stock purchase agreement, or otherwise modify any of
the terms of any of the Company's stock option or other employee benefit
plans or any outstanding option, warrant or other equity security of the
Company;
(v) amend the Company Certificate of Incorporation or
Bylaws, adopt any stock purchase rights plan (or "poison pill") or effect or
become a party to any merger, consolidation, share exchange, business
combination, recapitalization, reclassification of shares, stock split,
reverse stock split or similar transaction;
(vi) acquire (by purchasing any material portion of the
capital stock or assets of or by any other means) any business or any Entity
or division thereof;
(vii) form any subsidiary or acquire any equity interest
or other interest in any other Entity;
(viii) acquire, lease or license any right or other asset
from any other Person or sell or otherwise dispose of, or lease or license,
any right or other asset to any other Person (except, in each case, for
immaterial assets acquired, leased, licensed or disposed of by
26.
<PAGE>
the Company in the ordinary course of business and consistent with past
practices), or waive any material provision;
(ix) except pursuant to lines of credit (including that
certain $2,000,000 line of credit evidenced by that certain Loan Agreement
between Parent and the Company) and subject to credit limits in effect prior
to the date of this Agreement in amounts not to exceed in the aggregate
$10,000, incur any indebtedness for borrowed money, or issue or sell any debt
securities or guarantee, endorse or otherwise become responsible for any
obligation of any other Person;
(x) make any loan or advance to any Person, other than
travel and similar advances to employees in the ordinary course of business
consistent with past practice;
(xi) prepay any material claim, Liability or obligation,
or pay, discharge or satisfy any material unliquidated or contingent
Liability;
(xii) enter into or amend any employment agreement,
severance agreement, special pay arrangement with respect to termination of
employment or other similar arrangement or agreement with any director,
officer or employee of the Company, or establish, adopt or amend any employee
benefit plan;
(xiii) pay any bonus or make any profit-sharing or similar
payment or change any compensation payable or to become payable to any of its
directors, officers or employees (other than any adjustment to the salary of
any non-exempt and exempt employee that is made in the ordinary course of
business consistent with past practice or bonuses payable in accordance with
existing bonus obligations or plans);
(xiv) change any of the Company's methods of accounting or
accounting practices in any material respect;
(xv) except in the ordinary course of business consistent
with past practice, enter into any material Contract or amend or terminate,
or waive any material provision under, any Material Company Contract;
(xvi) make any capital expenditure in excess of $10,000;
(xvii) make or fail to make any material election concerning
the term, scope or termination of any real property Lease, or waive any material
provision of any such Lease or enter into any new real property lease;
(xviii) commence, settle or compromise any Legal Proceeding;
(xix) engage in any transaction with any stockholder,
director, officer or employee other than in the ordinary course of business
consistent with past practice;
(xx) enter into any material transaction or take any
other material action outside the ordinary course of business or inconsistent
with past practice; or
27.
<PAGE>
(xxi) authorize or propose, or enter into any Contract
contemplating, any of the items or actions set forth in clauses (i) through
(xx) above.
4.5 CONDUCT BY PARENT. During the Pre-Closing Period, Parent shall not,
without the prior written consent of the Company (i) declare, accrue, set aside
or pay any dividend or any other distribution in respect of any shares of its
capital stock, (ii) repurchase, redeem or otherwise reacquire any shares of its
capital stock or other securities, or (iii) amend or permit the adoption of any
amendments to its Certificate of Incorporation or bylaws in a manner that would
materially adversely affect the terms and provisions of the Parent Common Stock,
or (iv) take, or agree in writing or otherwise to take, any of the foregoing
actions.
4.6 NOTIFICATION. During the Pre-Closing Period, each party hereto shall
promptly notify the other party in writing of: (i) the discovery by such party
of any event, condition, fact or circumstance that occurred or existed on or
prior to the date of this Agreement and that caused or constitutes a material
inaccuracy in any representation or warranty made by such party in this
Agreement; (ii) any event, condition, fact or circumstance that occurs, arises
or exists after the date of this Agreement and that would cause or constitute a
material inaccuracy in any representation or warranty made by such party in this
Agreement if (A) such representation or warranty had been made as of the time of
the occurrence, existence or discovery of such event, condition, fact or
circumstance, or (B) such event, condition, fact or circumstance had occurred,
arisen or existed on or prior to the date of this Agreement; (iii) any material
breach of any covenant or obligation of such party; and (iv) any event,
condition, fact or circumstance that would make the timely satisfaction of any
of the conditions set forth in Article 5 or Article 6 impossible or unlikely or
that has had or could reasonably be expected to have a Material Adverse Effect
on any of the parties. No notification given by any party pursuant to this
Section 4.6 shall limit or otherwise affect any of the representations,
warranties, covenants or obligations of such party contained in this Agreement.
4.7 NO SHOP.
(a) During the Pre-Closing Period, the Company shall not permit any
Representative of the Company to, (i) solicit, initiate, or encourage the
making, submission or announcement of any Acquisition Proposal, (ii) furnish any
information regarding the Company to any Person in connection with or in
response to an Acquisition Proposal, (iii) engage in discussions or negotiations
with any Person with respect to any Acquisition Proposal, (iv) subject to
Section 4.9(c), approve, endorse or recommend any Acquisition Proposal or
(v) enter into any letter of intent or similar document or any Contract
contemplating or otherwise relating to any Acquisition Transaction; PROVIDED,
HOWEVER, that: (A) nothing herein shall prohibit the Company's Board of
Directors from disclosing to the Company Stockholders a position with respect to
a tender offer pursuant to Rules 14d-9 and 14e-2 promulgated under the Exchange
Act; (B) nothing herein shall prohibit the Company's Board of Directors from
making any disclosure to the Company Stockholders, if, in the good faith
judgment of the Board of Directors of the Company after consultation with its
outside legal counsel, failure to so disclose would be inconsistent with
applicable laws; and (C) the Company shall not be prohibited by this Section 4.7
from (x) furnishing nonpublic information regarding the Company to any Person in
response to an Acquisition Proposal that is submitted by such Person (and not
withdrawn), or (y) entering into discussions with any Person in response to a
Superior Offer that is submitted by such Person
28.
<PAGE>
(and not withdrawn) if, in either such case: (1) neither the Company nor any
Representative of the Company shall have violated any of the restrictions set
forth in this Section 4.7, (2) the Board of Directors of the Company believes in
good faith, after consultation with its outside legal counsel, that such action
is required in order for the Board of Directors of the Company to avoid a
substantial risk of liability with respect to its fiduciary obligations to the
Company's stockholders under applicable law, (3) prior to furnishing any such
nonpublic information to, or entering into discussions with, such Person, the
Company gives Parent written notice of the identity of such Person and of the
Company's intention to furnish nonpublic information to, or enter into
discussions with, such Person, and the Company receives from such Person an
executed confidentiality agreement containing limitations no less restrictive
than the limitations imposed on Parent pursuant to that certain Mutual
Non-Disclosure Agreement dated as of January 27, 1998 between Parent and the
Company, and (4) contemporaneously furnishing any such nonpublic information to
such Person, the Company furnishes such nonpublic information to Parent (to the
extent such nonpublic information has not been previously furnished by the
Company to Parent). Without limiting the generality of the foregoing, the
Company acknowledges and agrees that any violation of any of the restrictions
set forth in the preceding sentence by any Representative of the Company,
whether or not such Representative is purporting to act on behalf of the
Company, shall be deemed to constitute a breach of this Section 4.7 by the
Company; PROVIDED, HOWEVER, that this sentence shall not limit the rights of any
Representative who is a stockholder of the Company to freely vote his stock and
to exercise all of his rights as a stockholder of the Company, subject to any
contractual restrictions that may apply.
(b) The Company shall promptly advise Parent orally and in writing of
the receipt of any Acquisition Proposal (including the identity of the Person
making or submitting such Acquisition Proposal and the terms thereof) that is
made or submitted by any Person during the Pre-Closing Period or any inquiry
relating to an Acquisition Proposal prior to the Effective Time.
(c) Subject to Section 4.7(a), the Company shall immediately cease
and cause to be terminated any discussions or negotiations with any parties
existing as of the date of this Agreement and that relate to any Acquisition
Proposal.
4.8 REGISTRATION STATEMENT; PROSPECTUS/JOINT PROXY STATEMENT.
(a) As promptly as practicable after the date of this Agreement,
the Company and Parent shall prepare and cause to be filed with the SEC the
Prospectus/Joint Proxy Statement and Parent shall prepare and cause to be
filed with the SEC the S-4 Registration Statement (in which the
Prospectus/Joint Proxy Statement will be included as a prospectus) and any
other documents required by the Securities Act or Exchange Act to be filed in
connection with the Merger; PROVIDED, HOWEVER, that notwithstanding anything
to the contrary contained in this Section 4.8(a), if (and to the extent)
Parent and the Company so elect: (i) the Prospectus/Joint Proxy Statement
shall initially be filed with the SEC on a confidential basis as a proxy
statement of the Company and Parent under Section 14 of the Exchange Act (and
not as a registration statement of Parent); (ii) until it is reasonably
likely that the SEC will declare the S-4 Registration Statement (in which the
Prospectus/Joint Proxy Statement will be included as a prospectus) effective
under the Securities Act, all amendments to the Prospectus/Joint Proxy
29.
<PAGE>
Statement shall be filed with the SEC on a confidential basis as amendments
to the proxy statement of the Company and Parent under Section 14 of the
Exchange Act; and (iii) Parent shall not be obligated to file the S-4
Registration Statement (in which the Prospectus/Joint Proxy Statement will be
included as a prospectus) with the SEC until it is reasonably likely that the
SEC will promptly declare the S-4 Registration Statement effective under the
Securities Act. Each of Parent and the Company shall use reasonable efforts
to (A) cause the S-4 Registration Statement to comply with the rules and
regulations promulgated by the SEC, (B) respond promptly to any comments of
the SEC or its staff, (C) have the S-4 Registration Statement declared
effective under the Securities Act as promptly as practicable after such
filing, and (D) cause the Prospectus/Joint Proxy Statement to be mailed to
their respective stockholders as promptly as practicable after the S-4
Registration Statement is declared effective under the Securities Act. The
Company shall promptly furnish to Parent all information concerning the
Company, its subsidiaries and its stockholders as may be required or
reasonably requested in connection with any action contemplated by this
Section 4.8(a). Each of Parent and the Company shall (1) notify the other
promptly of the receipt of any comments from the SEC or its staff and of any
request by the SEC or its staff for amendments or supplements to the S-4
Registration Statement or the Prospectus/Joint Proxy Statement or for
additional information and (2) shall supply the other with copies of all
correspondence with the SEC or its staff with respect to the S-4 Registration
Statement or the Prospectus/Joint Proxy Statement. Neither Parent nor the
Company shall file any amendment or supplement to the S-4 Registration
Statement or the Prospectus/Joint Proxy Statement to which the other shall
have reasonably objected. Whenever any event occurs that should be set forth
in an amendment or supplement to the S-4 Registration Statement or the
Prospectus/Joint Proxy Statement, Parent or the Company, as the case may be,
shall promptly inform the other of such occurrence and shall cooperate in
filing with the SEC or its staff, and, if appropriate, mailing to
stockholders of Parent and the Company, such amendment or supplement.
(b) Prior to the Effective Time, Parent shall use reasonable efforts
to obtain all regulatory approvals needed to ensure that the shares of Parent
Common Stock to be issued to the Company Stockholders in the Merger (i) will be
qualified under the securities or "blue sky" law of every jurisdiction of the
United States in which any registered stockholder of the Company has an address
of record on the record date for determining the stockholders entitled to notice
of and to vote on the Merger; provided, however, that Parent shall not be
required to qualify to do business as a foreign corporation in any jurisdiction
in which it is not now qualified or to file a general consent to service of
process in any jurisdiction, and (ii) will be approved for listing (subject to
notice of issuance) at the Effective Time on the Nasdaq NMS.
4.9 COMPANY STOCKHOLDERS' MEETING.
(a) The Company shall take all action reasonably necessary under all
applicable Legal Requirements to call, give notice of, convene and hold a
meeting of the holders of Company Common Stock and Company Preferred Stock to
consider, act upon and vote upon the adoption and approval of this Agreement and
the approval of the Merger (the "Company Stockholders' Meeting"). The Company
Stockholders' Meeting will be held as promptly as practicable and in any event
within 45 days after the S-4 Registration Statement is declared effective under
the Securities Act. The Company will use reasonable efforts to ensure that,
within 45 days after the S-4 Registration Statement is declared effective under
the Securities Act,
30.
<PAGE>
the Company Stockholders' Meeting is called, noticed, convened, held and
conducted, and that all proxies solicited in connection with the Company
Stockholders' Meeting are solicited, in compliance with all applicable Legal
Requirements. Notwithstanding anything to the contrary contained in this
Agreement, the Company may adjourn or postpone the Company Stockholders' Meeting
to the extent necessary to ensure that any necessary supplement or amendment to
the Prospectus/Proxy Statement is provided to the Company Stockholders in
advance of a vote on the Merger and this Agreement, or, if as of the time for
which the Company Stockholders' Meeting is originally scheduled (as set forth in
the Prospectus/Proxy Statement) there are insufficient shares of Company Common
Stock represented (either in person or by proxy) to constitute a quorum
necessary to conduct the business of the Company Stockholders' Meeting. The
Company will use reasonable efforts to hold the Company Stockholders' Meeting as
soon as possible. The Company's obligation to call, give notice of, convene and
hold the Company Stockholders' Meeting in accordance with this Section 4.9(a)
shall not be limited or otherwise affected by the commencement, disclosure,
announcement or submission of any Superior Offer or other Acquisition Proposal,
or by any withdrawal, amendment or modification of the recommendation of the
Board of Directors of the Company with respect to the Merger.
(b) Subject to Section 4.9(c): (i) the Board of Directors of the
Company shall recommend that the Company Stockholders vote in favor of and adopt
and approve this Agreement and approve the Merger at the Company Stockholders'
Meeting; (ii) the Prospectus/Proxy Statement shall include a statement to the
effect that the Board of Directors of the Company has recommended that the
Company Stockholders vote in favor of and adopt and approve this Agreement and
approve the Merger at the Company Stockholders' Meeting; and (iii) neither the
Board of Directors of the Company nor any committee thereof shall withdraw,
amend or modify, or propose or resolve to withdraw, amend or modify, in a manner
adverse to Parent, the recommendation of the Board of Directors of the Company
that the Company Stockholders vote in favor of and adopt and approve this
Agreement and approve the Merger.
(c) Nothing in this Agreement shall prevent the Board of Directors of
the Company from withholding, withdrawing, amending or modifying its
recommendation in favor of the Merger and amending the Prospectus/Proxy
Statement at any time prior to the adoption and approval of this Agreement by
the Required Company Stockholder Vote if (i) a Superior Offer is made to the
Company and is not withdrawn, (ii) neither the Company nor any of its
Representatives shall have violated any of the restrictions set forth in Section
4.7, and (iii) the Board of Directors of the Company concludes in good faith,
after consultation with its outside counsel, that, in light of such Superior
Offer, the withdrawal, amendment or modification of such recommendation is
required in order for the Board of Directors of the Company to avoid a
substantial risk of liability with respect to its fiduciary obligations to the
Company Stockholders under applicable law. Nothing contained in this Section
4.9 shall limit the Company's obligation to call, give notice of, convene and
hold the Company Stockholders' Meeting (regardless of whether the recommendation
of the Board of Directors of the Company shall have been withdrawn, amended or
modified).
4.10 PARENT STOCKHOLDERS' MEETING.
(a) Parent shall take all action reasonably necessary under all
applicable Legal Requirements to call, give notice of, convene and hold a
meeting of the holders of Parent
31.
<PAGE>
Common Stock to consider, act upon and vote upon the adoption and approval of
this Agreement and the approval of the Merger (the "Parent Stockholders'
Meeting"). The Parent Stockholders' Meeting will be held as promptly as
practicable and in any event within 45 days after the S-4 Registration Statement
is declared effective under the Securities Act. Parent will use reasonable
efforts to ensure that, within 45 days after the S-4 Registration Statement is
declared effective under the Securities Act, the Parent Stockholders' Meeting is
called, noticed, convened, held and conducted, and that all proxies solicited in
connection with the Parent Stockholders' Meeting are solicited, in compliance
with all applicable Legal Requirements. Notwithstanding anything to the
contrary contained in this Agreement, Parent may adjourn or postpone the Parent
Stockholders' Meeting to the extent necessary to ensure that any necessary
supplement or amendment to the Prospectus/Proxy Statement is provided to the
Parent Stockholders in advance of a vote on the Merger and this Agreement, or,
if as of the time for which the Parent Stockholders' Meeting is originally
scheduled (as set forth in the Prospectus/Proxy Statement) there are
insufficient shares of Parent Common Stock represented (either in person or by
proxy) to constitute a quorum necessary to conduct the business of the Parent
Stockholders' Meeting. Parent will use reasonable efforts to hold the Parent
Stockholders' Meeting as soon as possible.
(b) (i) The Board of Directors of Parent shall recommend that the
Parent's stockholders vote in favor of and adopt and approve this Agreement and
approve the Merger at the Parent Stockholders' Meeting; (ii) the
Prospectus/Joint Proxy Statement shall include a statement to the effect that
the Board of Directors of Parent has recommended that the Parent's stockholders
vote in favor of and adopt and approve this Agreement and approve the Merger at
the Parent Stockholders' Meeting; and (iii) neither the Board of Directors of
Parent nor any committee thereof shall withdraw, amend or modify, or propose or
resolve to withdraw, amend or modify, in a manner adverse to the Company, the
recommendation of the Board of Directors of Parent that the Parent's
stockholders vote in favor of and adopt and approve this Agreement and approve
the Merger.
4.11 REGULATORY APPROVALS. The Company and Parent shall use reasonable
efforts to file as soon as practicable after the date of this Agreement all
notices, reports and other documents required by law to be filed with any
Governmental Authority with respect to the Merger and the other transactions
contemplated by this Agreement and to submit promptly any additional information
requested by any such Governmental Authority. The Company and Parent shall
(i) give each other prompt notice of the commencement of any Legal Proceeding by
or before any court on Governmental Authority with respect to the Merger or any
of the transactions contemplated by this Agreement, and (ii) keep each other
informed as to the status of any such Legal Proceeding.
4.12 ADDITIONAL AGREEMENTS.
(a) Parent and the Company shall use reasonable efforts to take, or
cause to be taken, all actions necessary to consummate the Merger and make
effective the other transactions contemplated by this Agreement. Without
limiting the generality of the foregoing, each party to this Agreement (i) shall
make all filings (if any) and give all notices (if any) required to be made and
given by such party in connection with the Merger and the other transactions
contemplated by this Agreement, (ii) shall use reasonable efforts to obtain each
Consent (if any) required to be obtained (pursuant to any applicable Legal
Requirement or Contract, or otherwise) by such party
32.
<PAGE>
in connection with the Merger or any of the other transactions contemplated by
this Agreement, and (iii) shall use reasonable efforts to lift any restraint,
injunction or other legal bar to the Merger. Each of Parent and the Company
shall promptly deliver to the other a copy of each such filing made, each such
notice given and each such Consent obtained by Parent or the Company, as the
case may be, during the Pre-Closing Period.
(b) The Company will use reasonable efforts to resolve all Legal
Proceedings against the Company in a manner reasonably acceptable to Parent.
4.13 DISCLOSURE. Except as otherwise required by applicable law, Parent
and the Company shall keep confidential the existence, status and terms of the
negotiations and agreements regarding the Merger. Parent and the Company shall
consult with each other before issuing any press release or otherwise making any
public statements with respect to the Merger or any of the other Transactions.
Without limiting the generality of the foregoing, neither party shall permit any
of its Representatives to, make any disclosure regarding the Merger or any of
the other transactions contemplated by this Agreement unless (a) the other party
shall have approved such disclosure, or (b) such party shall have determined
after consultation with its outside legal counsel that such disclosure is
required by applicable law.
4.14 LETTER OF THE COMPANY'S ACCOUNTANTS. The Company shall cause to be
delivered to Parent a letter of Arthur Andersen LLP, dated no more than two
business days before the date on which the S-4 Registration Statement becomes
effective (and reasonably satisfactory in form and substance to Parent), that is
customary in scope and substance for letters delivered by independent
accountants in connection with the registration statements similar to the S-4
Registration Statement.
4.15 COMPANY AFFILIATE AGREEMENTS. The Company shall use reasonable
efforts to cause each Person who becomes a Company Affiliate after the date of
this Agreement to execute and deliver to Parent, on or prior to the Effective
Time, an affiliate agreement in the form of Exhibit F attached hereto (the
"Company Affiliate Agreement").
4.16 TAX MATTERS. At or prior to the Closing, Parent and the Company shall
execute and deliver to Parent's counsel and to the Company's counsel tax
representation letters in customary form. Parent and the Company shall use
reasonable efforts prior to the Effective Time to cause the Merger to qualify as
a tax free reorganization under Section 368(a)(1) of the Code.
4.17 EMPLOYMENT OR CONSULTING AGREEMENT AND NONCOMPETITION AGREEMENT. The
Company shall use reasonable efforts to cause to be executed and delivered to
Parent employment agreements or consulting agreements, as applicable, between
Parent and those Persons identified on Exhibit G.
4.18 EMPLOYEE BENEFITS. Parent intends to maintain or cause the Surviving
Corporation to maintain employee benefit plans (as defined in Section 3(3) of
ERISA) for the benefit of employees of the Company which are substantially
similar to those benefits provided for Parent's employees, including, without
limitation, any of the following benefit plans maintained by Parent:
medical/dental/vision care, life insurance, disability income, sick pay,
33.
<PAGE>
holiday and vacation pay, 401(k) plan coverage, Section 125 benefit
arrangements, bonus profit-sharing or other incentive plans, pension or
retirement programs, dependent care assistance, severance benefits, and employee
stock option and stock purchase plans, to the extent the Company employees meet
the eligibility requirements for each such plan or program. To the extent
permitted and commercially practicable under applicable plans and laws, Parent
intends that the Company's employees (i) shall be given credit, for purposes of
any service requirements for participation, for their period of service with the
Company prior to the Closing Date, and (ii) shall also, with respect to any
Parent plans or programs which have co-payment, deductible or other co-insurance
features, receive credit for any amounts such employees have paid to date in
1998 in co-payments, deductibles or co-insurance under comparable programs
maintained by Company prior to the date hereof. In addition, Parent intends
that, to the extent permitted and commercially practicable under the Company's
medical/health plans, no Company employee who participates in any medical/health
plan of Company at the Closing date shall be denied coverage under Parent's
medical/health plan by reason of any pre-existing condition exclusions.
4.19 INDEMNIFICATION.
(a) From and after the Effective Time, Parent will, or Parent will
cause the Surviving Corporation to, fulfill and honor in all respects the
obligations of the Company pursuant to any indemnification agreements between
the Company and its directors and officers as of the date hereof (the
"Indemnified Parties") and any indemnification provisions under the Certificate
of Incorporation and Bylaws of the Surviving Corporation will contain provisions
with respect to exculpation and indemnification that are at least as favorable
to the Indemnified Parties as those contained in the Certificate of
Incorporation and Bylaws of the Company as in effect on the date hereof, which
provisions will not be amended, repealed or otherwise modified for a period of
six years from the Effective Time in any manner that would adversely affect the
rights thereunder of individuals who, immediately prior to the Effective Time,
were directors, officers, employees or agents of the Company, unless such
modification is required by law.
(b) From the Effective Time until the sixth anniversary thereof,
Parent shall, or Parent shall cause the Surviving Corporation to, maintain in
effect, for the benefit of the current directors and officers of the Company
with respect to acts or omissions occurring prior to the Effective Time, the
existing policy of directors' and officers' liability insurance maintained by
the Company as of the date of this Agreement (the "Existing Policy"); PROVIDED,
HOWEVER, that (i) Parent or the Surviving Corporation may substitute for the
Existing Policy a policy or policies of comparable coverage, and (ii) neither
Parent nor the Surviving Corporation shall be required to pay an annual premium
for the Existing Policy (or for any substitute policies) in excess of the amount
of the last annual premium paid by the Company prior to the date of this
Agreement for the Existing Policy, which amount was $119,500 (the "Past Premium
Amount"). In the event any future annual premium for the Existing Policy (any
substitute policies) exceeds the Past Premium Amount, Parent or the Surviving
Corporation shall be entitled to reduce the amount of coverage of the Existing
Policy (or any substitute policies) to the amount of coverage that can be
obtained for a premium equal to the Past Premium Amount.
(c) This Section 4.19 shall survive the consummation of the Merger,
is intended to be for the benefit of, and enforceable by, each person entitled
to indemnification
34.
<PAGE>
pursuant hereto and each such person's or entity's heirs and representatives,
and shall be binding on all successors and assigns of Parent and the Surviving
Corporation.
4.20 NASDAQ LISTING. Parent agrees to authorize for listing on Nasdaq the
shares of Parent Common Stock issuable, and those required to be reserved for
issuance, in connection with the Merger, upon official notice of issuance.
4.21 BLUE SKY LAWS. Parent shall take such steps as may be reasonably
necessary to comply with the securities and blue sky laws of all jurisdictions
which are applicable to the issuance of Parent Common Stock pursuant hereto.
The Company shall use its reasonable efforts to assist Parent as may be
necessary to comply with the securities and blue sky laws of all jurisdictions
which are applicable in connection with the issuance of Parent Common Stock
pursuant hereto.
4.22 RESIGNATION OF OFFICERS AND DIRECTORS. The Company shall use
reasonable efforts to obtain and deliver to Parent prior to the Closing the
written resignation of each officer and director of the Company.
ARTICLE 5
CONDITIONS PRECEDENT TO OBLIGATIONS OF PARENT AND MERGER SUB
The obligations of Parent and Merger Sub to effect the Merger and otherwise
consummate the transactions contemplated by this Agreement are subject to the
fulfillment, at or prior to the Closing, of each of the following conditions:
5.1 REPRESENTATIONS AND WARRANTIES ACCURATE.
(a) Without limiting the effect or independence of the conditions set
forth in Sections 5.1(b) and 5.1(c), the representations and warranties of the
Company contained in Sections 2.1(c), 2.1(d) and 2.1(e) shall have been accurate
in all respects as of the date of this Agreement (it being understood that for
purposes of determining the accuracy of the representations and warranties of
the Company contained in Sections 2.1(c), 2.1(d) and 2.1(e) with respect to the
fully-diluted capitalization of the Company (A) such representations and
warranties shall be deemed to have been accurate as long as the actual
fully-diluted capitalization of the Company does not exceed the fully-diluted
capitalization of the Company as represented in Sections 2.1(c), 2.1(d) and
2.1(e) by more than 15,000 shares of Company Common Stock, (B) changes in the
number of outstanding shares of Company Common Stock resulting solely from the
conversion of the Company Preferred Stock shall be disregarded and (C) any
update of or modification to the Company Disclosure Schedule made or purported
to have been made after the date of this Agreement shall be disregarded).
(b) Without limiting the effect or independence of the conditions set
forth in Sections 5.1(a) and 5.1(c), the representations and warranties of the
Company contained in this Agreement (other than the representations and
warranties of the Company contained in Sections 2.1(c), 2.1(d) and 2.1(e)) shall
have been accurate in all respects as of the date of this Agreement (it being
understood that, for purposes of determining the accuracy of such
representations and warranties any inaccuracies that, in the aggregate, do not
have a Material
35.
<PAGE>
Adverse Effect on the Company shall be disregarded and (ii) any update of or
modification to the Company Disclosure Schedule made or purported to have been
made after the date of this Agreement shall be disregarded).
(c) Without limiting the effect or independence of the conditions set
forth in Sections 5.1(a) and 5.1(b), the representations and warranties of the
Company contained in this Agreement (except for any representation or warranty
that refers specifically to "the date of this Agreement" or to any specific date
or period prior to the date of this Agreement) shall be accurate in all respects
as of the Closing Date as if made on and as of the Closing Date (it being
understood that, for purposes of determining the accuracy of such
representations and warranties as of the Closing Date: (i) any inaccuracies
that, in the aggregate, do not have a Material Adverse Effect on the Company
shall be disregarded and (ii) any update of or modification to the Company
Disclosure Schedule made or purported to have been made after the date of this
Agreement shall be disregarded).
5.2 COMPLIANCE WITH COVENANTS. The Company shall have complied with and
performed in all material respects each covenant contained in this Agreement
that is required to be complied with or performed by the Company on or prior to
the Closing Date.
5.3 NO MATERIAL ADVERSE EFFECT. There shall have been no change in the
Company's business, capitalization, operations or financial condition since the
date of this Agreement which has had or would reasonably be expected to have a
Material Adverse Effect on the Company.
5.4 EFFECTIVENESS OF REGISTRATION STATEMENT. The S-4 Registration
Statement shall have become effective in accordance with the provisions of the
Securities Act, and no stop order shall have been issued by the SEC with respect
to the S-4 Registration Statement.
5.5 COMPANY STOCKHOLDER APPROVAL. This Agreement and the Merger shall
have been adopted and approved by the Required Company Stockholder Vote.
5.6 PARENT STOCKHOLDER APPROVAL. This Agreement and the Merger shall have
been adopted and approved by the Required Parent Stockholder Vote.
5.7 AGREEMENTS AND DOCUMENTS. Parent shall have received the following
agreements and documents, each of which shall be in full force and effect:
(a) A letter from Arthur Andersen LLP, dated as of the Closing Date
and addressed to Parent, reasonably satisfactory in form and substance to
Parent, updating the letter referred to in Section 4.14;
(b) A Company Affiliate Agreement in the form of Exhibit F executed
by each Company Affiliate as of the Closing Date, or who was a Company Affiliate
on the date on which the Company Stockholders' Meeting was held or on the date
30 days prior to the Closing;
(c) An employment or consulting agreement and noncompetition
agreement with Parent executed by each Person identified on Exhibit G;
36.
<PAGE>
(d) A legal opinion of Cooley Godward LLP, outside counsel to Parent,
dated as of the Closing Date and addressed to Parent, to the effect that the
Merger will constitute a reorganization within the meaning of Section 368(a) of
the Code (it being understood that, in rendering such opinion, such outside
counsel may rely upon the tax representation letters referred to in Section
4.16);
(e) The written resignations of all officers and directors of the
Company; and
(f) A certificate of the Chief Executive Officer of the Company
evidencing compliance with the conditions set forth in Sections 5.1, 5.2, 5.3
and 5.5.
5.8 ABSENCE OF RESTRAINT. No order to restrain, enjoin or otherwise
prevent the consummation of the Merger or any of the other transactions
contemplated by this Agreement shall have been entered by any court or
Governmental Authority, and there shall not be any Legal Requirement enacted or
deemed applicable to the Merger that makes the consummation of the Merger
illegal.
5.9 NO GOVERNMENTAL LITIGATION. There shall not be pending or threatened
any Legal Proceeding in which a Governmental Authority is or is threatened to
become a party: (a) challenging or seeking to restrain or prohibit the
consummation of the Merger or any of the other transactions contemplated by this
Agreement; (b) relating to the Merger and seeking to obtain from Parent or any
of its subsidiaries or from the Company any damages that may be material to
Parent or the Company; (c) seeking to prohibit or limit in any material respect
Parent's ability to vote, receive dividends with respect to or otherwise
exercise ownership rights with respect to the stock of the Surviving
Corporation; or (d) which would materially and adversely affect the right of
Parent, the Surviving Corporation or any subsidiary of Parent to own the assets
or operate the business of the Company.
5.10 OTHER REQUIRED CONSENTS AND APPROVALS. All Consents required to be
obtained in connection with the Merger and the other transactions contemplated
by this Agreement shall have been obtained and shall be in full force and effect
(except where the failure to obtain such Consents has not had, and would not
reasonably be expected to have, a Material Adverse Effect on Parent or the
Company.
5.11 STOCK OPTIONS. All outstanding Company Options not exercised prior to
the Effective Time shall have terminated and ceased to remain outstanding.
ARTICLE 6
CONDITIONS PRECEDENT TO THE COMPANY'S OBLIGATIONS
The obligations of the Company to effect the Merger and otherwise
consummate the transactions contemplated by this Agreement are subject to the
fulfillment, at or prior to the Closing, of each of the following conditions:
37.
<PAGE>
6.1 REPRESENTATIONS AND WARRANTIES ACCURATE.
(a) Without limiting the effect or independence of the condition set
forth in Section 6.1(b), the representations and warranties of Parent and Merger
Sub contained in this Agreement shall have been accurate in all respects as of
the date of this Agreement (it being understood that, for purposes of
determining the accuracy of such representations and warranties any inaccuracies
that, in the aggregate, do not have a Material Adverse Effect on Parent shall be
disregarded).
(b) Without limiting the effect or independence of the condition set
forth in Section 6.1(a), the representations and warranties of Parent and Merger
Sub contained in this Agreement (except for any representation or warranty that
refers specifically to "the date of this Agreement" or to any specific date or
period prior to the date of this Agreement) shall be accurate in all respects as
of the Closing Date as if made on and as of the Closing Date (it being
understood that, for purposes of determining the accuracy of such
representations and warranties as of the Closing Date any inaccuracies that, in
the aggregate, do not have a Material Adverse Effect on Parent shall be
disregarded.
6.2 COMPLIANCE WITH COVENANTS. Parent and Merger Sub shall have complied
with and performed in all material respects each covenant contained in this
Agreement that is required to be complied with or performed by Parent and Merger
Sub on or prior to the Closing Date.
6.3 NO MATERIAL ADVERSE EFFECT. There shall have been no change in
Parent's business, capitalization, operations or financial condition since the
date of this Agreement which has had or would reasonably be expected to have a
Material Adverse Effect on Parent.
6.4 EFFECTIVENESS OF REGISTRATION STATEMENT. The S-4 Registration
Statement shall have become effective in accordance with the provisions of the
Securities Act, and no stop order shall have been issued by the SEC with respect
to the S-4 Registration Statement.
6.5 COMPANY STOCKHOLDER APPROVAL. This Agreement and the Merger shall
have been adopted and approved by the Required Company Stockholder Vote.
6.6 PARENT STOCKHOLDER APPROVAL. This Agreement and the Merger shall have
been adopted and approved by the Required Parent Stockholder Vote.
6.7 AGREEMENTS AND DOCUMENTS. The Company shall have received the
following agreements and documents, each of which shall be in full force and
effect:
(a) A legal opinion of Brobeck, Phleger & Harrison LLP, counsel to
the Company, dated as of the Closing Date and addressed to the Company, to the
effect that the Merger will constitute a reorganization within the meaning of
Section 368(a) of the Code (it being understood that, in rendering such opinion,
such outside counsel may rely upon the tax representation letters referred to in
Section 4.16); and
(b) A certificate of the Chief Executive Officer of Parent evidencing
compliance with the conditions set forth in Sections 6.1, 6.2, 6.3 and 6.6.
38.
<PAGE>
6.8 ABSENCE OF RESTRAINT. No order to restrain, enjoin or otherwise
prevent the consummation of the Merger or any of the other transactions
contemplated by this Agreement shall have been entered by any court or
Governmental Authority and there shall not be any Legal Requirement enacted or
deemed applicable to the Merger that makes the consummation of the Merger
illegal.
6.9 LISTING. The shares of Parent Common Stock to be issued to the
Company Stockholders in the Merger shall have been approved for quotation on the
Nasdaq NMS upon official notice of issuance thereof.
6.10 CLOSING PRICE. The Closing Price of Parent Common Stock shall be more
than $6.34.
6.11 NO GOVERNMENTAL LITIGATION. There shall not be pending or threatened
any Legal Proceeding in which a Governmental Authority is or is threatened to
become a party: (a) challenging or seeking to restrain or prohibit the
consummation of the Merger or any of the other transactions contemplated by this
Agreement; (b) relating to the Merger and seeking to obtain from Parent or any
of its subsidiaries any damages that may be material to Parent; (c) seeking to
prohibit or limit in any material respect Parent's ability to vote, receive
dividends with respect to or otherwise exercise ownership rights with respect to
the stock of the Surviving Corporation; or (d) which would materially and
adversely affect the right of Parent, the Surviving Corporation or any
subsidiary of Parent to own the assets or operate the business of the Company.
ARTICLE 7
TERMINATION OF AGREEMENT
7.1 TERMINATION. This Agreement may be terminated prior to the Effective
Time, whether before or after approval of the Merger by the Company
Stockholders:
(a) by mutual written consent of Parent and the Company;
(b) by either Parent or the Company if the Merger shall not have been
consummated by December 31, 1998 (unless the failure to consummate the Merger is
attributable to a failure on the part of the party seeking to terminate this
Agreement to perform any material obligation required to be performed by such
party at or prior to the Effective Time);
(c) by the Company if the Closing Price of Parent Common Stock is
less than $6.34;
(d) by either Parent or the Company if a court of competent
jurisdiction or Governmental Authority shall have issued a final and
nonappealable order, decree or ruling, or shall have taken any other action,
having the effect of permanently restraining, enjoining or otherwise prohibiting
the Merger;
(e) by either Parent or the Company if (i) the Company Stockholders'
Meeting shall have been held, and (ii) this Agreement and the Merger shall not
have been
39.
<PAGE>
adopted and approved at such meeting by the Required Company Stockholder Vote;
PROVIDED, HOWEVER, that the Company shall not be permitted to terminate this
Agreement pursuant to this Section 7.1(e) if the failure of the Company
Stockholders to adopt and approve this Agreement and approve the Merger at the
Company Stockholders' Meeting is attributable to a failure on the part of the
Company to perform any material obligation required to have been performed by
the Company under this Agreement; and PROVIDED FURTHER, that the Company may so
terminate this Agreement only following its compliance with Sections 7.3(b) and
(c);
(f) by either Parent or the Company if (i) the Parent Stockholders'
Meeting shall have been held, and (ii) this Agreement and the Merger shall not
have been adopted or approved at such meeting by the Required Parent Stockholder
Vote; PROVIDED, HOWEVER, that Parent shall not be permitted to terminate this
Agreement pursuant to this Section 7.1(f) if the failure of the Parent
Stockholders to adopt and approve this Agreement and approve the Merger at the
Parent Stockholders' Meeting is attributable to a failure on the part of Parent
to perform any material obligation required to have been performed by Parent
under this Agreement;
(g) by Parent (at any time prior to the adoption and approval of this
Agreement and the Merger by the Required Company Stockholder Vote) if a
Triggering Event shall have occurred;
(h) by Parent, following a breach of any covenant or agreement of the
Company contained in this Agreement, or if any representation or warranty of the
Company contained in this Agreement shall be or shall have become inaccurate, in
either case such that any of the conditions set forth in Sections 5.1(a),
5.1(b), 5.1(c) and 5.2 would not be satisfied as of the time of such breach or
as of the time such representation or warranty was or shall have become
inaccurate; PROVIDED, HOWEVER, that: (A) if such breach or inaccuracy is curable
by the Company, then Parent may not terminate this Agreement under this Section
7.1(h) with respect to a particular breach or inaccuracy prior to or during the
30-day period commencing upon delivery by Parent of written notice to the
Company of such breach or inaccuracy, provided that the Company continues to
exercise all reasonable efforts to cure such breach or inaccuracy; and (B) the
right to terminate this Agreement under this Section 7.1(h) shall not be
available to Parent if Parent shall have committed a material uncured breach of
this Agreement; or
(i) by the Company, following a breach of any covenant or agreement
of Parent contained in this Agreement, or if any representation or warranty of
Parent contained in this Agreement shall be or shall have become inaccurate, in
either case such that any of the conditions set forth in Sections 6.1(a), 6.1(b)
and 6.2 would not be satisfied as of the time of such breach or as of the time
such representation or warranty was or shall have become inaccurate; PROVIDED,
HOWEVER, that: (A) if such breach or inaccuracy is curable by Parent, then the
Company may not terminate this Agreement under this Section 7.1(i) with respect
to a particular breach or inaccuracy prior to or during the 30-day period
commencing upon delivery by the Company of written notice to Parent of such
breach or inaccuracy, provided Parent continues to exercise reasonable efforts
to cure such breach or inaccuracy; and (B) the right to terminate this Agreement
under this Section 7.1(i) shall not be available to the Company if the Company
shall have committed a material uncured breach of this Agreement.
40.
<PAGE>
7.2 EFFECT OF TERMINATION. In the event of the termination of this
Agreement as provided in Section 7.1, this Agreement shall be of no further
force or effect; PROVIDED, HOWEVER, that (i) this Section 7.2, Section 7.3 and
Article 8 shall survive the termination of this Agreement and shall remain in
full force and effect and, (ii) subject to Section 7.3(b) below, the termination
of this Agreement shall not relieve any party from any liability for any breach
of this Agreement.
7.3 FEES AND EXPENSES.
(a) Except as set forth in this Section 7.3, all fees and expenses
incurred in connection with this Agreement and the transactions contemplated by
this Agreement shall be paid by the party incurring such expenses, whether or
not the Merger is consummated; PROVIDED, HOWEVER, that Parent and the Company
shall share equally all fees and expenses, other than attorneys' and
accountants' fees, incurred in connection with the printing and filing of the
S-4 Registration Statement and the Prospectus/Joint Proxy Statement and any
amendments or supplements thereto with the SEC.
(b) In consideration of the substantial time, expense and forgoing of
other opportunities that the Parent has invested in the transactions
contemplated hereby, if this Agreement is terminated by either Parent or the
Company pursuant to Section 7.1(e) or if this Agreement is terminated by Parent
pursuant to Section 7.1(g), then the Company shall pay to Parent a nonrefundable
fee, in cash, of $1,000,000 (the "Break-Up Fee");
(c) In the case of termination of this Agreement pursuant to Section
7.1(e), the Break-Up Fee shall be paid within one business day after such
termination. In the case of termination of this Agreement pursuant to Section
7.1(g), the Break-Up Fee shall be paid within one business day after such
termination.
ARTICLE 8
MISCELLANEOUS
8.1 AMENDMENT. This Agreement may be amended with the approval of the
respective Boards of Directors of the Company and Parent at any time before or
after approval of this Agreement by the Company Stockholders; PROVIDED, HOWEVER,
that after any such stockholder approval, no amendment shall be made except as
permitted by applicable law. This Agreement may not be amended except by an
instrument in writing signed on behalf of each of the parties hereto.
8.2 WAIVER.
(a) No failure on the part of any party to exercise any power, right,
privilege or remedy under this Agreement, and no delay on the part of any party
in exercising any power, right, privilege or remedy under this Agreement, shall
operate as a waiver of such power, right, privilege or remedy; and no single or
partial exercise of any such power, right, privilege or remedy shall preclude
any other or further exercise thereof or of any other power, right, privilege or
remedy.
41.
<PAGE>
(b) No party shall be deemed to have waived any claim arising out of
this Agreement, or any power, right, privilege or remedy under this Agreement,
unless the waiver of such claim, power, right, privilege or remedy is expressly
set forth in a written instrument duly executed and delivered on behalf of such
party; and any such waiver shall not be applicable or have any effect except in
the specific instance in which it is given.
8.3 NO SURVIVAL OF REPRESENTATIONS AND WARRANTIES. None of the
representations and warranties contained in this Agreement or in any instrument
delivered pursuant to this Agreement shall survive the Merger.
8.4 ENTIRE AGREEMENT; COUNTERPARTS. This Agreement and the other
agreements referred to herein and in that certain Mutual Non-Disclosure
Agreement dated January 27, 1998 between Parent and the Company constitute the
entire agreement and supersede all prior agreements and understandings, both
written and oral, among or between any of the parties with respect to the
subject matter hereof. This Agreement may be executed in several counterparts,
each of which shall be deemed an original and all of which shall constitute one
and the same instrument.
8.5 APPLICABLE LAW; JURISDICTION. This Agreement is made under, and shall
be construed and enforced in accordance with, the laws of the State of Delaware
applicable to agreements made and to be performed solely therein, without giving
effect to principles of conflicts of law. In any action between or among any of
the parties, whether arising out of this Agreement or otherwise: (a) each of the
parties irrevocably and unconditionally consents and submits to the exclusive
jurisdiction and venue of the state and federal courts located in Maryland;
(b) if any such action is commenced in a state court, then, subject to
applicable law, no party shall object to the removal of such action to any
federal court located in Montgomery County, Maryland; (c) each of the parties
irrevocably waives the right to trial by jury; and (d) each of the parties
irrevocably consents to service of process by first class certified mail, return
receipt requested, postage prepaid, to the address at which such party is to
receive notice in accordance with Section 8.7.
8.6 ASSIGNABILITY. This Agreement shall be binding upon, and shall be
enforceable by and inure solely to the benefit of, the parties hereto and their
respective successors; PROVIDED, HOWEVER, that neither this Agreement nor any of
the rights or obligations of the Company, Parent or Merger Sub hereunder may be
assigned by any party without the prior written consent of the other parties
hereto, and any attempted assignment without such consent shall be void and of
no effect. Nothing in this Agreement, express or implied, is intended to or
shall confer upon any Person any right, benefit or remedy of any nature
whatsoever under or by reason of this Agreement, except as specifically provided
in Section 4.19.
8.7 NOTICES. All notices and other communications required or permitted
to be delivered to any party pursuant to this Agreement shall be in writing and
shall be deemed properly given if delivered personally, by facsimile, sent by
nationally-recognized, overnight courier or mailed by registered or certified
mail (postage prepaid, return receipt requested) to the parties at the following
addresses (or at such other address for a party as shall be specified by like
notice):
42.
<PAGE>
To Parent or Merger Sub:
Gene Logic Inc.
708 Quince Orchard Road
Gaithersburg, MD 20878
Attention: President and Chief Executive Officer
Telephone: (301) 987-1700
Fax: (301) 987-1701
with a copy to:
Cooley Godward LLP
4365 Executive Drive, Suite 1100
San Diego, CA 92109
Attention: Frederick T. Muto, Esq.
Telephone: (619) 550-6000
Fax: (619) 453-3555
To the Company:
Oncormed, Inc.
205 Perry Parkway
Gaithersburg, MD 20877
Attention: Chief Executive Officer
Telephone: (301) 208-1888
Fax: (301) 926-6329
with a copy to:
Brobeck, Phleger & Harrison LLP
1633 Broadway, 47th Floor
New York, NY 10019
Attention: Alexander D. Lynch, Esq.
Telephone: (212) 581-1600
Fax: (212) 586-7878
All such notices and other communications shall be deemed to have been received
(a) in the case of personal delivery, on the date of such delivery, (b) in the
case of a facsimile, when the party receiving such facsimile shall have
confirmed receipt of the communication, (c) in the case of delivery by
nationally-recognized, overnight courier, on the Business Day following dispatch
and (d) in the case of registered or certified mail, on the fifth Business Day
following such mailing.
8.8 COOPERATION. Each of the Company and Parent agrees to cooperate fully
with the other and to execute and deliver such further documents, certificates,
agreements and instruments and to take such other actions as may be reasonably
requested by the other to evidence or reflect the transactions contemplated
hereby and to carry out the intent and purposes of this Agreement.
43.
<PAGE>
8.9 CONSTRUCTION. The parties hereto agree that any rule of construction
to the effect that ambiguities are to be resolved against the drafting party
shall not be applied in the construction or interpretation of this Agreement.
Except as otherwise indicated, all references in this Agreement to "Articles,"
"Sections" and "Exhibits" are intended to refer to Articles and Sections of this
Agreement and Exhibits to this Agreement. The titles and captions of the
Articles and Sections of this Agreement are included for convenience of
reference only and shall have no effect on the construction or meaning of this
Agreement. As used in this Agreement, the words "include" and "including," and
variations thereof, shall not be deemed to be terms of limitation, but rather
shall be deemed to be followed by the words "without limitation."
[THIS SPACE INTENTIONALLY LEFT BLANK]
44.
<PAGE>
IN WITNESS WHEREOF, the parties hereby have executed this Agreement and
Plan of Reorganization as of the date first above written.
GENE LOGIC INC.
/s/ Michael J. Brennan
--------------------------------
By: Michael J. Brennan, M.D., Ph.D.
Title: President and Chief Executive Officer
GENE LOGIC ACQUISITION CORP.
/s/ Michael J. Brennan
--------------------------------
By: Michael J. Brennan, M.D., Ph.D.
Title: President and Chief Executive Officer
ONCORMED, INC.
/s/ Timothy J. Triche
--------------------------------
By: Timothy J. Triche
----------------------------
Title:
-------------------------
[AGREEMENT AND PLAN OF MERGER AND REORGANIZATION]
<PAGE>
EXHIBIT A
CERTAIN DEFINITIONS
For purposes of the Agreement (including this Exhibit A):
ACQUISITION PROPOSAL. "Acquisition Proposal" shall mean any offer, proposal
or inquiry (other than an offer, proposal or inquiry by Parent) contemplating or
otherwise relating to any Acquisition Transaction.
ACQUISITION TRANSACTION. "Acquisition Transaction" shall mean any
transaction or series of related transactions involving:
(a) any merger, consolidation, share exchange, business combination,
issuance of securities, acquisition of securities, tender offer, exchange offer
or other similar transaction (i) in which the Company is a constituent
corporation, (ii) in which a Person or "group" (as defined in the Exchange Act
and the rules promulgated thereunder) of Persons directly or indirectly acquires
the Company or more than 50% of the Company's business or directly or indirectly
acquires beneficial or record ownership of securities representing more than 50%
of the outstanding securities of any class of voting securities of the Company,
or (iii) in which the Company issues securities representing more than 50% of
the outstanding securities of any class of voting securities of the Company; or
(b) any sale, lease (other than in the ordinary course of business),
exchange, transfer, license (other than in the ordinary course of business),
acquisition or disposition of more than 50% of the assets of the Company, or any
liquidation or dissolution of the Company.
AGREEMENT. "Agreement" shall mean the Agreement and Plan of Merger and
Reorganization to which this Exhibit A is attached, as it may be amended from
time to time.
BREAK-UP FEE. "Break-up Fee" shall have the meaning set forth in Section
7.3(b).
CERTIFICATE OF MERGER. "Certificate of Merger" shall have the meaning set
forth in Section 1.3.
CLOSING. "Closing" shall have the meaning set forth in Section 1.3.
CLOSING DATE. "Closing Date" shall have the meaning set forth in Section
1.3.
CLOSING PRICE. "Closing Price" shall have the meaning set forth in Section
1.5(b)(i).
CODE. "Code" shall have the meaning set forth in the recitals.
COMPANY. "Company" shall have the meaning set forth in the preamble.
COMPANY AFFILIATES. "Company Affiliates" shall have the meaning set forth
in Section 2.12.
A-1
<PAGE>
COMPANY AFFILIATE AGREEMENT. "Company Affiliate Agreement" shall have the
meaning set forth in Section 4.15.
COMPANY CERTIFICATE OF INCORPORATION. "Company Certificate of
Incorporation" shall have the meaning set forth in Section 2.1(g).
COMPANY COMMON STOCK. "Company Common Stock" shall have the meaning set
forth in Section 1.5(a)(i).
COMPANY CONTRACT. "Company Contract" shall mean any Contract: (a) to
which the Company is a party; (b) by which the Company or any of its assets is
or may become bound or under which the Company has, or may become subject to,
any obligation; or (c) under which the Company has or may acquire any right or
interest.
COMPANY DISCLOSURE SCHEDULE. "Company Disclosure Schedule" shall have the
meaning set forth in the preamble to Article 2.
COMPANY FINANCIAL STATEMENTS. "Company Financial Statements" shall have
the meaning set forth in Section 2.2(b).
COMPANY OPTIONS. "Company Options" shall have the meaning set forth in
Section 1.8.
COMPANY PREFERRED STOCK. "Company Preferred Stock" shall have the meaning
set forth in Section 1.5(a)(i).
COMPANY PROPRIETARY ASSETS. "Company Proprietary Assets" shall have the
meaning set forth in Section 2.5(a).
COMPANY SEC DOCUMENTS. "Company SEC Documents" shall have the meaning set
forth in Section 2.2(a).
COMPANY STOCK CERTIFICATE. "Company Stock Certificate" shall have the
meaning set forth in Section 1.6.
COMPANY STOCKHOLDERS. "Company Stockholders" shall have the meaning set
forth in Section 1.5(a).
COMPANY STOCKHOLDERS' MEETING. "Company Stockholders' Meeting" shall have
the meaning set forth in Section 4.9(a).
COMPANY WARRANTS. "Company Warrants" shall have the meaning set forth in
Section 1.9.
CONFIDENTIAL INFORMATION. "Confidential Information" shall have the
meaning set forth in Section 2.5(g).
CONSENT. "Consent" shall mean any approval, consent, ratification,
permission, waiver or authorization (including any Governmental Authorization).
A-2
<PAGE>
CONTRACT. "Contract" shall mean any written, oral or other agreement,
contract, subcontract, lease, understanding, instrument, note, option, warranty,
purchase order, license, sublicense or legally binding commitment or undertaking
of any nature.
DGCL. "DGCL" shall have the meaning set forth in Section 1.2.
EFFECTIVE TIME. "Effective Time" shall have the meaning set forth in
Section 1.3.
ENCUMBRANCE. "Encumbrance" shall mean any lien, pledge, hypothecation,
charge, mortgage, security interest, encumbrance, claim, infringement,
interference, option, right of first refusal, preemptive right, community
property interest or restriction of any nature (including any restriction on the
voting of any security, any restriction on the transfer of any security or other
asset, any restriction on the receipt of any income derived from any asset, any
restriction on the use of any asset and any restriction on the possession,
exercise or transfer of any other attribute of ownership of any asset).
ENTITY. "Entity" shall mean any corporation (including any non-profit
corporation), general partnership, limited partnership, limited liability
partnership, joint venture, estate, trust, company (including any limited
liability company or joint stock company), firm or other enterprise,
association, organization or entity.
ENVIRONMENTAL LAW. "Environmental Law" shall have the meaning set forth in
Section 2.10.
ERISA. "ERISA" shall have the meaning set forth in Section 2.7(b).
EXCHANGE ACT. "Exchange Act" shall mean the Securities Exchange Act of
1934, as amended.
EXCHANGE AGENT. "Exchange Agent" shall have the meaning set forth in
Section 1.7(a).
EXCHANGE FUND. "Exchange Fund" shall have the meaning set forth in Section
1.7(a).
EXCHANGE RATIO. "Exchange Ratio" shall have the meaning set forth in
Section 1.5(b)(ii).
EXISTING POLICY. "Existing Policy" shall have the meaning set forth in
Section 4.19(b).
GAAP. "GAAP" shall mean generally accepted accounting principles.
GOVERNMENTAL AUTHORIZATION. "Governmental Authorization" shall mean any:
(a) permit, license, certificate, franchise, permission, clearance,
registration, qualification or authorization issued, granted, given or otherwise
made available by or under the authority of any Governmental Authority or
pursuant to any Legal Requirement; or (b) right under any Contract with any
Governmental Authority.
GOVERNMENTAL AUTHORITY. "Governmental Authority" shall mean any:
(a) nation, state, commonwealth, province, territory, county, municipality,
district or other jurisdiction of any
A-3
<PAGE>
nature; (b) federal, state, local, municipal, foreign or other government; or
(c) governmental or quasi-governmental authority of any nature (including any
governmental division, department, agency, commission, instrumentality,
official, organization, unit, body or Entity and any court or other tribunal).
INDEMNIFIED PARTIES. "Indemnified Parties" shall have the meaning set
forth in Section 4.19(a).
LEASES. "Leases" shall have the meaning set forth in Section 2.9(a).
LEGAL PROCEEDING. "Legal Proceeding" shall mean any action, suit,
litigation, arbitration, proceeding (including any civil, criminal,
administrative, investigative or appellate proceeding), hearing, inquiry, audit,
examination or investigation commenced, brought, conducted or heard by or
before, or otherwise involving, any court or other Governmental Authority or any
arbitrator or arbitration panel.
LEGAL REQUIREMENT. "Legal Requirement" shall mean any federal, state,
local, municipal, foreign or other law, statute, constitution, principle of
common law, resolution, ordinance, code, edict, decree, rule, regulation, ruling
or requirement issued, enacted, adopted, promulgated, implemented or otherwise
put into effect by or under the authority of any Governmental Authority.
LIABILITIES. "Liabilities" shall mean any liability or obligation of any
kind or nature, secured or unsecured (whether absolute, accrued, contingent or
otherwise, and whether due or to become due).
MARCH 1998 BALANCE SHEET. "March 1998 Balance Sheet" shall have the
meaning set forth in Section 2.2(b).
MATERIAL ADVERSE EFFECT. An event, violation, change, failure, inaccuracy,
circumstance or other matter will be deemed to have a "Material Adverse Effect"
on the Company if such event, violation, change, failure, inaccuracy,
circumstance or other matter (considered together with all other matters that
would constitute exceptions to the representations and warranties set forth in
Article 2 of the Agreement but for the presence of "Material Adverse Effect" or
other materiality qualifications, or any similar qualifications, in such
representations and warranties) would have a material adverse effect on (i) the
business, capitalization, operations or financial condition of the Company taken
as a whole, (ii) the ability of the Company to consummate the Merger or any of
the other transactions contemplated by the Agreement or to perform any of its
obligations under the Agreement, or (iii) Parent's ability to vote, receive
dividends with respect to or otherwise exercise ownership rights with respect to
the stock of the Surviving Corporation; PROVIDED, HOWEVER, that: (A) any
material adverse effect that results from general economic, business or industry
conditions or legislative or regulatory initiatives shall be disregarded in
determining whether there has been a "Material Adverse Effect" on the Company;
(B) any material adverse effect that results from the taking of any action
required by this Agreement or from the announcement or pendency of the
transactions contemplated by this Agreement shall be disregarded in determining
whether there has been a "Material Adverse Effect" on the Company; (C) any
material adverse effect that results from the issuance of a report by the
Company's
A-4
<PAGE>
accountant that expresses doubt as to the Company's ability to continue as a
going concern or the Company's lack of liquidity and capital resources shall be
disregarded in determining whether there has been a "Material Adverse Effect" on
the Company; and (D) a decline in the Company's stock price shall not, in and of
itself, constitute a "Material Adverse Effect" on the Company and shall be
disregarded in determining whether there has been a Material Adverse Effect on
the Company. An event, violation, change, failure, inaccuracy, circumstance or
other matter will be deemed to have a "Material Adverse Effect" on Parent if
such event, violation, change, failure, inaccuracy, circumstance or other matter
(considered together with all other matters that would constitute exceptions to
the representations and warranties set forth in Article 3 of the Agreement but
for the presence of "Material Adverse Effect" or other materiality
qualifications, or any similar qualifications, in such representations and
warranties) would have a material adverse effect on the business, operations or
financial condition of Parent and its subsidiaries taken as a whole; PROVIDED,
HOWEVER, that: (A) any material adverse effect that results from general
economic, business or industry conditions or legislative or regulatory
initiatives shall be disregarded in determining whether there has been a
"Material Adverse Effect" on Parent; (B) any material adverse effect that
results from the taking of any action required by this Agreement or from the
announcement or pendency of the transactions contemplated by this Agreement
shall be disregarded in determining whether there has been a "Material Adverse
Effect" on Parent; and (C) a decline in Parent's stock price shall not, in and
of itself, constitute a "Material Adverse Effect" on Parent and shall be
disregarded in determining whether there has been a "Material Adverse Effect" on
Parent.
MATERIAL COMPANY CONTRACT. "Material Company Contract" shall have the
meaning set forth in Section 2.6(a).
MATERIAL PARENT CONTRACTS. "Material Parent Contracts" shall have the
meaning set forth in Section 3.16.
MATERIALS OF ENVIRONMENTAL CONCERN. "Materials of Environmental Concern"
shall have the meaning set forth in Section 2.10.
MERGER. "Merger" shall have the meaning set forth in the recitals.
MERGER SUB. "Merger Sub" shall have the meaning set forth in the preamble.
NASD. "NASD" shall mean the National Association of Securities Dealers.
NASDAQ NMS. "Nasdaq NMS" shall have the meaning set forth in Section
1.5(b)(i).
OUTSTANDING SHARES. "Outstanding Shares" shall have the meaning set forth
in Section 1.5(b)(iii).
PARENT. "Parent" shall have the meaning set forth in the preamble.
PARENT COMMON STOCK. "Parent Common Stock" shall have the meaning set
forth in Section 1.5(a)(iii).
A-5
<PAGE>
PARENT DISCLOSURE SCHEDULE. "Parent Disclosure Schedule" shall have the
meaning set forth in the preamble to Article 3.
PARENT OPTIONS. "Parent Options" shall mean all outstanding options to
purchase shares of capital stock of Parent.
PARENT SEC DOCUMENTS. "Parent SEC Documents" shall have the meaning set
forth in Section 3.2(a).
PARENT STOCKHOLDERS' MEETING. "Parent Stockholders' Meeting" shall have
the meaning set forth in Section 4.10(a).
PARENT WARRANTS. "Parent Warrants" shall mean all outstanding Warrants to
purchase shares of capital stock of Parent.
PAST PREMIUM AMOUNT. "Past Premium Amount" shall have the meaning set
forth in Section 4.19(b).
PERSON. "Person" shall mean any individual, Entity or Governmental
Authority.
PRE-CLOSING PERIOD. "Pre-Closing Period" shall have the meaning set forth
in Section 4.1.
PROPRIETARY ASSET. "Proprietary Asset" shall mean any: (a) patent, patent
application, trademark (whether registered or unregistered), trademark
application, trade name, fictitious business name, service mark (whether
registered or unregistered), service mark application, copyright (whether
registered or unregistered), copyright application, maskwork, maskwork
application, trade secret, know-how, sample, media and/or cell line and
procedures and formulations for producing any such sample, media and/or cell
line, process, formula, test data, customer list, franchise, system, computer
software, source code, computer program, invention, design, blueprint,
engineering drawing, proprietary product, technology, proprietary right or other
intellectual property right or intangible asset; or (b) right to use or exploit
any of the foregoing.
PROSPECTUS/JOINT PROXY STATEMENT. "Prospectus/Joint Proxy Statement" shall
mean the prospectus/joint proxy statement, filed as a part of the S-4
Registration Statement, to be sent to the Company's stockholders in connection
with the Company Stockholders' Meeting and to Parent's stockholders in
connection with the Parent Stockholders' Meeting.
REPRESENTATIVES. "Representatives" shall mean officers, directors,
employees, agents, attorneys, accountants and advisors.
REQUIRED COMPANY STOCKHOLDER VOTE. "Required Company Stockholder Vote"
shall have the meaning set forth in Section 2.13.
REQUIRED PARENT STOCKHOLDER VOTE. "Required Parent Stockholder Vote" shall
have the meaning set forth in Section 3.8.
A-6
<PAGE>
S-4 REGISTRATION STATEMENT. "S-4 Registration Statement" shall have the
meaning set forth in Section 2.25(d).
SEC. "SEC" shall have the meaning set forth in Section 2.2(a).
SECURITIES ACT. "Securities Act" shall mean the Securities Act of 1933, as
amended.
SUPERIOR OFFER. "Superior Offer" shall mean an unsolicited, bona fide
written offer made by a third party to purchase more than 50% of the outstanding
shares of Company Common Stock on terms that the Board of Directors of the
Company determines, in its reasonable judgment, after consultation with its
financial advisor, to be more favorable from a financial point of view to the
Company's stockholders than the terms of the Merger; PROVIDED, HOWEVER, that any
such offer shall not be deemed to be a "Superior Offer" if any financing
required to consummate the transaction contemplated by such offer is not
committed and is not likely to be obtained by such third party on a timely
basis.
SURVIVING CORPORATION. "Surviving Corporation" shall have the meaning set
forth in Section 1.1.
TAX. "Tax" shall mean any tax (including any income tax, franchise tax,
capital gains tax, gross receipts tax, value-added tax, surtax, excise tax, ad
valorem tax, transfer tax, stamp tax, sales tax, use tax, property tax, business
tax, withholding tax or payroll tax), levy, assessment, tariff, duty (including
any customs duty), deficiency or fee, and any related charge or amount
(including any fine, penalty or interest), imposed, assessed or collected by or
under the authority of any Governmental Authority.
TAX RETURN. "Tax Return" shall mean any return (including any information
return), report, statement, declaration, estimate, schedule, notice,
notification, form, election, certificate or other document or information filed
with or submitted to, or required to be filed with or submitted to, any
Governmental Authority in connection with the determination, assessment,
collection or payment of any Tax or in connection with the administration,
implementation or enforcement of or compliance with any Legal Requirement
relating to any Tax.
THIRD PARTY PROPRIETARY ASSETS. "Third Party Proprietary Assets" shall
have the meaning set forth in Section 2.5(b).
TOTAL MERGER SHARES. "Total Merger Shares" shall have the meaning set
forth in Section 1.5(b)(i).
TRIGGERING EVENT. A "Triggering Event" shall be deemed to have occurred
if: (i) this Agreement is terminated due to breach of this Agreement by the
Company; (ii) the Board of Directors of the Company shall have failed to
recommend, or shall for any reason have withdrawn or shall have amended or
modified in a manner adverse to Parent its recommendation in favor of the
adoption and approval of this Agreement or the approval of the Merger; (iii) the
Company shall have failed to include in the Prospectus/Joint Proxy Statement the
recommendation of the Board of Directors of the Company in favor of adoption and
approval of this Agreement and approval of the Merger; (iv) the Company shall
have approved, endorsed or recommended any Acquisition Proposal or Parent
terminates this Agreement after the Company
A-7
<PAGE>
publicly announces it is considering an Acquisition Proposal; (v) a tender or
exchange offer relating to securities of the Company shall have been commenced
and the Company shall not have sent to its securityholders, within ten (10)
business days after the commencement of such tender or exchange offer, a
statement disclosing that the Company does not recommend acceptance of such
tender or exchange offer; (vi) an Acquisition Proposal is publicly announced,
and the Company (A) fails to issue a press release announcing its opposition to
such Acquisition Proposal within five (5) business days after such Acquisition
Proposal is announced or (B) otherwise fails to actively oppose such Acquisition
Proposal; or (vii) the Company shall have failed to hold the Company
Stockholders' Meeting as promptly as practicable and in any event within 45 days
after the S-4 Registration Statement is declared effective under the Securities
Act.
A-8
<PAGE>
EXHIBIT B
[RESERVED]
<PAGE>
EXHIBIT C
DIRECTORS OF SURVIVING CORPORATION
Michael J. Brennan, M.D., Ph.D.
Alan G. Walton, Ph.D., D.Sc.
OFFICERS OF SURVIVING CORPORATION
Michael J. Brennan, M.D., Ph.D., President and Chief Executive Officer
Mark D. Gessler, Senior Vice President, Corporate Development and Chief
Financial Officer
Alan G. Walton, Ph.D., D.Sc., Chairman of the Board of Directors
<PAGE>
EXHIBIT D
FORM OF COMPANY STOCK OPTION AGREEMENT
<PAGE>
ONCORMED, INC.
STOCK OPTION AGREEMENT
WITNESSETH:
RECITALS
A. The Board of Directors (the "Board") of OncorMed, Inc. (the
"Corporation") has adopted the Corporation's Restated 1993 Stock Option Plan
(the "Plan") for the purpose of attracting and retaining the services of
employees (including officers and directors), non-employee Board members and
consultants.
B. Optionee is an individual who is to render valuable services to the
Corporation or one or more parent or subsidiary corporations, and this Agreement
is executed pursuant to, and is intended to carry out the purposes of, the Plan
in connection with the grant of a stock option to purchase shares of the
Corporation's common stock ("Common Stock") under the Plan.
NOW, THEREFORE, it is hereby agreed as follows:
1. GRANT OF OPTION. Subject to and upon the terms and conditions set
forth in this Agreement, the Corporation hereby grants to Optionee, as of the
grant date (the "Grant Date") specified in the accompanying Notice of Grant of
Stock Option (the "Grant Notice"), a stock option to purchase up to that number
of shares of the Corporation's Common Stock (the "Option Shares") as is
specified in the Grant Notice. Such Option Shares shall be purchasable from
time to time during the option term at the exercise price (the "Exercise Price")
specified in the Grant Notice.
2. OPTION TERM. This option shall expire at the close of business on the
expiration date (the "Expiration Date") specified in the Grant Notice, unless
sooner terminated in accordance with Paragraph 5 or 6.
3. LIMITED TRANSFERABILITY. This option shall be exercisable only by
Optionee during Optionee's lifetime and shall not be transferable or assignable
by Optionee other than by will or by the laws of descent and distribution
following Optionee's death.
4. EXERCISABILITY. This option shall become exercisable for the Option
Shares in accordance with the installment schedule specified in the Grant
Notice. As this option becomes exercisable for one or more installments, those
installments shall accumulate, and the option shall remain exercisable for the
accumulated installments until the Expiration Date or sooner termination of the
option term under Paragraph 5 or 6. In no event shall this option become
exercisable for any additional Option Shares following Optionee's cessation of
Service.
5. CESSATION OF SERVICE. The option term specified in Paragraph 2 shall
terminate (and this option shall cease to remain outstanding) prior to the
Expiration Date in accordance with the following provisions:
1.
<PAGE>
(a) This option shall immediately terminate and cease to remain
outstanding for any Option Shares for which it is not exercisable at the time of
Optionee's cessation of Service (as defined below).
(b) Should Optionee cease to remain in Service for any reason other
than death or permanent disability, then the period during which this option is
to remain exercisable shall be limited to the three (3)-month period following
the date of such cessation of Service.
(c) Should such Service terminate by reason of permanent disability,
then the period during which this option is to remain exercisable shall be
limited to the twelve (12)-month period following the date of such cessation of
Service.
(d) Should Optionee die while holding this option, then the period
during which this option is to remain exercisable shall be limited to the twelve
(12)-month period following the date of Optionee's death. During such limited
period, this option may be exercised by the personal representative of
Optionee's estate or by the person or persons to whom this option is transferred
pursuant to Optionee's will or in accordance with the laws of descent and
distribution.
(e) Under no circumstances, however, shall this option be exercisable
after the specified expiration date of the option term.
(f) During the applicable limited post-Service exercise period, this
option may not be exercised in the aggregate for more than the number of vested
shares for which this option is exercisable on the date of Optionee's cessation
of Service. Upon the expiration of such limited exercise period or (if earlier)
upon the expiration of the option term, this option shall terminate and cease to
be exercisable for any vested shares for which this option has not been
exercised. However, this option shall, immediately upon Optionee's cessation of
Service, terminate and cease to be outstanding with respect to any Option Shares
for which this option is not at that time exercisable or in which Optionee is
not otherwise at that time vested.
(g) For purposes of this Agreement, the following definitions shall
be in effect:
Optionee shall be deemed to remain in Service for so long as such
individual performs services on a periodic basis to the Corporation (or any
parent or subsidiary corporation) in the capacity of an Employee, a non-employee
member of the Board, a consultant or an independent contractor.
Optionee shall be considered to be an Employee for so long as such
individual performs services while in the employ of the Corporation or any
parent or subsidiary, subject to the control and direction of the employer
entity not only as to the work to be performed but also as to the manner and
method of performance.
Optionee shall be deemed to have incurred a permanent disability if
Optionee is unable to engage in any substantial gainful activity by reason of
any medically determinable physical or mental impairment expected to result in
death or to be of continuous duration of twelve (12) months or more.
2.
<PAGE>
A corporation shall be considered to be a subsidiary of the Corporation if
it is a member of an unbroken chain of corporations beginning with the
Corporation, provided each such corporation in the unbroken chain (other than
the last corporation) owns, at the time of determination, stock possessing fifty
percent (50%) or more of the total combined voting power of all classes of stock
in one of the other corporations in such chain. A corporation shall be
considered to be a parent of the Corporation if it is a member of an unbroken
chain ending with the Corporation provided each such corporation in the unbroken
chain (other than the Corporation) owns, at the time of determination, stock
possessing fifty percent (50%) or more of the total combined voting power of all
classes of stock in one of the other corporations in such chain.
6. CORPORATE TRANSACTION.
(a) In the event of any of the following stockholder-approved
transactions to which the Corporation is a party (a "Corporate Transaction"):
(i) a merger or consolidation in which more than fifty
percent (50%) of the Corporation's outstanding voting stock is transferred to a
person or persons different from those who held the stock immediately prior to
such transaction, or
(ii) the sale, transfer or other disposition of all or
substantially all of the Corporation's assets in complete liquidation or
dissolution of the Corporation,
this option, to the extent outstanding at such time but not otherwise
exercisable, shall automatically accelerate so that such option shall,
immediately prior to the specified effective date for the Corporate Transaction,
become fully exercisable for all the Option Shares at the time subject to such
option and may be exercised for all or any portion of such shares. No such
acceleration of this option, however, shall occur if and to the extent: (i) this
option is, in connection with the Corporate Transaction, either to be assumed by
the successor corporation or parent thereof or replaced with a comparable option
to purchase shares of the capital stock of the successor corporation or parent
thereof or (ii) this option is to be replaced by a comparable cash incentive
program of the successor corporation based on the option spread existing at the
time of the Corporate Transaction. The determination of option comparability
under clause (i) or (ii) shall be made by the Plan Administrator, and such
determination shall be final, binding and conclusive.
(b) The portion of this option accelerated in connection with any
Corporate Transaction shall remain exercisable as an incentive stock option
under the Federal tax laws (if the option is designated as such in the Grant
Notice) only to the extent the applicable dollar limitation of Paragraph 17 is
not exceeded in the calendar year of such Corporate Transaction.
(c) This option, to the extent not previously exercised, shall
terminate immediately after the consummation of such Corporate Transaction and
cease to remain outstanding, unless it is expressly assumed by the successor
corporation or parent thereof.
(d) This Agreement shall not in any way affect the right of the
Corporation to adjust, reclassify, reorganize or otherwise make changes in its
capital or business structure or to merge, consolidate, dissolve, liquidate or
sell or transfer all or any part of its business or assets.
3.
<PAGE>
7. ADJUSTMENT IN OPTION SHARES.
(a) In the event any change is made to the Common Stock issuable
under the Plan by reason of any stock split, stock dividend, recapitalization,
combination of shares, exchange of shares or other change affecting the
outstanding Common Stock as a class effected without the Corporation's receipt
of consideration, the Plan Administrator shall make appropriate adjustments to
(i) the number and/or class of securities subject to this option and (ii) the
Exercise Price payable per share in order to prevent any dilution or enlargement
of rights and benefits hereunder. Such adjustments shall be final, binding and
conclusive.
(b) If this option is to be assumed in connection with any Corporate
Transaction under Paragraph 6 or is otherwise to continue outstanding, then this
option shall, immediately after the effective date of such Corporate
Transaction, be appropriately adjusted to apply and pertain to the number and
class of securities which would have been issued to Optionee in the consummation
of such Corporate Transaction had the option been exercised immediately prior to
such Corporate Transaction. Appropriate adjustments shall also be made to the
Exercise Price payable per share, PROVIDED the aggregate Exercise Price payable
hereunder shall remain the same.
8. PRIVILEGE OF STOCK OWNERSHIP. The holder of this option shall not
have any of the rights of a stockholder with respect to the Option Shares until
such individual shall have exercised the option and paid the Exercise Price for
the purchased Option Shares.
9. MANNER OF EXERCISING OPTION.
(a) In order to exercise this option with respect to all or any part
of the Option Shares for which this option is at the time exercisable, Optionee
(or in the case of exercise after Optionee's death, Optionee's executor,
administrator, heir or legatee, as the case may be) must take the following
actions:
(i) Deliver to the Secretary of the Corporation an executed
notice of exercise in substantially the form of Exhibit I to this Agreement (the
"Exercise Notice") in which there is specified the number of Option Shares which
are to be purchased under the exercised option.
(ii) Pay the aggregate Exercise Price for the purchased shares
through one of the following alternatives:
(1) full payment in cash or by check made payable to the
Corporation's order;
(2) full payment in shares of Common Stock held for the
requisite period necessary to avoid a charge to the Corporation's earnings for
financial reporting purposes and valued at Fair Market Value (as such term is
defined below) on the Exercise Date (as such term is defined below); or
(3) full payment effected through a broker-dealer sale and
remittance procedure pursuant to which Optionee shall provide concurrent
irrevocable written
4.
<PAGE>
instructions (i) to a Corporation-designated brokerage firm to effect the
immediate sale of the purchased shares and remit to the Corporation, out of the
sale proceeds available on the settlement date, sufficient funds to cover the
aggregate Exercise Price payable for the purchased shares plus all applicable
Federal, state and local income and employment taxes required to be withheld in
connection with such purchase and (ii) to the Corporation to deliver the
certificates for the purchased shares directly to such brokerage firm in order
to complete the sale transaction.
(iii) Furnish to the Corporation appropriate documentation that
the person or persons exercising this option (if other than Optionee) have the
right to exercise the option.
(b) For purposes of this Agreement, the Exercise Date shall be the
date on which the executed Exercise Notice shall have been delivered to the
Corporation. Except to the extent the sale and remittance procedure specified
above is utilized in connection with the option exercise, payment of the
Exercise Price for the purchased shares must accompany such Exercise Notice.
(c) For all valuation purposes under this Agreement, the Fair Market
Value per share of Common Stock on any relevant date shall be determined in
accordance with the following provisions:
(i) If the Common Stock is not at the time listed or admitted
to trading on any Stock Exchange but is traded on the Nasdaq National Market,
the Fair Market Value shall be the closing selling price per share of Common
Stock on the date in question, as the price is reported by the National
Association of Securities Dealers through the Nasdaq National Market or any
successor system. If there is no closing selling price for the Common Stock on
the date in question, then the Fair Market Value shall be the closing selling
price on the last preceding date for which such quotation exists.
(ii) If the Common Stock is not at the time listed or admitted
to trading on any Stock Exchange or the Nasdaq National Market, but is traded on
the Nasdaq SmallCap Market or over-the-counter market, the fair market value
shall be the mean between the highest bid and lowest asked prices of one share
of Common Stock on the day preceding the date in question on the Nasdaq SmallCap
Market or over-the-counter market, as such prices are reported by the National
Association of Securities Dealers through its Nasdaq system or any successor
system. If there are no reported bid and asked prices for the Common Stock on
such day, then the mean between the highest bid and lowest asked prices on the
last preceding date for which such quotations exist shall be determinative of
fair market value.
(iii) If the Common Stock is at the time listed or admitted to
trading on any Stock Exchange, then the Fair Market Value shall be the closing
selling price per share of Common Stock on the date in question on the Stock
Exchange determined by the Plan Administrator to be the primary market for the
Common Stock, as such price is officially quoted in the composite tape of
transactions on such exchange. If there is no closing selling price for the
Common Stock on the date in question, then the Fair Market Value shall be the
closing selling price on the last preceding date for which such quotation
exists.
5.
<PAGE>
(iv) If the Common Stock is at the time neither listed nor
admitted to trading on any Stock Exchange nor traded on the Nasdaq National
Market, the Nasdaq SmallCap Market or in the over-the-counter market, or if the
Plan Administrator determines that the value determined pursuant to subparagraph
(1), (2) or (3) does not accurately reflect the fair market value of the Common
Stock, then such Fair Market Value shall be determined by the Plan Administrator
after taking into account such factors as the Plan Administrator shall deem
appropriate.
(d) For purposes of this Agreement, Stock Exchange shall mean either
the American Stock Exchange or the New York Stock Exchange.
(e) As soon as practical after receipt of the Exercise Notice, the
Corporation shall mail or deliver to or on behalf of Optionee (or any other
person or persons exercising this option in accordance herewith) a certificate
or certificates representing the purchased Option Shares.
(f) In no event may this option be exercised for any fractional
share.
10. GOVERNING LAW. The interpretation, performance and enforcement of
this Agreement shall be governed by the laws of the State of Maryland without
resort to that State's conflict-of-laws provisions.
11. COMPLIANCE WITH LAWS AND REGULATIONS. The exercise of this option and
the issuance of Option Shares upon such exercise shall be subject to compliance
by the Corporation and Optionee with all applicable requirements of law relating
thereto and with all applicable regulations of any securities exchange on which
shares of the Corporation's Common Stock may be listed at the time of such
exercise and issuance.
12. SUCCESSORS AND ASSIGNS. The provisions of this Agreement shall inure
to the benefit of, and be binding upon, the Corporation and its successors or
assigns, whether by Corporate Transaction or otherwise, and Optionee, the legal
representatives of his or her estate, his or her respective heirs or legatees
and permitted assignees.
13. LIABILITY OF CORPORATION.
(a) If the Option Shares covered by this Agreement exceed, as of the
Grant Date, the number of shares which may without stockholder approval be
issued under the Plan, then this option shall be void with respect to such
excess shares unless stockholder approval of an amendment sufficiently
increasing the number of shares issuable under the Plan is obtained in
accordance with the provisions of Section II of Article Four of the Plan.
(b) The inability of the Corporation to obtain approval from any
regulatory body having authority deemed by the Corporation to be necessary to
the lawful issuance and sale of any Common Stock pursuant to this option
shall relieve the Corporation of any liability with respect to the
non-issuance or sale of the Common Stock as to which such approval shall not
have been obtained. The Corporation shall use its best efforts to obtain all
such approvals.
6.
<PAGE>
14. NO EMPLOYMENT/SERVICE CONTRACT. Nothing in this Agreement or in the
Plan shall confer upon Optionee any right to continue in the Service of the
Corporation (or any parent or subsidiary employing or retaining Optionee) for
any period of specific duration or interfere with or otherwise restrict in any
way the rights of the Corporation (or any such parent or subsidiary) or
Optionee, which rights are hereby expressly reserved by each party, to terminate
Optionee's Service at any time for any reason whatsoever, with or without cause.
15. NOTICES. Any notice required to be given or delivered to the
Corporation under the terms of this Agreement shall be in writing and addressed
to the Corporation in care of the Secretary at the Corporation's principal
offices at 205 Perry Parkway, Gaithersburg, MD 20877. Any notice required to be
given or delivered to Optionee shall be in writing and addressed to Optionee at
the address indicated on the Grant Notice. All notices shall be deemed to have
been given or delivered upon personal delivery or upon deposit in the U.S. mail,
by registered or certified mail, postage prepaid and properly addressed to the
party to be notified.
16. CONSTRUCTION. This Agreement and the option evidenced hereby are made
and granted pursuant to the Plan and are in all respects limited by and subject
to the express terms and provisions of the Plan. All decisions of the Plan
Administrator with respect to any question or issue arising under the Plan or
this Agreement shall be conclusive and binding on all persons having an interest
in this option.
17. ADDITIONAL TERMS APPLICABLE TO AN INCENTIVE STOCK OPTION. In the
event this option is designated an incentive stock option in the Grant Notice,
the following terms and conditions shall also apply to the grant:
(a) This option shall cease to qualify for favorable tax treatment as
an incentive stock option under the Federal tax laws if (and to the extent) this
option is exercised for one or more Option Shares: (i) more than three (3)
months after the date Optionee ceases to be an Employee for any reason other
than death or permanent disability (as defined in Paragraph 5) or (ii) more than
one (1) year after the date Optionee ceases to be an Employee by reason of
permanent disability.
(b) If this option is to become exercisable in a series of
installments as indicated in the Grant Notice, no such installment shall qualify
for favorable tax treatment as an incentive stock option under the Federal tax
laws if (and to the extent) the aggregate Fair Market Value (determined at the
Grant Date) of the shares of the Corporation's Common Stock for which such
installment first becomes exercisable hereunder will, when added to the
aggregate value (determined as of the respective date or dates of grant) of the
Common Stock or other securities for which this option or one or more other
incentive stock options granted to Optionee prior to the Grant Date (whether
under the Plan or any other option plan of the Corporation or any parent or
subsidiary) first become exercisable during the same calendar year, exceed One
Hundred Thousand Dollars ($100,000) in the aggregate. Should the number of
shares of Common Stock for which this option first becomes exercisable in any
calendar year exceed the applicable One Hundred Thousand Dollar ($100,000)
limitation, the option may nevertheless be exercised for those excess shares in
such calendar year as a non-statutory option.
7.
<PAGE>
(c) Should the exercisability of this option be accelerated upon a
Corporate Transaction in accordance with Paragraph 6, then this option shall
qualify for favorable tax treatment as an incentive stock option under the
Federal tax laws only to the extent the aggregate Fair Market Value (determined
at the Grant Date) of the number of shares of the Corporation's Common Stock for
which this option first becomes exercisable in the calendar year in which the
Corporate Transaction occurs does not, when added to the aggregate value
(determined as of the respective date or dates of grant) of the shares of Common
Stock or other securities for which this option or one or more other incentive
stock options granted to Optionee prior to the Grant Date (whether under the
Plan or any other option plan of the Corporation or any parent or subsidiary)
first become exercisable during the same calendar year, exceed One Hundred
Thousand Dollars ($100,000) in the aggregate. Should the number of shares of
Common Stock for which this option first becomes exercisable in the calendar
year of such Corporate Transaction exceed the applicable One Hundred Thousand
Dollar ($100,000) limitation, the option may nevertheless be exercised for the
excess shares in such calendar year as a non-statutory option.
(d) Should Optionee hold, in addition to this option, one or more
other options to purchase shares of the Corporation's Common Stock which become
exercisable for the first time in the same calendar year as this option, then
the foregoing limitations on the exercisability of such options as incentive
stock options under the Federal tax laws shall be applied on the basis of the
order in which such options are granted.
(e) To the extent this option should fail to qualify for incentive
stock option treatment under the Federal tax laws, Optionee shall recognize
compensation income at the time the option is exercised in an amount equal to
the Fair Market Value of the purchased Option Shares less the aggregate Exercise
Price paid for those shares, and Optionee must make appropriate arrangements
with the Corporation or any parent or subsidiary employing Optionee for the
satisfaction of all Federal, state or local income and employment tax
withholding requirements applicable to such compensation income.
18. ADDITIONAL TERMS APPLICABLE TO A NON-STATUTORY STOCK OPTION.
In the event this option is designated a non-statutory stock option in the
Grant Notice, Optionee shall make appropriate arrangements with the
Corporation or any parent or subsidiary employing Optionee for the
satisfaction of all Federal, state or local income and employment tax
withholding requirements applicable to the exercise of this option.
19. MARKET STAND-OFF. In connection with any public offering of
the Corporation's securities, Optionee hereby agrees to be subject to a
lock-up for such period following the public offering as required by the
underwriter or underwriters of such public offering. During such periods,
Optionee agrees not to directly or indirectly sell, offer to sell, contract
to sell (including, without limitation, any short sale), grant any option to
purchase or otherwise transfer or dispose of (other than to donees who agree
to be similarly bound) any Option Shares during such period without the prior
written consent of such underwriter or underwriters.
8.
<PAGE>
EXHIBIT I
NOTICE OF EXERCISE OF STOCK OPTION
I hereby notify OncorMed, Inc. (the "Corporation") that I elect to purchase
___________ shares of the Corporation's Common Stock (the "Purchased Shares") at
the option exercise price of $_____ per share (the "Exercise Price") pursuant to
that certain option (the "Option") granted to me under the Corporation's
Restated 1993 Stock Option Plan on _________, 199__ to purchase up to
___________ shares of the Corporation's Common Stock.
Concurrently with the delivery of this Exercise Notice to the Secretary of
the Corporation, I shall hereby pay to the Corporation the Exercise Price for
the Purchased Shares in accordance with the provisions of my agreement with the
Corporation evidencing this Option and shall deliver whatever additional
documents may be required by such agreement as a condition for exercise.
Alternatively, I may utilize the special broker-dealer sale and remittance
procedure specified in my agreement to effect the payment of the Exercise Price
for the Purchased Shares.
, 199
- ------------------- --
Date
-----------------------------
Optionee
Address:
-------------------
-------------------
Print name in exact manner it
is to appear on the stock
certificate: ---------------------
Address to which certificate
is to be sent, if different
from address above: ---------------------
---------------------
Social Security Number: ---------------------
9.
<PAGE>
EXHIBIT E
FORM OF COMPANY PROPRIETARY INFORMATION AND ASSIGNMENT AGREEMENT
<PAGE>
PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT
--------------------------
(Date)
OncorMed, Inc.
205 Perry Parkway
Gaithersburg, MD 20877
Ladies and Gentlemen:
The following confirms an agreement between OncorMed, Inc., a Delaware
corporation (the "Company"), and any successor in interest, and me, which is a
material part of the consideration for my employment or continued employment by
the Company:
1. PROPRIETARY INFORMATION. I recognize that the Company is engaged
in a continuous program of research, development and production. I also
recognize that the Company possesses or has rights to information (including
information developed by me during my employment by the Company) which has
commercial value in the Company's business ("Proprietary Information"). By way
of illustration, but not limitation, Proprietary Information includes
inventions, products, processes, methods, techniques, formulas, compositions,
compounds, projects, developments, plans, research data, clinical data,
financial data, personnel data, computer programs, customer and supplier lists,
and contacts at or knowledge of customers or prospective customers of the
Company.
2. OBLIGATION OF CONFIDENTIALITY. I understand and agree that my
employment creates a relationship of confidence and trust between the Company
and me with respect to (i) all Proprietary Information, and (ii) the
confidential information of others with which the Company has a business
relationship. At all times, both during my employment by the Company and after
its termination, I will keep in confidence and trust all such information, and I
will not use or disclose any such information without the written consent of the
Company, except as may be necessary in the ordinary course of performing my
duties to the Company.
3. DISCLOSURE AND ASSIGNMENT OF INVENTIONS. In addition, I hereby
agree as follows:
<PAGE>
(a) All Proprietary Information shall be the sole property of
the Company and its assigns, and the Company and its assigns shall be the sole
owner of all trade secrets, patents, trademarks, copyrights, and other rights in
connection therewith. I hereby assign to the Company any rights I may have or
acquire in such Proprietary Information.
(b) All documents, records, apparatus, equipment and other
physical property, whether or not pertaining to Proprietary Information,
furnished to me by the Company or produced by me or others in connection with my
employment shall be and remain the sole property of the Company. I shall return
to the Company all such materials and property as and when requested by the
Company. Even if the Company does not so request, I shall return all such
materials and property upon termination of my employment by me or by the Company
for any reason, and I will not take with me any such material or property or any
reproduction thereof upon such termination.
(c) I will promptly disclose to the Company, or any persons
designated by it, all improvements, inventions, works of authorship, formulas,
ideas, processes, techniques, know-how and data, whether or not patentable
(collectively, "Inventions"), made or conceived, reduced to practice or learned
by me, either alone or jointly with others, during the term of my employment and
for one (1) year thereafter.
(d) All Inventions which I conceive, develop or have developed
(in whole or in part, either alone or jointly with others) and (i) which use or
have used equipment, supplies, facilities or trade secret information of the
Company, or (ii) which use or have used the hours for which I am to be or was
compensated by the Company, or (iii) which relate at the time of conception or
reduction to practice thereof to the business of the Company or to its actual or
demonstrably anticipated research and development or (iv) which result from any
work performed by me for the Company, shall be the sole property of the Company
and its assigns (and to the fullest extent permitted by law shall be deemed
works made for hire), and the Company and its assigns shall be the sole owner of
all patents, copyrights and other rights in connection therewith. I hereby
assign to the Company any rights I may have or acquire in such Inventions. I
agree that any Invention required to be disclosed under paragraph (c) above
within one (1) year after the term of my employment shall be presumed to have
been conceived during my employment. I understand that I may overcome the
presumption by showing that such Invention was conceived after the termination
of my employment.
(e) With respect to Inventions described in paragraph (d) above,
I will assist the Company in every proper way (but at the Company's expense) to
obtain and from time to time enforce patents, copyrights or other rights on said
Inventions in any and
- 2 -
<PAGE>
all countries, and will execute all documents reasonably necessary or
appropriate for this purpose. This obligation shall survive the termination
of my employment, but the Company shall compensate me at a reasonable rate
after such termination for time actually spent by me at the Company's request
on such assistance. In the event that the Company is unable for any reason
whatsoever to secure my signature to any document reasonably necessary or
appropriate for any of the foregoing purposes, (including renewals,
extensions, continuations, divisions or continuations in part), I hereby
irrevocably designate and appoint the Company and its duly authorized
officers and agents, as my agents and attorneys-in-fact to act for and in my
behalf and instead of me, but only for the purpose of executing and filing
any such document and doing all other lawfully permitted acts to accomplish
the foregoing purposes with the same legal force and effect as if executed by
me.
(f) I understand that this Agreement does not require
assignment of an invention for which no equipment, supplies, facility, or
trade secret information of the Company was used and which was developed
entirely on my own time, unless the invention relates (i) directly to the
business of the Company, or (ii) to the Company's actual or demonstrably
anticipated research or development. However, I will disclose any Inventions
as required by paragraph (c) above in order to permit the Company to
determine such issues as may arise. Such disclosure shall be received in
confidence by the Company.
4. OTHER BUSINESS ACTIVITIES. So that the Company may be aware of
the extent of any other demands upon my time and attention, I will disclose to
the Company (such disclosure to be held in confidence by the Company) the nature
and scope of any other business activity in which I am or become engaged during
the term of my employment. During the term of my employment, I will not engage
in any business activity which is related to the Company's business or its
actual or demonstrably anticipated research and development.
5. NON-SOLICITATION OF EMPLOYEES, CUSTOMERS OR OTHERS. I will not
now or in the future disrupt, damage, impair or interfere with the business of
the Company, whether by way of interfering with or raiding its employees,
disrupting its relationships with customers, agents, vendors, distributors or
representatives, or otherwise. During my employment with the Company and for
one (1) year thereafter, I will not encourage or solicit any employee of the
Company to leave the Company for any reason; provided, however, that this
obligation shall not affect any responsibility I may have as an employee of the
Company with respect to the bona fide hiring and firing of Company personnel.
6. PRIOR INVENTIONS. As a matter of record I attach hereto a
complete list of all inventions or improvements relevant to the subject matter
of my employment by the Company which have been made or conceived or first
reduced to practice by me, alone or jointly with others, prior to my employment
with the Company that I desire to remove from
- 3 -
<PAGE>
the operation of this Agreement, and I covenant that such list is complete.
If no such list is attached to this Agreement, I represent that I have no such
inventions and improvements at the time of signing this
Agreement.
7. OBLIGATIONS TO FORMER EMPLOYERS. I represent that my execution
of this Agreement, my employment with the Company and my performance of my
proposed duties to the Company in the development of its business will not
violate any obligations I may have to any former employer or any other third
party, including any obligations to keep confidential any proprietary or
confidential information. I have not entered into, and I will not enter into,
any agreement which conflicts with or would, if performed by me, cause me to
breach this Agreement.
8. CONFIDENTIAL INFORMATION OF FORMER EMPLOYERS. In the course of
performing my duties to the Company, I will not utilize any proprietary or
confidential information of any former employer.
9. NO EMPLOYMENT AGREEMENT. I agree that this Agreement does not
constitute an employment agreement and that, unless otherwise provided in a
written contract signed by both the Company and me, (i) my employment with the
Company is "at will," and (ii) I shall have the right to resign my employment,
and the Company shall have the right to terminate my employment, at any time and
for any reason, with or without cause.
10. UNITED STATES GOVERNMENT OBLIGATIONS. I acknowledge that the
Company from time to time may have agreements with other persons or with the
United States Government, or agencies thereof, which impose obligations or
restrictions on the Company regarding inventions made during the course of work
under such agreements or regarding the confidential nature of such work. I
agree to be bound by all such obligations and restrictions which are made known
to me and to take all action necessary to discharge the obligations of the
Company under such agreements.
11. MISCELLANEOUS.
(a) If one or more provisions of this Agreement are held to be
unenforceable under applicable law, such provision shall be construed, if
possible, so as to be enforceable under applicable law, else, such provision
shall be excluded from this Agreement and the balance of the Agreement shall be
interpreted as if such provision were so excluded and shall be enforceable in
accordance with its terms.
(b) No delay or omission by the Company in exercising any right
hereunder will operate as a waiver of that or any other right. A waiver or
consent given by
- 4 -
<PAGE>
the Company on any one occasion is effective only in that instance and will not
be construed as a bar to or waiver of any right on any other occasion.
(c) I expressly consent to be bound by the provisions hereof for
the benefit of the Company or any subsidiary or affiliate thereof to whose
employ I may be transferred without the necessity that this Agreement be
reassigned at the time of such transfer.
(d) This Agreement shall be governed by and construed under the
laws of the State of Maryland as applied to agreements among Maryland residents
entered into and to be performed entirely within Maryland, without regards to
the application of choice of law rules.
(e) This Agreement shall be effective as of the first day of my
employment by the Company, shall be binding upon me, my heirs, executors,
assigns and administrators and shall inure to the benefit of the Company, its
successors and assigns.
Dated:
------------
-----------------------------------
Employee Signature
Name:
-----------------------------
SS#:
-----------------------------
Accepted and Agreed to:
ONCORMED, INC.
By:
------------------
Name:
---------------------------
Title:
--------------
- 5 -
<PAGE>
EXHIBIT A
OncorMed, Inc.
205 Perry Parkway
Gaithersburg, MD 20877
Ladies and Gentlemen:
1. The following is a complete list of all inventions or
improvements relevant to the subject matter of my employment by OncorMed, Inc.
(the "Company") that have been made or conceived or first reduced to practice by
me, alone or jointly with others, prior to my employment by the Company that I
desire to remove from the operation of the Company's Proprietary Information and
Inventions.
- ----- No inventions or improvements.
- ----- See below: Any and all inventions regarding
- ----- Additional sheets attached.
2. I propose to bring to my employment the following materials and
documents of a former employer:
- ----- No materials or documents.
- ----- See below:
Date:
--------------------------------------
Employee Signature
Name:
------------------------
- 1 -
<PAGE>
EXHIBIT F
FORM OF COMPANY AFFILIATE AGREEMENT
<PAGE>
AFFILIATE AGREEMENT
This Affiliate Agreement (this "Agreement") is entered into as of July 6,
1998, by and between GENE LOGIC INC., a Delaware corporation ("Parent"), and the
undersigned affiliate ("Affiliate") of ONCORMED, INC., a Delaware corporation
(the "Company").
RECITALS
A. Pursuant to that certain Agreement and Plan of Merger and
Reorganization (the "Merger Agreement"), dated as of July 6, 1998, by and among
Parent, GENE LOGIC ACQUISITION CORP., a Delaware corporation ("Merger Sub") and
the Company, the Company will merge with and into Merger Sub (the "Merger").
B. As a result of the Merger, the stockholders of the Company will
receive shares (the "Shares") of Parent Common Stock (as defined in the Merger
Agreement). Affiliate understands that he, she or it may be deemed an
"affiliate" of the Company as such term is used in paragraphs (c) and (d) of
Rule 145 ("Rule 145") under the Securities Act of 1933, as amended (the "Act"),
and as such Affiliate may only transfer, sell or dispose of Shares in accordance
with this Agreement and Rule 145.
C. Affiliate understands that the representations, warranties and
covenants set forth herein will be relied upon by Parent, Merger Sub and the
Company, and their respective counsel.
AGREEMENT
NOW, THEREFORE, the parties hereby agree as follows:
1. Capitalized terms used in this Agreement and not otherwise defined
shall have the meanings given them in the Merger Agreement.
2. Affiliate represents, warrants, understands and agrees that:
(a) Affiliate has the requisite power and capacity to execute and
deliver this Agreement and to make the representations, warranties and
agreements herein and to perform Affiliate's obligations hereunder;
(b) Affiliate has carefully read this Agreement and has discussed the
terms hereof with counsel, to the extent Affiliate felt necessary, the
requirements, limitations and restrictions on Affiliate's ability to sell,
transfer or otherwise dispose of the Shares Affiliate may receive upon the
consummation of the Merger and fully understands the requirements, limitations
and restrictions this Agreement places upon Affiliate's ability to transfer,
sell or otherwise dispose of such Shares;
(c) If Affiliate has executed any other agreement in connection
herewith (the "Other Agreements"), Affiliate understands and agrees to abide by
all restrictions contained therein;
1.
<PAGE>
(d) Affiliate will not sell, pledge, transfer or otherwise dispose of
any of the Shares held by Affiliate unless at such time either (i) such transfer
shall be in conformity with the provisions of Rule 145, (ii) Affiliate shall
have furnished to Parent an opinion of counsel reasonably satisfactory to
Parent, to the effect that no registration under the Act would be required in
connection with the proposed offer, sale, pledge, transfer or other disposition
or (iii) a registration statement under the Act covering the proposed offer,
sale, pledge, or other disposition shall be effective under the Act; and
(e) Affiliate is the beneficial owner of the Company Common Stock,
Company Preferred Stock, Company Options and/or Company Warrants set forth
below, or, if not set forth below, that Affiliate is not the beneficial owner of
any Company Common Stock, Company Preferred Stock, Company Options or Company
Warrants.
3. Affiliate understands and agrees that, except as set forth in the
Merger Agreement, Parent is under no obligation to register the sale, transfer
or other disposition of the Shares or to take any other action necessary in
order to make compliance with an exemption from registration available.
4. Each party hereto acknowledges that (i) it will be impossible to
measure in money the damage to Parent if Affiliate fails to comply with any of
the obligations imposed by this Agreement, (ii) every such obligation is
material and (iii) in the event of any such failure, Parent will not have an
adequate remedy at law or damages and, accordingly, each party hereto agrees
that injunctive relief or other equitable remedy, in addition to remedies at law
or damages, is an appropriate remedy for any such failure.
5. This Agreement is made under, and shall be construed and enforced in
accordance with, the laws of the State of Delaware applicable to agreements made
and to be performed solely therein, without giving effect to principles of
conflicts of law. In any action between or among any of the parties, whether
arising out of this Affiliate Agreement or otherwise: (a) each of the parties
irrevocably and unconditionally consents and submits to the exclusive
jurisdiction and venue of the state and federal courts located in Maryland; (b)
if any such action is commenced in a state court, then, subject to applicable
law, no party shall object to the removal of such action to any federal court
located in Montgomery County, Maryland; (c) each of the parties irrevocably
waives the right to trial by jury; and (d) each of the parties irrevocably
consents to service of process by first class certified mail, return receipt
requested, postage prepaid, to the address appearing under such party's name on
the signature page hereto.
6. This Agreement constitutes the entire agreement between the parties
with respect to the subject matter hereof and supersedes all prior agreements
and understandings between the parties with respect thereto. No addition to or
modification of any provision of this Agreement shall be binding upon either
party hereto unless made in writing and signed by both parties hereto. The
parties hereto waive their right to a trial by jury in any action at law or suit
in equity based upon, or arising out of, this Agreement or the subject matter
hereof.
7. This Agreement shall be binding upon, enforceable by and inure to the
benefit of the parties named herein and their respective successors; this
Agreement may not be assigned by any party without the prior written consent of
Parent. Any attempted assignment not in
2.
<PAGE>
compliance with this paragraph shall be void and have no effect.
Notwithstanding anything contained in this Agreement to the contrary, nothing in
this Agreement, expressed or implied, is intended to confer on any Person other
than the parties hereto or their respective heirs, successors and assigns, any
rights, remedies, obligations or liabilities under or by reason of this
Agreement.
8. This Agreement may be executed in one or more counterparts, each of
which shall be deemed to be an original but all of which together shall
constitute one and the same agreement.
[THIS SPACE INTENTIONALLY LEFT BLANK]
3.
<PAGE>
IN WITNESS WHEREOF, the parties hereto have executed and delivered this
Agreement as of the date first written above.
GENE LOGIC INC.
By:
----------------------------
-------------------------------
Print Name and Title
Address: 708 Quince Orchard Road
Gaithersburg, Maryland 20878
AFFILIATE
-------------------------------
-------------------------------
Print Name, and Title (if applicable)
Address:
-----------------------
-------------------------------
Shares of Company Common
Stock Beneficially Owned:
------------
Shares of Company Preferred
Stock Beneficially Owned:
------------
Shares of Company Common
Stock Subject to Company Options:
------------
Shares of Company Common
Stock Subject to Company Warrants:
------------
[AFFILIATE AGREEMENT]
<PAGE>
EXHIBIT G
LIST OF PERSONS TO ENTER INTO EMPLOYMENT OR CONSULTING AND
NONCOMPETITION AGREEMENTS
EMPLOYMENT AND NONCOMPETITION AGREEMENT
Dr. Douglas Dolginow
Dr. Joseph Vockley
CONSULTING AND NONCOMPETITION AGREEMENT
Dr. Timothy J. Triche
<PAGE>
VOTING AGREEMENT
THIS VOTING AGREEMENT is entered into as of July 6, 1998 by and between
GENE LOGIC INC., a Delaware corporation ("Parent"), GENE LOGIC ACQUISITION
CORP., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger
Sub"), and ______________ ("Stockholder").
RECITALS
A. Parent, ONCORMED, INC., a Delaware corporation ("Company"), and Merger
Sub are entering into an Agreement and Plan of Merger and Reorganization of even
date herewith and entered into immediately prior to the execution of this Voting
Agreement (the "Merger Agreement"), which provides for the merger of the Company
with and into Merger Sub (the "Merger"). Capitalized terms used but not
otherwise defined in this Voting Agreement shall have the meanings given to such
terms in the Merger Agreement.
B. As a condition to the willingness of Parent and Merger Sub to enter
into the Merger Agreement, Parent and Merger Sub have required that Stockholder
agree, and in order to induce Parent and Merger Sub to enter into the Merger
Agreement, Stockholder has agreed, to enter into this Voting Agreement.
AGREEMENT
The parties to this Voting Agreement, intending to be legally bound, agree
as follows:
SECTION 1. CERTAIN DEFINITIONS
1.1 "SUBJECT SECURITIES" shall mean: (i) all securities of the Company
(including shares of Company Common Stock and Company Preferred Stock and all
options, warrants and other rights to acquire shares of Company capital stock)
Owned by Stockholder as of the date of this Agreement; and (ii) all additional
securities of the Company (including all additional shares of Company Common
Stock, Company Preferred Stock and all additional options, warrants and other
rights to acquire shares of Company capital stock) of which Stockholder acquires
Ownership during the period from the date of this Agreement through the
Expiration Date.
1.2 Stockholder shall be deemed to "OWN" or to have acquired "OWNERSHIP"
of a security of the Company if Stockholder: (i) is the record owner of such
security; or (ii) is the "beneficial owner" (within the meaning of Rule 13d-3
under the Exchange Act) of such security.
1.3 "EXPIRATION DATE" shall mean the earlier of the date upon which (i)
the Merger becomes effective, or (ii) the Merger Agreement is validly
terminated; PROVIDED, HOWEVER, that the "Expiration Date" shall be the date 180
days following the date on which the Merger Agreement is validly terminated if
an Identified Termination occurs.
1.4 An "IDENTIFIED TERMINATION" shall occur if (i) the Merger Agreement
is terminated by Parent pursuant to Section 7.1(e) of the Merger Agreement, or
(ii) the Merger
1.
<PAGE>
Agreement is terminated by Parent pursuant to Section 7.1(g) of the Merger
Agreement (other than pursuant to subsection (i) thereof).
SECTION 2. DISPOSITION AND VOTING OF SUBJECT SECURITIES.
2.1 NO DISPOSITION OR ENCUMBRANCE OF SUBJECT SECURITIES. Stockholder
hereby covenants and agrees that, prior to the Expiration Date, Stockholder will
not, directly or indirectly, (i) offer, sell, offer to sell, contract to sell,
pledge, grant any option to purchase or otherwise dispose of or transfer (or
announce any offer, sale, offer of sale, contract of sale or grant of any option
to purchase or other disposition or transfer of) any Subject Securities to any
Person other than Parent or Parent's designee, (ii) create or permit to exist
any Encumbrance with respect to any of the Subject Securities, (iii) reduce
Stockholder's beneficial ownership of, interest in or risk relating to, any of
the Subject Securities or (iv) commit or agree to do any of the foregoing.
2.2 NO TRANSFER OF VOTING RIGHTS. Stockholder covenants and agrees that,
prior to the Expiration Date, Stockholder will not deposit any of the Subject
Securities into a voting trust or grant another proxy (except as provided
herein) or enter into a voting agreement with respect to any of the Subject
Securities.
SECTION 3. VOTING OF SUBJECT SECURITIES
3.1 PRE-TERMINATION VOTING AGREEMENT. Stockholder hereby agrees that,
prior to the Expiration Date, at any meeting of the stockholders of the Company,
however called, and in any written action by consent of the stockholders of the
Company, unless otherwise directed in writing by Parent, Stockholder shall cause
the Subject Securities to be voted:
(a) in favor of the issuance of shares of Parent Common Stock to
the Company Stockholders in the Merger, the Merger, the execution, delivery and
performance by the Company of the Merger Agreement and the adoption and approval
of the terms thereof and in favor of each of the other actions contemplated by
the Merger Agreement and any action required in furtherance hereof and thereof;
(b) against any action or agreement that would result in a breach
of any representation, warranty, covenant or obligation of the Company in the
Merger Agreement; and
(c) against the following actions (other than the Merger and the
transactions contemplated by the Merger Agreement): (A) any extraordinary
corporate transaction, such as a merger, consolidation or other business
combination involving the Company; (B) any sale, lease or transfer of
substantially all of the assets of the Company; (C) any reorganization,
recapitalization, dissolution or liquidation of the Company; (D) any change in a
majority of the board of directors of the Company; (E) any amendment to the
Company's Certificate of Incorporation or Bylaws; (F) any material change in the
capitalization of the Company or the Company's corporate structure; or (G) any
other action which is intended to, or would, impede, interfere with, delay,
postpone, discourage or adversely affect the Merger or any of the other
transactions contemplated by the Merger Agreement or this Voting Agreement.
2.
<PAGE>
3.2 Prior to the Expiration Date, Stockholder shall not enter into any
Contract with any Person to vote or give instructions in any manner inconsistent
with Sections 3.1(a), 3.1(b) or 3.1(c).
3.3 POST-TERMINATION VOTING AGREEMENT. If an Identified Termination
occurs, then, prior to the Expiration Date, at any meeting of the stockholders
of the Company, however called, and in any written action by the consent of the
stockholders of the Company, unless otherwise directed in writing by Parent,
Stockholder shall vote the Subject Securities (a) against any Acquisition
Proposal and any related transaction or agreement, and (b) against any action
which is intended, or could reasonably be expected, to facilitate the
consummation of any Acquisition Transaction. Stockholder shall not enter into
any Contract with any Person prior to the Expiration Date to vote or give
instructions in any manner inconsistent with clause "(a)" or "(b)" of the
preceding sentence.
3.4 PROXY. Contemporaneously with the execution of this Voting
Agreement, (i) Stockholder shall deliver to Parent a proxy in the form attached
hereto as Exhibit A, which shall be irrevocable to the fullest extent permitted
by law, with respect to the shares referred to therein (the "Proxy"); and (ii)
Stockholder shall deliver to Parent an additional proxy in the form attached
hereto as Exhibit A executed on behalf of the record owner of any issued and
outstanding shares of Company Common Stock and Company Preferred Stock that are
owned beneficially (but are not owned of record) by Stockholder.
SECTION 4. WAIVER OF APPRAISAL RIGHTS
Stockholder hereby waives any rights of appraisal and any dissenters'
rights that Stockholder may have in connection with the Merger.
SECTION 5. NO SOLICITATION
Stockholder covenants and agrees that, during the period commencing on the
date of this Voting Agreement and ending on the Expiration Date, Stockholder
shall not, and shall not authorize or permit any Representative of Stockholder,
to: (i) solicit, initiate or encourage the making, submission or announcement of
any Acquisition Proposal, (ii) furnish any information regarding the Company to
any Person in connection with or in response to an Acquisition Proposal, (iii)
engage in discussions or negotiations with any Person with respect to any
Acquisition Proposal, (iv) approve, endorse or recommend any Acquisition
Proposal or (v) enter into any letter of intent or other similar document or any
Contract contemplating or otherwise relating to any Acquisition Transaction;
PROVIDED, HOWEVER, that: (A) nothing herein shall prohibit the Stockholder from
disclosing, or causing the Company to disclose, to the Company's stockholders a
position with respect to a tender offer pursuant to Rules 14d-9 and 14e-2
promulgated under the Exchange Act; (B) nothing herein shall prohibit
Stockholder from making any disclosure to the Company's Stockholders if, in the
good faith judgment of the Stockholder after consultation with its outside legal
counsel, failure to so disclose would be inconsistent with applicable laws; and
(C) the Stockholder shall not be prohibited by this Section 5 from (x)
furnishing or causing to be furnished nonpublic information regarding the
Company to any Person in response to an Acquisition Proposal that is submitted
by such Person (and not withdrawn), or (y) entering into discussions with any
Person in response to a Superior Offer that
3.
<PAGE>
is submitted by such Person (and not withdrawn) if, in either such case: (1)
neither Stockholder or the Company nor any of their respective Representatives
shall have violated any of the restrictions set forth in this Section 5, (2) the
Stockholder believes in good faith, after consultation with its outside legal
counsel to the Company, that such action is required in order for the
Stockholder to comply with such Stockholder's fiduciary obligations to the
Company's other stockholders under applicable law, (3) prior to furnishing or
causing to be furnished any such nonpublic information to, or entering into
discussions with, such Person, the Stockholder gives Parent written notice of
the identity of such Person and of such Stockholder's intention to furnish or to
cause to be furnished nonpublic information to, or enter into discussions with,
such Person, and the Stockholder causes the Company to receive from such Person
an executed confidentiality agreement containing limitations no less restrictive
than the limitations imposed on Parent pursuant to that certain Mutual
Non-Disclosure Agreement dated as of January 27, 1998 between Parent and the
Company, and (4) contemporaneously with furnishing any such nonpublic
information to such Person, the Stockholder furnishes or causes to be furnished
such nonpublic information to Parent (to the extent such nonpublic information
has not been previously furnished by the Company to Parent).
SECTION 6. REPRESENTATIONS AND WARRANTIES OF STOCKHOLDER
Stockholder hereby represents and warrants to Parent as follows:
6.1 DUE AUTHORIZATION. Stockholder has all requisite power and capacity
to execute and deliver this Voting Agreement and to perform Stockholder's
obligations hereunder. This Voting Agreement has been duly executed and
delivered by Stockholder and constitutes a legal, valid and binding obligation
of Stockholder, enforceable against Stockholder in accordance with its terms,
except as enforcement thereof may be limited by bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting
enforcement of creditors' rights generally, as limited by laws relating to the
availability of specific performance, injunctive relief, or by general equitable
principles, and to the extent any indemnification or contribution provisions
thereof may be limited by applicable federal or state securities laws.
6.2 NO CONFLICTS, REQUIRED FILINGS AND CONSENTS.
(a) The execution and delivery of this Voting Agreement by
Stockholder do not, and the performance of this Voting Agreement by Stockholder
will not: (i) conflict with or violate any order, decree or judgment applicable
to Stockholder or by which Stockholder or any of Stockholder's properties are
bound or affected; or (ii) result in any breach of or constitute a default (with
notice or lapse of time, or both) under, or give to others any rights of
termination, amendment, acceleration or cancellation of, or result in the
creation of an Encumbrance on the Subject Securities pursuant to any Contract
other than this Voting Agreement to which Stockholder is a party or by which
Stockholder or any of Stockholder's properties is bound or affected.
(b) The execution and delivery of this Voting Agreement by
Stockholder do not, and the performance of this Voting Agreement by Stockholder
will not, require any Consent of any Person.
4.
<PAGE>
6.3 TITLE TO SUBJECT SECURITIES. As of the date hereof, Stockholder Owns
in the aggregate (including shares owned of record and shares owned
beneficially) the number of issued and outstanding shares of Company Common
Stock and Company Preferred Stock set forth below Stockholder's name on the
signature page hereof, and the number of options, warrants and other rights to
acquire shares of Company capital stock set forth below Stockholder's name on
the signature page hereof, and does not directly or indirectly Own, any shares
of capital stock of the Company, or any option, warrant or other right to
acquire any shares of capital stock of the Company, other than the shares,
options, warrants and other rights set forth below Stockholder's name on the
signature page hereof.
6.4 ACCURACY OF REPRESENTATIONS. The representations and warranties
contained in this Voting Agreement are accurate in all respects as of the date
of this Voting Agreement, will be accurate in all respects at all times through
the Expiration Date and will be accurate in all material respects as of the date
of the consummation of the Merger as if made on that date.
SECTION 7. COVENANTS OF STOCKHOLDER
7.1 FURTHER ASSURANCES. From time to time and without additional
consideration, Stockholder will execute and deliver, or cause to be executed and
delivered, such additional or further arrangements, proxies, consents and other
instruments as Parent may reasonably request for the purpose of effectively
carrying out and furthering the intent of this Voting Agreement.
7.2 LEGEND. Immediately after the execution of this Voting Agreement,
Stockholder shall instruct the Company to cause each certificate of Stockholder
evidencing the Subject Securities to bear a legend in the following form:
THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD, EXCHANGED
OR OTHERWISE TRANSFERRED OR DISPOSED OF EXCEPT IN COMPLIANCE WITH THE TERMS
AND CONDITIONS OF THE VOTING AGREEMENT DATED AS OF JULY 6, 1998, AS IT MAY
BE AMENDED, EXECUTED BY THE REGISTERED HOLDER OF THIS CERTIFICATE, A COPY
OF WHICH IS ON FILE AT THE PRINCIPAL EXECUTIVE OFFICES OF THE ISSUER.
SECTION 8. MISCELLANEOUS
8.1 SURVIVAL OF REPRESENTATIONS, WARRANTIES AND AGREEMENTS. All
representations, warranties and agreements made by Stockholder in this Voting
Agreement shall survive (i) the consummation of the Merger, (ii) any termination
of the Merger Agreement, and (iii) the Expiration Date.
8.2 INDEMNIFICATION. Stockholder shall hold harmless and indemnify
Parent, and Parent's Representatives from and against any damages (regardless of
whether such damages relate to a third-party claim) suffered or incurred by
Parent or Parent's Representatives and that arise from any breach of any
representation, warranty, covenant or obligation of Stockholder contained
herein.
5.
<PAGE>
8.3 EXPENSES. All costs and expenses incurred in connection with the
transactions contemplated by this Voting Agreement shall be paid by the party
incurring such costs and expenses.
8.4 NOTICES. All notices and other communications required or permitted
to be delivered to any party pursuant to this Voting Agreement shall be in
writing and shall be deemed properly given if delivered personally, by
facsimile, sent by nationally-recognized, overnight courier or mailed by
registered or certified mail (postage prepaid, return receipt requested) to the
parties at the following addresses (or at such other address for a party as
shall be specified by like notice):
if to Stockholder:
at the address set forth below Stockholder's signature on the
signature page hereto
with a copy to:
Brobeck, Phleger & Harrison LLP
1633 Broadway, 47th Floor
New York, NY 10019
Attention: Alexander D. Lynch, Esq.
Telephone: (212) 581-1600
Fax: (212) 586-7878
if to Parent:
Gene Logic Inc.
708 Quince Orchard Road
Gaithersburg, MD 20878
Attention: President and Chief Executive Officer
Facsimile: (301) 987-1701
with a copy to:
Cooley Godward LLP
4365 Executive Drive
Suite 1100
San Diego, CA 92121-2128
Attention: Frederick T. Muto, Esq.
Facsimile: (619) 453-3555
All such notices and other communications shall be deemed to have been received
(a) in the case of personal delivery, on the date of such delivery, (b) in the
case of a facsimile, when the party receiving such facsimile shall have
confirmed receipt of the communication, (c) in the case of delivery by
nationally-recognized, overnight courier, on the Business Day following dispatch
and (d) in the case of registered or certified mail, on the fifth Business Day
following such mailing.
6.
<PAGE>
8.5 SEVERABILITY. Any term or provision of this Voting Agreement which
is invalid or unenforceable in any jurisdiction shall, as to that jurisdiction,
be ineffective to the extent of such invalidity or unenforceability without
rendering invalid or unenforceable the remaining terms and provisions of this
Voting Agreement or affecting the validity or enforceability of any of the terms
or provisions of this Voting Agreement in any other jurisdiction. If any
provision of this Voting Agreement is so broad as to be unenforceable, the
provision shall be interpreted to be only so broad as is enforceable.
8.6 ENTIRE AGREEMENT. This Voting Agreement and any documents delivered
by the parties in connection herewith constitute the entire agreement between
the parties with respect to the subject matter hereof and thereof and supersede
all prior agreements and understandings between the parties with respect
thereto. No addition to or modification of any provision of this Voting
Agreement shall be binding upon either party hereto unless made in writing and
signed by both parties hereto. The parties hereto waive their right to a trial
by jury in any action at law or suit in equity based upon, or arising out of,
this Voting Agreement or the subject matter hereof.
8.7 ASSIGNMENT, BINDING EFFECT. Except as provided herein, neither this
Voting Agreement nor any of its rights, interests or obligations shall be
assigned by Stockholder without the prior written consent of Parent. Subject to
the preceding sentence, this Voting Agreement shall be binding upon and shall
inure to the benefit of (i) Stockholder and Stockholder's heirs, successors and
assigns and (ii) Parent and its successors and assigns. Notwithstanding
anything contained in this Voting Agreement to the contrary, nothing in this
Voting Agreement, expressed or implied, is intended to confer on any Person
other than the parties hereto or their respective heirs, successors and assigns
any rights, remedies, obligations or liabilities under or by reason of this
Voting Agreement.
8.8 SPECIFIC PERFORMANCE. The parties hereto agree that irreparable
damage would occur in the event that any of the provisions of this Voting
Agreement was not performed in accordance with its specific terms or was
otherwise breached. It is accordingly agreed that Parent shall be entitled to
an injunction or injunctions to prevent breaches of this Voting Agreement and to
enforce specifically the terms and provisions hereof, this being in addition to
any other remedy to which Parent is entitled at law or in equity.
8.9 OTHER AGREEMENTS. Nothing in this Voting Agreement shall limit any
of the rights or remedies of Parent or any of the obligations of Stockholder
under any agreement between Parent and Stockholder.
8.10 GOVERNING LAW. This Voting Agreement is made under, and shall be
construed and enforced in accordance with, the laws of the State of Delaware
applicable to agreements made and to be performed solely therein, without giving
effect to principles of conflicts of law. In any action between or among any of
the parties, whether arising out of this Voting Agreement or otherwise: (a) each
of the parties irrevocably and unconditionally consents and submits to the
exclusive jurisdiction and venue of the state and federal courts located in
Maryland; (b) if any such action is commenced in a state court, then, subject to
applicable law, no party shall object to the removal of such action to any
federal court located in Montgomery County, Maryland; (c) each of the parties
irrevocably waives the right to trial by jury; and (d) each of the parties
7.
<PAGE>
irrevocably consents to service of process by first class certified mail, return
receipt requested, postage prepaid, to the address at which such party is to
receive notice in accordance with Section 8.4.
8.11 COUNTERPARTS. This Voting Agreement may be executed by the parties
hereto in separate counterparts, each of which when so executed and delivered
shall be an original, but all such counterparts shall together constitute one
and the same instrument.
8.12 CONSTRUCTION.
(a) Headings of the Sections of this Voting Agreement are for the
convenience of the parties only, and shall be given no substantive or
interpretive effect whatsoever.
(b) For purposes of this Voting Agreement, whenever the context
requires: the singular number shall include the plural, and vice versa; the
masculine gender shall include the feminine and neuter genders; the feminine
gender shall include the masculine and neuter genders; and the neuter gender
shall include masculine and feminine genders.
(c) The parties hereto agree that any rule of construction to the
effect that ambiguities are to be resolved against the drafting party shall not
be applied in the construction or interpretation of this Voting Agreement.
(d) As used in this Voting Agreement, the words "include" and
"including," and variations thereof, shall not be deemed to be terms of
limitation, but rather shall be deemed to be followed by the words "without
limitation."
[THIS SPACE INTENTIONALLY LEFT BLANK]
8.
<PAGE>
IN WITNESS WHEREOF, Parent, Merger Sub and Stockholder have caused this
Voting Agreement to be executed as of the date first written above.
GENE LOGIC INC.
By:
------------------------------------
Name:
Title:
GENE LOGIC ACQUISITION CORP.
By:
------------------------------------
Name:
Title:
STOCKHOLDER:
------------------------------------
Name:
-------------------------
Address:
-------------------------
-------------------------
-------------------------
Facsimile:
-------------------------
Number of issued and outstanding shares of COMPANY COMMON STOCK Owned OF RECORD
as of the date of this Voting Agreement:
---------------
Number of additional issued and outstanding shares of COMPANY COMMON STOCK Owned
BENEFICIALLY (but not of record) as of the date of this Voting
Agreement:
------------------
Number of issued and outstanding shares of COMPANY PREFERRED STOCK Owned OF
RECORD OR BENEFICIALLY as of the date of this Voting Agreement:
----------------
Number of additional issued and outstanding shares of COMPANY PREFERRED STOCK
Owned BENEFICIALLY (but not of record) as of the date of this Voting
Agreement:
------------------
Number of options, warrants and other rights to acquire shares of Company
capital stock Owned OF RECORD as of the date of this Voting
Agreement:
------------------
Number of options, warrants and other rights to acquire shares of Company
capital stock Owned BENEFICIALLY (but not of record) as of the date of this
Voting Agreement:
-----------------
[VOTING AGREEMENT]
<PAGE>
EXHIBIT A
FORM OF IRREVOCABLE PROXY
IRREVOCABLE PROXY
The undersigned stockholder of Company, Inc., a Delaware corporation
("Company"), hereby irrevocably (to the fullest extent permitted by law)
appoints and constitutes Michael J. Brennan, M.D., Ph.D. and Parent Inc., a
Delaware corporation ("Parent"), and each of them, the attorneys and proxies of
the undersigned with respect to voting (i) the shares of capital stock of
Company owned by the undersigned as of the date of this proxy, which shares are
specified on the final page of this proxy and (ii) any and all other shares of
capital stock of Company which the undersigned may acquire after the date
hereof. The shares of the capital stock of Company referred to in clauses
(i) and (ii) of the immediately preceding sentence are collectively referred to
as the "Shares." Upon the execution hereof, all prior proxies given by the
undersigned with respect to any of the Shares are hereby revoked, and no
subsequent proxies will be given with respect to any of the Shares.
This proxy is irrevocable, is coupled with an interest and is granted in
connection with the Voting Agreement, dated as of the date hereof, between
Parent and the beneficial owner of the shares of capital stock of the Company
set forth on the signature page hereof (the "Voting Agreement"), and is granted
in consideration of Parent entering into the Agreement and Plan of Merger and
Reorganization, dated as of the date hereof, among Parent, Parent Acquisition
Corp., a Delaware corporation and wholly-owned subsidiary of Parent, and the
Company (the "Merger Agreement"). Capitalized terms used but not otherwise
defined in this proxy have the meanings ascribed to such terms in the Voting
Agreement and Merger Agreement.
The attorneys and proxies named above will be empowered, and may exercise
this proxy, to vote the Shares at any time until the earlier to occur of the
termination of the Merger Agreement or the Effective Time at any meeting of the
stockholders of the Company, however called, or in any written action by consent
of stockholders of the Company:
1. in favor of the issuance of shares of Parent Common Stock to the
Company Stockholders in the Merger, the Merger, the execution, delivery and
performance by the Company of the Merger Agreement and the adoption and approval
of the terms thereof and in favor of each of the other actions contemplated by
the Merger Agreement and any action required in furtherance hereof and thereof;
2. against any action or agreement that would result in a breach of any
representation, warranty, covenant or obligation of the Company in the Merger
Agreement; and
3. against the following actions (other than the Merger and the
transactions contemplated by the Merger Agreement): (A) any extraordinary
corporate transaction, such as a merger, consolidation or other business
combination involving the Company; (B) any sale, lease or transfer of
substantially all of the assets of the Company; (C) any reorganization,
recapitalization, dissolution or liquidation of the Company; (D) any change in a
majority of the board of directors of the Company; (E) any amendment to the
Company's Certificate of Incorporation or Bylaws; (F) any material change in the
capitalization of the Company or the
1.
<PAGE>
Company's corporate structure; or (G) any other action which is intended to, or
would, impede, interfere with, delay, postpone, discourage or adversely affect
the Merger or any of the other transactions contemplated by the Merger Agreement
or this Voting Agreement.
The undersigned stockholder may vote the Shares on all other matters.
Any obligation of the undersigned hereunder shall be binding upon the
heirs, successors and assigns of the undersigned (including any transferee of
any of the Shares).
[THIS SPACE INTENTIONALLY LEFT BLANK]
2.
<PAGE>
This proxy shall terminate upon the Expiration Date.
Dated: July 6, 1998
STOCKHOLDER
----------------------------------------
Print Name
-----------------------------
If executed by record holder on behalf
of the beneficial owner, print name of
beneficial owner:
----------------------------------------
Number of issued and outstanding shares of COMPANY COMMON STOCK Owned OF RECORD
as of the date hereof:
------------------
Number of issued and outstanding shares of COMPANY PREFERRED STOCK Owned OF
RECORD as of the date hereof:
-------------------
Number of issued and outstanding shares of COMPANY COMMON STOCK Owned
BENEFICIALLY (but not of record) as of the date hereof:
-------------------
Number of issued and outstanding shares of COMPANY PREFERRED STOCK Owned
BENEFICIALLY (but not of record) as of the date hereof:
-------------------
<PAGE>
VOTING AGREEMENT
THIS VOTING AGREEMENT is entered into as of July 6, 1998 by and between
PARENT INC., a Delaware corporation ("Parent"), PARENT ACQUISITION CORP., a
Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"), and
ONCOR, INC., a Delaware corporation ("Stockholder").
RECITALS
A. Parent, TARGET, INC., a Delaware corporation ("Company"), and Merger
Sub are entering into an Agreement and Plan of Merger and Reorganization of even
date herewith (the "Merger Agreement"), which provides for the merger of the
Company with and into Merger Sub (the "Merger"). Capitalized terms used but
not otherwise defined in this Voting Agreement shall have the meanings given to
such terms in the Merger Agreement.
B. As a condition to the willingness of Parent and Merger Sub to enter
into the Merger Agreement, Parent and Merger Sub have required that Stockholder
agree, and in order to induce Parent and Merger Sub to enter into the Merger
Agreement, Stockholder has agreed, to enter into this Voting Agreement.
AGREEMENT
The parties to this Voting Agreement, intending to be legally bound, agree
as follows:
SECTION 1. CERTAIN DEFINITIONS
1.1 "SUBJECT SECURITIES" shall mean: (i) all securities of the Company
(including shares of Company Common Stock and Company Preferred Stock and all
options, warrants and other rights to acquire shares of Company capital stock)
Owned by Stockholder as of the date of this Agreement, and (ii) all additional
securities of the Company (including all additional shares of Company Common
Stock, Company Preferred Stock and all additional options, warrants and other
rights to acquire shares of Company capital stock) of which Stockholder acquires
Ownership during the period from the date of this Agreement through the
Expiration Date.
1.2 Stockholder shall be deemed to "OWN" or to have acquired "OWNERSHIP"
of a security of the Company if Stockholder: (i) is the record owner of such
security, or (ii) is the "beneficial owner" (within the meaning of Rule 13d-3
under the Exchange Act) of such security.
1.3 "EXPIRATION DATE" shall mean the earlier of the date upon which (i)
the Merger becomes effective, or (ii) the Merger Agreement is validly
terminated; PROVIDED, HOWEVER, that the "Expiration Date" shall be the date 180
days following the date on which the Merger Agreement is validly terminated if
an Identified Termination occurs.
1.4 An "IDENTIFIED TERMINATION" shall occur if (i) the Merger Agreement
is terminated by Parent pursuant to Section 7.1(e) of the Merger Agreement, or
(ii) the Merger Agreement is terminated by Parent pursuant to Section 7.1(g) of
the Merger Agreement (other than pursuant to subsection (i) thereof).
1.
<PAGE>
SECTION 2. DISPOSITION AND VOTING OF SUBJECT SECURITIES.
2.1 NO DISPOSITION OR ENCUMBRANCE OF SUBJECT SECURITIES. Stockholder
hereby covenants and agrees that, prior to the Expiration Date, Stockholder will
not, directly or indirectly, (i) offer, sell, offer to sell, contract to sell,
pledge, grant any option to purchase or otherwise dispose of or transfer (or
announce any offer, sale, offer of sale, contract of sale or grant of any option
to purchase or other disposition or transfer of) any Subject Securities to any
Person other than Parent or Parent's designee, (ii) create or permit to exist
any Encumbrance with respect to any of the Subject Securities, (iii) reduce
Stockholder's beneficial ownership of, interest in or risk relating to, any of
the Subject Securities or (iv) commit or agree to do any of the foregoing.
Notwithstanding the foregoing, Stockholder may sell in any one or more private
transactions (i) any of the Subject Securities prior to the Expiration Date
provided that prior to any proposed sale of Subject Securities under this clause
(i) the proposed transferee enters into a written instrument reasonably
satisfactory to Parent in which the proposed transferee agrees with Parent to be
bound by all of the terms and conditions of this Voting Agreement, (ii) up to
133,333 shares of Subject Securities to JIBS Equities, L.P. pursuant to an
option granted by Stockholder to such party on October 24, 1997, (iii) up to
333,333 shares of Subject Securities to Edgewater Private Equity Fund, L.P.
pursuant to an option granted by Stockholder to such party on October 24, 1997,
and (iv) up to 250,000 shares of Subject Securities to Mr. John Pappajohn
pursuant to an option granted by Stockholder to such party on October 24, 1997.
2.2 NO TRANSFER OF VOTING RIGHTS. Stockholder covenants and agrees that,
prior to the Expiration Date, Stockholder will not deposit any of the Subject
Securities into a voting trust or grant another proxy (except as provided
herein) or enter into a voting agreement with respect to any of the Subject
Securities.
SECTION 3. VOTING OF SUBJECT SECURITIES
3.1 PRE-TERMINATION VOTING AGREEMENT. Stockholder hereby agrees that,
prior to the Expiration Date, at any meeting of the stockholders of the Company,
however called, and in any written action by consent of the stockholders of the
Company, unless otherwise directed in writing by Parent, Stockholder shall cause
the Subject Securities to be voted:
(a) in favor of the issuance of shares of Parent Common Stock to
the Company Stockholders in the Merger, the Merger, the execution, delivery and
performance by the Company of the Merger Agreement and the adoption and approval
of the terms thereof and in favor of each of the other actions contemplated by
the Merger Agreement and any action required in furtherance hereof and thereof;
(b) against any action or agreement that would result in a breach
of any representation, warranty, covenant or obligation of the Company in the
Merger Agreement; and
(c) against the following actions (other than the Merger and the
transactions contemplated by the Merger Agreement): (A) any extraordinary
corporate transaction, such as a merger, consolidation or other business
combination involving the Company; (B) any sale, lease or transfer of
substantially all of the assets of the Company; (C) any reorganization,
recapitalization, dissolution or liquidation of the Company; (D) any change in a
majority of the
2.
<PAGE>
board of directors of the Company; (E) any amendment to the Company's
Certificate of Incorporation or Bylaws; (F) any material change in the
capitalization of the Company or the Company's corporate structure; or (G) any
other action which is intended to, or would, impede, interfere with, delay,
postpone, discourage or adversely affect the Merger or any of the other
transactions contemplated by the Merger Agreement or this Voting Agreement.
3.2 Prior to the Expiration Date, Stockholder shall not enter into any
Contract with any Person to vote or give instructions in any manner inconsistent
with Sections 3.1(a), 3.1(b) or 3.1(c).
3.3 POST-TERMINATION VOTING AGREEMENT. If an Identified Termination
occurs, then, prior to the Expiration Date, at any meeting of the stockholders
of the Company, however called, and in any written action by the consent of the
stockholders of the Company, unless otherwise directed in writing by Parent,
Stockholder shall vote the Subject Securities (a) against any Acquisition
Proposal and any related transaction or agreement, and (b) against any action
which is intended, or could reasonably be expected, to facilitate the
consummation of any Acquisition Transaction. Stockholder shall not enter into
any Contract with any Person prior to the Expiration Date to vote or give
instructions in any manner inconsistent with clause "(a)" or "(b)" of the
preceding sentence.
3.4 PROXY. Contemporaneously with the execution of this Voting
Agreement, (i) Stockholder shall deliver to Parent a proxy in the form attached
hereto as Exhibit A, which shall be irrevocable to the fullest extent permitted
by law, with respect to the shares referred to therein (the "Proxy"); and (ii)
Stockholder shall deliver to Parent an additional proxy in the form attached
hereto as Exhibit A executed on behalf of the record owner of any issued and
outstanding shares of Company Common Stock and Company Preferred Stock that are
owned beneficially (but are not owned of record) by Stockholder.
SECTION 4. WAIVER OF APPRAISAL RIGHTS
Stockholder hereby waives any rights of appraisal and any dissenters'
rights that Stockholder may have in connection with the Merger.
SECTION 5. NO SOLICITATION
Stockholder covenants and agrees that, during the period commencing on the
date of this Voting Agreement and ending on the Expiration Date, Stockholder
shall not, and shall not authorize or permit any Representative of Stockholder,
to: (i) solicit, initiate or encourage the making, submission or announcement of
any Acquisition Proposal, (ii) furnish any information regarding the Company to
any Person in connection with or in response to an Acquisition Proposal, (iii)
engage in discussions or negotiations with any Person with respect to any
Acquisition Proposal, (iv) approve, endorse or recommend any Acquisition
Proposal or (v) enter into any letter of intent or other similar document or any
Contract contemplating or otherwise relating to any Acquisition Transaction;
PROVIDED, HOWEVER, that: (A) nothing herein shall prohibit the Stockholder from
disclosing, or causing the Company to disclose, to the Company's stockholders a
position with respect to a tender offer pursuant to Rules 14d-9 and 14e-2
promulgated under the Exchange Act; (B) nothing herein shall prohibit
Stockholder from making
3.
<PAGE>
any disclosure to the Company's Stockholders if, in the good faith judgment of
the Stockholder after consultation with its outside legal counsel, failure to so
disclose would be inconsistent with applicable laws; and (C) the Stockholder
shall not be prohibited by this Section 5 from (x) furnishing or causing to be
furnished nonpublic information regarding the Company to any Person in response
to an Acquisition Proposal that is submitted by such Person (and not withdrawn),
or (y) entering into discussions with any Person in response to a Superior Offer
that is submitted by such Person (and not withdrawn) if, in either such case:
(1) neither Stockholder or the Company nor any of their respective
Representatives shall have violated any of the restrictions set forth in this
Section 5, (2) the Stockholder believes in good faith, after consultation with
its outside legal counsel to the Company, that such action is required in order
for the Stockholder to comply with such Stockholder's fiduciary obligations to
the Company's other stockholders under applicable law, (3) prior to furnishing
or causing to be furnished any such nonpublic information to, or entering into
discussions with, such Person, the Stockholder gives Parent written notice of
the identity of such Person and of such Stockholder's intention to furnish or to
cause to be furnished nonpublic information to, or enter into discussions with,
such Person, and the Stockholder causes the Company to receive from such Person
an executed confidentiality agreement containing limitations no less restrictive
than the limitations imposed on Parent pursuant to that certain Mutual
Non-Disclosure Agreement dated as of January 27, 1998 between Parent and the
Company, and (4) contemporaneously with furnishing any such nonpublic
information to such Person, the Stockholder furnishes or causes to be furnished
such nonpublic information to Parent (to the extent such nonpublic information
has not been previously furnished by the Company to Parent).
SECTION 6. REPRESENTATIONS AND WARRANTIES OF STOCKHOLDER
Stockholder hereby represents and warrants to Parent as follows:
6.1 DUE AUTHORIZATION. Stockholder has the requisite corporate power to
execute and deliver this Voting Agreement and to perform Stockholder's
obligations hereunder. This Voting Agreement has been duly executed and
delivered by Stockholder and, assuming its due authorization, execution and
delivery by the other parties hereto, constitutes a legal, valid and binding
obligation of Stockholder, enforceable against Stockholder in accordance with
its terms, except as enforcement thereof may be limited by bankruptcy,
insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors' rights generally, as limited by laws
relating to the availability of specific performance, injunctive relief, or by
general equitable principles, and to the extent any indemnification or
contribution provisions thereof may be limited by applicable federal or state
securities laws.
6.2 NO CONFLICTS, REQUIRED FILINGS AND CONSENTS.
(a) The execution and delivery of this Voting Agreement by
Stockholder do not, and the performance of this Voting Agreement by Stockholder
will not: (i) conflict with or violate any order, decree or judgment applicable
to Stockholder or by which Stockholder or any of Stockholder's properties are
bound or affected; or (ii) result in any breach of or constitute a default (with
notice or lapse of time, or both) under, or give to others any rights of
termination, amendment, acceleration or cancellation of, or result in the
creation of an Encumbrance on the Subject Securities pursuant to any Contract
other than this Voting Agreement to which
4.
<PAGE>
Stockholder is a party or by which Stockholder or any of Stockholder's
properties is bound or affected.
(b) The execution and delivery of this Voting Agreement by
Stockholder do not, and the performance of this Voting Agreement by Stockholder
will not, require any Consent of any Person.
6.3 TITLE TO SUBJECT SECURITIES. As of the date hereof, Stockholder Owns
in the aggregate (including shares owned of record and shares owned
beneficially) the number of issued and outstanding shares of Company Common
Stock and Company Preferred Stock set forth below Stockholder's name on the
signature page hereof, and the number of options, warrants and other rights to
acquire shares of Company capital stock set forth below Stockholder's name on
the signature page hereof, and does not directly or indirectly Own, any shares
of capital stock of the Company, or any option, warrant or other right to
acquire any shares of capital stock of the Company, other than the shares,
options, warrants and other rights set forth below Stockholder's name on the
signature page hereof.
6.4 ACCURACY OF REPRESENTATIONS. The representations and warranties
contained in this Voting Agreement are accurate in all respects as of the date
of this Voting Agreement, will be accurate in all respects at all times through
the Expiration Date and will be accurate in all material respects as of the date
of the consummation of the Merger as if made on that date.
SECTION 7. COVENANTS OF STOCKHOLDER
7.1 FURTHER ASSURANCES. From time to time and without additional
consideration, Stockholder will execute and deliver, or cause to be executed and
delivered, such additional or further arrangements, proxies, consents and other
instruments as Parent may reasonably request for the purpose of effectively
carrying out and furthering the intent of this Voting Agreement.
7.2 LEGEND. Immediately after the execution of this Voting Agreement,
Stockholder shall instruct the Company to cause each certificate of Stockholder
evidencing the Subject Securities to bear a legend in the following form:
THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD, EXCHANGED
OR OTHERWISE TRANSFERRED OR DISPOSED OF EXCEPT IN COMPLIANCE WITH THE TERMS
AND CONDITIONS OF THE VOTING AGREEMENT DATED AS OF JULY 6, 1998, AS IT MAY
BE AMENDED, EXECUTED BY THE REGISTERED HOLDER OF THIS CERTIFICATE, A COPY
OF WHICH IS ON FILE AT THE PRINCIPAL EXECUTIVE OFFICES OF THE ISSUER.
SECTION 8. REGISTRATION RIGHTS. Parent will register for resale the Subject
Securities pursuant to and in accordance with the terms set forth in Exhibit B.
SECTION 9. MISCELLANEOUS
9.1 SURVIVAL OF REPRESENTATIONS, WARRANTIES AND AGREEMENTS. All
representations, warranties and agreements made by Stockholder in this Voting
Agreement shall survive (i) any
5.
<PAGE>
termination of the Merger Agreement but not the consummation of the Merger, and
(ii) the Expiration Date if the Merger has not theretofore been consummated.
9.2 INDEMNIFICATION. Stockholder shall hold harmless and indemnify
Parent, and Parent's Representatives from and against any damages (regardless of
whether such damages relate to a third-party claim) suffered or incurred by
Parent or Parent's Representatives and that arise from any breach of any
representation, warranty, covenant or obligation of Stockholder contained
herein.
9.3 EXPENSES. All costs and expenses incurred in connection with the
transactions contemplated by this Voting Agreement shall be paid by the party
incurring such costs and expenses.
9.4 NOTICES. All notices and other communications required or permitted
to be delivered to any party pursuant to this Voting Agreement shall be in
writing and shall be deemed properly given if delivered personally, by
facsimile, sent by nationally-recognized, overnight courier or mailed by
registered or certified mail (postage prepaid, return receipt requested) to the
parties at the following addresses (or at such other address for a party as
shall be specified by like notice):
if to Stockholder:
at the address set forth below Stockholder's signature on the
signature page hereto
with a copy to:
Brobeck, Phleger & Harrison LLP
1633 Broadway, 47th Floor
New York, NY 10019
Attention: Alexander D. Lynch, Esq.
Telephone: (212) 581-1600
Fax: (212) 586-7878
if to Parent:
Gene Logic Inc.
708 Quince Orchard Road
Gaithersburg, MD 20878
Attention: President and Chief Executive Officer
Facsimile: (301) 987-1701
with a copy to:
Cooley Godward LLP
4365 Executive Drive
Suite 1100
San Diego, CA 92121-2128
6.
<PAGE>
Attention: Frederick T. Muto, Esq.
Facsimile: (619) 453-3555
All such notices and other communications shall be deemed to have been received
(a) in the case of personal delivery, on the date of such delivery, (b) in the
case of a facsimile, when the party receiving such facsimile shall have
confirmed receipt of the communication, (c) in the case of delivery by
nationally-recognized, overnight courier, on the Business Day following dispatch
and (d) in the case of registered or certified mail, on the fifth Business Day
following such mailing.
9.5 SEVERABILITY. Any term or provision of this Voting Agreement which
is invalid or unenforceable in any jurisdiction shall, as to that jurisdiction,
be ineffective to the extent of such invalidity or unenforceability without
rendering invalid or unenforceable the remaining terms and provisions of this
Voting Agreement or affecting the validity or enforceability of any of the terms
or provisions of this Voting Agreement in any other jurisdiction. If any
provision of this Voting Agreement is so broad as to be unenforceable, the
provision shall be interpreted to be only so broad as is enforceable.
9.6 ENTIRE AGREEMENT. This Voting Agreement and any documents delivered
by the parties in connection herewith constitute the entire agreement between
the parties with respect to the subject matter hereof and thereof and supersede
all prior agreements and understandings between the parties with respect
thereto. No addition to or modification of any provision of this Voting
Agreement shall be binding upon either party hereto unless made in writing and
signed by both parties hereto. The parties hereto waive their right to a trial
by jury in any action at law or suit in equity based upon, or arising out of,
this Voting Agreement or the subject matter hereof.
9.7 ASSIGNMENT, BINDING EFFECT. Except as provided herein, neither this
Voting Agreement nor any of its rights, interests or obligations shall be
assigned by Stockholder without the prior written consent of Parent. Subject to
the preceding sentence, this Voting Agreement shall be binding upon and shall
inure to the benefit of (i) Stockholder and Stockholder's heirs, successors and
assigns and (ii) Parent and its successors and assigns. Notwithstanding
anything contained in this Voting Agreement to the contrary, nothing in this
Voting Agreement, expressed or implied, is intended to confer on any Person
other than the parties hereto or their respective heirs, successors and assigns
any rights, remedies, obligations or liabilities under or by reason of this
Voting Agreement.
9.8 SPECIFIC PERFORMANCE. The parties hereto agree that irreparable
damage would occur in the event that any of the provisions of this Voting
Agreement was not performed in accordance with its specific terms or was
otherwise breached. It is accordingly agreed that Parent shall be entitled to
an injunction or injunctions to prevent breaches of this Voting Agreement and to
enforce specifically the terms and provisions hereof, this being in addition to
any other remedy to which Parent is entitled at law or in equity.
9.9 OTHER AGREEMENTS. Nothing in this Voting Agreement shall limit any
of the rights or remedies of Parent or any of the obligations of Stockholder
under any agreement between Parent and Stockholder.
7.
<PAGE>
9.10 GOVERNING LAW. This Voting Agreement is made under, and shall be
construed and enforced in accordance with, the laws of the State of Delaware
applicable to agreements made and to be performed solely therein, without giving
effect to principles of conflicts of law. In any action between or among any of
the parties, whether arising out of this Voting Agreement or otherwise: (a) each
of the parties irrevocably and unconditionally consents and submits to the
exclusive jurisdiction and venue of the state and federal courts located in
Maryland; (b) if any such action is commenced in a state court, then, subject to
applicable law, no party shall object to the removal of such action to any
federal court located in Montgomery County, Maryland; (c) each of the parties
irrevocably waives the right to trial by jury; and (d) each of the parties
irrevocably consents to service of process by first class certified mail, return
receipt requested, postage prepaid, to the address at which such party is to
receive notice in accordance with Section 8.4.
9.11 COUNTERPARTS. This Voting Agreement may be executed by the parties
hereto in separate counterparts, each of which when so executed and delivered
shall be an original, but all such counterparts shall together constitute one
and the same instrument.
9.12 CONSTRUCTION.
(a) Headings of the Sections of this Voting Agreement are for the
convenience of the parties only, and shall be given no substantive or
interpretive effect whatsoever.
(b) For purposes of this Voting Agreement, whenever the context
requires: the singular number shall include the plural, and vice versa; the
masculine gender shall include the feminine and neuter genders; the feminine
gender shall include the masculine and neuter genders; and the neuter gender
shall include masculine and feminine genders.
(c) The parties hereto agree that any rule of construction to the
effect that ambiguities are to be resolved against the drafting party shall not
be applied in the construction or interpretation of this Voting Agreement.
(d) As used in this Voting Agreement, the words "include" and
"including," and variations thereof, shall not be deemed to be terms of
limitation, but rather shall be deemed to be followed by the words "without
limitation."
[THIS SPACE INTENTIONALLY LEFT BLANK]
8.
<PAGE>
IN WITNESS WHEREOF, Parent, Merger Sub and Stockholder have caused this
Voting Agreement to be executed as of the date first written above.
GENE LOGIC INC.
By: /s/ Michael J. Brennan
------------------------------------
Name: Michael J. Brennan
Title: President & CEO
GENE LOGIC ACQUISITION CORP.
By: /s/ Michael J. Brennan
------------------------------------
Name: Michael J. Brennan
Title: President & CEO
ONCOR, INC.
By: /s/ Cecil Kost
------------------------------------
Name: Cecil Kost
-------------------------
Title: President & CEO
-------------------------
Address: 209 Perry Parkway
-------------------------
Gaithersburg, MD 20877
-------------------------
(301) 330-3940
-------------------------
Facsimile:
-------------------------
Number of issued and outstanding shares of COMPANY COMMON STOCK Owned OF RECORD
as of the date of this Voting Agreement:
---------------
Number of additional issued and outstanding shares of COMPANY COMMON STOCK Owned
BENEFICIALLY (but not of record) as of the date of this Voting
Agreement:
-----------------
Number of issued and outstanding shares of COMPANY PREFERRED STOCK Owned OF
RECORD OR BENEFICIALLY as of the date of this Voting Agreement:
----------------
Number of additional issued and outstanding shares of COMPANY PREFERRED STOCK
Owned BENEFICIALLY (but not of record) as of the date of this Voting
Agreement:
-----------------
Number of options, warrants and other rights to acquire shares of Company
capital stock Owned OF RECORD as of the date of this Voting
Agreement:
-----------------
Number of options, warrants and other rights to acquire shares of Company
capital stock Owned BENEFICIALLY (but not of record) as of the date of this
Voting Agreement:
------------------
[VOTING AGREEMENT]
<PAGE>
EXHIBIT A
FORM OF IRREVOCABLE PROXY
IRREVOCABLE PROXY
The undersigned stockholder of Company, Inc., a Delaware corporation
("Company"), hereby irrevocably (to the fullest extent permitted by law)
appoints and constitutes Michael J. Brennan, M.D., Ph.D. and Parent Inc., a
Delaware corporation ("Parent"), and each of them, the attorneys and proxies of
the undersigned with respect to voting (i) the shares of capital stock of
Company owned by the undersigned as of the date of this proxy, which shares are
specified on the final page of this proxy and (ii) any and all other shares of
capital stock of Company which the undersigned may acquire after the date
hereof. The shares of the capital stock of Company referred to in clauses
(i) and (ii) of the immediately preceding sentence are collectively referred to
as the "Shares." Upon the execution hereof, all prior proxies given by the
undersigned with respect to any of the Shares are hereby revoked, and no
subsequent proxies will be given with respect to any of the Shares.
This proxy is irrevocable, is coupled with an interest and is granted in
connection with the Voting Agreement, dated as of the date hereof, between
Parent and the beneficial owner of the shares of capital stock of the Company
set forth on the signature page hereof (the "Voting Agreement"), and is granted
in consideration of Parent entering into the Agreement and Plan of Merger and
Reorganization, dated as of the date hereof, among Parent, Parent Acquisition
Corp., a Delaware corporation and wholly-owned subsidiary of Parent, and the
Company (the "Merger Agreement"). Capitalized terms used but not otherwise
defined in this proxy have the meanings ascribed to such terms in the Voting
Agreement and Merger Agreement.
The attorneys and proxies named above will be empowered, and may exercise
this proxy, to vote the Shares at any time until the earlier to occur of the
termination of the Merger Agreement or the Effective Time at any meeting of the
stockholders of the Company, however called, or in any written action by consent
of stockholders of the Company:
1. in favor of the issuance of shares of Parent Common Stock to the
Company Stockholders in the Merger, the Merger, the execution, delivery and
performance by the Company of the Merger Agreement and the adoption and approval
of the terms thereof and in favor of each of the other actions contemplated by
the Merger Agreement and any action required in furtherance hereof and thereof;
2. against any action or agreement that would result in a breach of any
representation, warranty, covenant or obligation of the Company in the Merger
Agreement; and
3. against the following actions (other than the Merger and the
transactions contemplated by the Merger Agreement): (A) any extraordinary
corporate transaction, such as a merger, consolidation or other business
combination involving the Company; (B) any sale, lease or transfer of
substantially all of the assets of the Company; (C) any reorganization,
recapitalization, dissolution or liquidation of the Company; (D) any change in a
majority of the board of directors of the Company; (E) any amendment to the
Company's Certificate of
[VOTING AGREEMENT]
<PAGE>
Incorporation or Bylaws; (F) any material change in the capitalization of the
Company or the Company's corporate structure; or (G) any other action which is
intended to, or would, impede, interfere with, delay, postpone, discourage or
adversely affect the Merger or any of the other transactions contemplated by the
Merger Agreement or this Voting Agreement.
The undersigned stockholder may vote the Shares on all other matters.
Any obligation of the undersigned hereunder shall be binding upon the
heirs, successors and assigns of the undersigned (including any transferee of
any of the Shares).
[THIS SPACE INTENTIONALLY LEFT BLANK]
2.
<PAGE>
This proxy shall terminate upon the Expiration Date.
Dated: July 6, 1998
ONCOR, INC.:
By: /s/ Cecil Kost
------------------------------------
Name: Cecil Kost
-------------------------------
Title: President & CEO
------------------------------
If executed by record holder on
behalf of the beneficial owner,
print name of beneficial owner:
------------------------------------
Number of issued and outstanding shares of COMPANY COMMON STOCK Owned OF RECORD
as of the date hereof:
-----------------
Number of issued and outstanding shares of COMPANY PREFERRED STOCK Owned OF
RECORD as of the date hereof:
------------------
Number of issued and outstanding shares of COMPANY COMMON STOCK Owned
BENEFICIALLY (but not of record) as of the date hereof:
-------------------
Number of issued and outstanding shares of COMPANY PREFERRED STOCK Owned
BENEFICIALLY (but not of record) as of the date hereof:
-------------------
3.
<PAGE>
EXHIBIT B
8.1 DEFINITIONS. For purposes of this Exhibit B, the following terms
have the following meanings when used herein with initial capital letters:
(a) PROSPECTUS: The prospectus included in any Registration
Statement, as amended or supplemented by any prospectus supplement, with respect
to the terms of the offering of any portion of the Registrable Securities
covered by such Registration Statement and all other amendments and supplements
to the prospectus, including post-effective amendments, and all material
incorporated by reference or deemed to be incorporated by reference in such
prospectus.
(b) REGISTRABLE SECURITIES: (i) All of Stockholder's Merger
Shares, and (ii) any Parent Common Stock that may be received by Stockholder (A)
as a result of a stock dividend on or stock split of the Merger Shares or (B) on
account of Merger Shares being exchanged in a recapitalization of or other
transaction involving Parent.
(c) REGISTRATION STATEMENT: Any registration statement of Parent
under the Securities Act that covers any of the Registrable Securities pursuant
to the provisions of this Agreement, including the related Prospectus, all
amendments and supplements to such registration statement, all exhibits and all
material incorporated by reference or deemed to be incorporated by reference in
such registration statement.
8.2 REGISTRATION OF RESALES.
(a) REGISTRATION OF RESALES ON FORM S-4. Parent will use its
reasonable efforts to register for resale all of Stockholder's Registrable
Securities under the Securities Act on the Form S-4 Registration Statement and
will use reasonable efforts to file and cause to become effective from and after
the Effective Time any post-effective amendment to the Form S-4 Registration
Statement necessary to effect such registration of such resale.
(b) CONVERSION OF FORM S-4. Subject to the other provisions of
this Agreement, the parties acknowledge that Parent may, in its discretion,
convert the Form S-4 Registration Statement to a Registration Statement on
another form permitted to be used by Parent for the registration under the
Securities Act of Stockholder's resale of its Merger Shares. References herein
to the "Form S-4 Registration Statement" will be deemed to include any
Registration Statement into which it will be converted, and the Form S-4
Registration Statement will be deemed to be a "Registration Statement" for all
purposes of this Exhibit B.
(c) MAINTENANCE OF EFFECTIVENESS. Parent agrees to use
commercially reasonable efforts to keep any Registration Statement described
above continuously effective until the earlier of (i) one year from the
Effective Date and (ii) the date on which Stockholder no longer holds any
Registrable Securities.
8.3 REGISTRATION PROCEDURES. In connection with Parent's registration
obligations pursuant to Section 8.2, Parent will as expeditiously as possible,
and in each case to the extent applicable:
<PAGE>
(a) Prepare and file with the SEC such amendments and
post-effective amendments to each Registration Statement as may be necessary to
keep such Registration Statement continuously effective for the applicable
periods specified in Section 8.2, cause the related Prospectus to be
supplemented by any required Prospectus supplement, and as so supplemented to be
filed pursuant to Rule 424 under the Securities Act, and comply with the
provisions of the Securities Act with respect to the disposition of all
securities covered by such Registration Statement during the applicable period.
(b) Use reasonable efforts to obtain the withdrawal of any order
suspending the effectiveness of a Registration Statement, or the lifting of any
suspension of the qualification (or exemption from qualification) of any of the
Registrable Securities for sale in any jurisdiction, at the earliest possible
moment.
(c) If requested by Stockholder, (i) promptly incorporate in a
Prospectus supplement or post-effective amendment such information as
Stockholder in good faith determines should be included therein to comply with
applicable law and (ii) make all required filings of such Prospectus supplement
or such post-effective amendment as soon as practicable after Parent has
received notification of the matters to be incorporated in such Prospectus
supplement or post-effective amendment; PROVIDED, HOWEVER, that Parent will not
be required to take any actions under this Section 8.3(c) that are not, in the
opinion of counsel for Parent, in compliance with applicable law.
8.4 REGISTRATION EXPENSES. All fees and expenses incident to the
performance of or compliance with this Agreement by Parent will be borne by
Parent whether or not any Registration Statement becomes effective. In no
event, however, will Parent be responsible for any underwriting discount or
selling commission with respect to any sale of Registrable Securities pursuant
to this Agreement, and Stockholder will be responsible for any taxes of any kind
(including without limitation transfer taxes) with respect to any disposition,
sale or transfer of Registrable Securities and for any legal, accounting and
other expenses incurred by it in connection with any Registration Statement.
8.5 INDEMNIFICATION.
(a) INDEMNIFICATION BY PARENT. Parent will, without limitation as
to time, indemnify and hold harmless, to the fullest extent permitted by law,
Stockholder, its officers, directors and agents and employees, each person who
controls Stockholder (within the meaning of Section 15 of the Securities Act or
Section 20 of the Exchange Act) and the officers, directors, agents and
employees of any such controlling person, from and against all losses, claims,
damages, liabilities, costs (including without limitation the costs of
investigation and attorneys' fees) and expenses (collectively, "Losses"), as
incurred, arising out of or based upon any untrue or alleged untrue statement of
a material fact contained in any Registration Statement, Prospectus or form of
Prospectus or in any amendment or supplement thereto or in any preliminary
prospectus, in which Stockholder is participating as a selling stockholder, or
arising out of or based upon any omission or alleged omission to state therein a
material fact required to be stated therein or necessary to make the statements
therein not misleading, except insofar as the same are based solely upon
information furnished in writing to Parent by such Stockholder expressly for use
therein; PROVIDED, HOWEVER, that Parent will not be liable to any Stockholder to
the extent
2.
<PAGE>
that any such Losses arise out of or are based upon an untrue statement or
alleged untrue statement or omission or alleged omission made in any
Registration Statement, Prospectus or preliminary prospectus if either (i)(A)
Stockholder failed to send or deliver a copy of the Prospectus with or prior to
the delivery of written confirmation of the sale by it of a Registrable Security
to the person asserting the claim from which such Losses arise and (B) the
Prospectus would have completely corrected such untrue statement or alleged
untrue statement or such omission or alleged omission; or (ii) such untrue
statement or alleged untrue statement, omission or alleged omission is
completely corrected in an amendment or supplement to the Prospectus previously
furnished by or on behalf of Parent with copies of the Prospectus, and
Stockholder thereafter fails to deliver such Prospectus as so amended or
supplemented prior to or concurrently with the sale of a Registrable Security to
the person asserting the claim from which such Losses arise.
(b) INDEMNIFICATION BY STOCKHOLDER. In connection with any
Registration Statement in which Stockholder is participating, Stockholder will
furnish to Parent in writing such information as Parent reasonably requests for
use in connection with any Registration Statement, Prospectus or preliminary
prospectus and will, without limitation as to time, indemnify and hold harmless,
to the fullest extent permitted by law, Parent and its directors and officers,
agents and employees, each person who controls Parent (within the meaning of
Section 15 of the Securities Act and Section 20 of the Exchange Act) and the
directors, officers, agents or employees of such controlling persons, from and
against all Losses as incurred arising out of or based upon any untrue or
alleged untrue statement of a material fact contained in any Registration
Statement, Prospectus or form of Prospectus or in any amendment or supplement
thereto or in any preliminary prospectus or arising out of or based upon any
omission or alleged omission to state therein a material fact required to be
stated therein or necessary to make the statements therein not misleading, to
the extent, but only to the extent, that such untrue or alleged untrue statement
or omission or alleged omission is contained in any information so furnished in
writing by Stockholder to Parent expressly for use in such Registration
Statement, Prospectus or preliminary prospectus.
(c) CONDUCT OF INDEMNIFICATION PROCEEDINGS. If any person becomes
entitled to indemnity under this Exhibit B (an "indemnified party"), such
indemnified party will give prompt notice to the party from which such indemnity
is sought (the "indemnifying party") of any claim or of the commencement of any
action or proceeding with respect to which such indemnified party seeks
indemnification or contribution pursuant hereto; PROVIDED, HOWEVER, that the
failure to so notify the indemnifying party will not relieve the indemnifying
party from any obligation or liability except to the extent that the
indemnifying party has been prejudiced materially by such failure. All fees and
expenses (including any fees and expenses incurred in connection with
investigating or preparing to defend such action or proceeding) will be paid to
the indemnified party, as incurred, within five calendar days of written notice
thereof to the indemnifying party (regardless of whether it is ultimately
determined that an indemnified party is not entitled to indemnification
hereunder). The indemnifying party will not consent to entry of any judgment or
enter into any settlement or otherwise seek to terminate any action or
proceeding in which any indemnified party is or could be a party and as to which
indemnification or contribution could be sought by such indemnified party under
this Section 8.5, unless such judgment, settlement or other termination includes
as an unconditional term thereof the giving by the claimant or plaintiff to such
indemnified party of a release, in form and substance satisfactory
3.
<PAGE>
to the indemnified party, from all liability in respect of such claim or
litigation for which such indemnified party would be entitled to indemnification
hereunder.
(d) CONTRIBUTION. If the indemnification provided for in this
Section 8.5 is unavailable to an indemnified party under Section 8.5(a) or
8.5(b) hereof in respect of any Losses or is insufficient to hold such
indemnified party harmless, then each applicable indemnifying party, in lieu of
indemnifying such indemnified party, will, severally but not jointly, contribute
to the amount paid or payable by such indemnified party as a result of such
Losses, in such proportion as is appropriate to reflect the relative fault of
the indemnifying party or indemnifying parties, on the one hand, and such
indemnified party, on the other hand, in connection with the actions, statements
or omissions that resulted in such Losses as well as any other relevant
equitable considerations. The relative fault of such indemnifying party or
indemnifying parties, on the one hand, and such indemnified party, on the other
hand, will be determined by reference to, among other things, whether any action
in question, including any untrue or alleged untrue statement of a material fact
or omission or alleged omission of a material fact, has been taken or made by,
or related to information supplied by, such indemnifying party or indemnified
party, and the parties' relative intent, knowledge, access to information and
opportunity to correct or prevent such action, statement or omission. The
amount paid or payable by a party as a result of any Losses will be deemed to
include any legal or other fees or expenses incurred by such party in connection
with any action or proceeding.
The parties hereto agree that it would not be just and equitable if
contribution pursuant to this Section 8.5(d) were determined by pro rata
allocation or by any other method of allocation that does not take into account
the equitable considerations referred to in the immediately preceding paragraph.
No person guilty of fraudulent misrepresentation (within the meaning of Section
11(f) of the Securities Act) will be entitled to contribution from any person
who was not guilty of such fraudulent misrepresentation.
The indemnity, contribution and expenses reimbursement obligations of the
parties hereunder will be in addition to any liability the parties may otherwise
have hereunder or otherwise. Notwithstanding any other provision of this
Agreement, the provisions of this Section 8.5 will survive so long as
Registrable Securities remain outstanding, notwithstanding any permitted
transfer of the Registrable Securities by Stockholder or any termination of this
Agreement.
8.6 REMEDIES. In the event of a breach by any party of such party's
obligations under this Schedule 8, the nonbreaching party, in addition to being
entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights hereunder. Each party
agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by them of any provision of this Exhibit B and
hereby further agrees that, in the event of any action for specific performance
in respect of such breach, it will waive the defense that a remedy at law would
be adequate.
4.
<PAGE>
VOTING AGREEMENT
THIS VOTING AGREEMENT is entered into as of July 6, 1998 by and between
GENE LOGIC INC., a Delaware corporation ("Parent"), GENE LOGIC ACQUISITION
CORP., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger
Sub"), and INCYTE PHARMACEUTICALS, INC. ("Stockholder").
RECITALS
A. Parent, ONCORMED, INC., a Delaware corporation ("Company"), and Merger
Sub are entering into an Agreement and Plan of Merger and Reorganization of even
date herewith and entered into immediately prior to the execution of this Voting
Agreement (the "Merger Agreement"), which provides for the merger of the Company
with and into Merger Sub (the "Merger"). Capitalized terms used but not
otherwise defined in this Voting Agreement shall have the meanings given to such
terms in the Merger Agreement.
B. As a condition to the willingness of Parent and Merger Sub to enter
into the Merger Agreement, Parent and Merger Sub have required that Stockholder
agree, and in order to induce Parent and Merger Sub to enter into the Merger
Agreement, Stockholder has agreed, to enter into this Voting Agreement.
AGREEMENT
The parties to this Voting Agreement, intending to be legally bound, agree
as follows:
SECTION 1. CERTAIN DEFINITIONS
1.1 "SUBJECT SECURITIES" shall mean: (i) all securities of the Company
(including shares of Company Common Stock and Company Preferred Stock and all
options, warrants and other rights to acquire shares of Company capital stock)
Owned by Stockholder as of the date of this Agreement; and (ii) all additional
securities of the Company (including all additional shares of Company Common
Stock, Company Preferred Stock and all additional options, warrants and other
rights to acquire shares of Company capital stock) of which Stockholder acquires
Ownership during the period from the date of this Agreement through the
Expiration Date.
1.2 Stockholder shall be deemed to "OWN" or to have acquired "OWNERSHIP"
of a security of the Company if Stockholder: (i) is the record owner of such
security; or (ii) is the "beneficial owner" (within the meaning of Rule 13d-3
under the Exchange Act) of such security.
1.3 "EXPIRATION DATE" shall mean the earlier of the date upon which (i)
the Merger becomes effective, or (ii) the Merger Agreement is validly
terminated; PROVIDED, HOWEVER, that the "Expiration Date" shall be the date 180
days following the date on which the Merger Agreement is validly terminated if
an Identified Termination occurs.
1.4 An "IDENTIFIED TERMINATION" shall occur if (i) the Merger Agreement
is terminated by Parent pursuant to Section 7.1(e) of the Merger Agreement, or
(ii) the Merger
1.
<PAGE>
Agreement is terminated by Parent pursuant to Section 7.1(g) of the Merger
Agreement (other than pursuant to subsection (i) thereof).
SECTION 2. DISPOSITION AND VOTING OF SUBJECT SECURITIES.
2.1 NO DISPOSITION OR ENCUMBRANCE OF SUBJECT SECURITIES. Stockholder
hereby covenants and agrees that, prior to the Expiration Date, Stockholder will
not, directly or indirectly, (i) offer, sell, offer to sell, contract to sell,
pledge, grant any option to purchase or otherwise dispose of or transfer (or
announce any offer, sale, offer of sale, contract of sale or grant of any option
to purchase or other disposition or transfer of) any Subject Securities to any
Person other than Parent or Parent's designee, (ii) create or permit to exist
any Encumbrance with respect to any of the Subject Securities, (iii) reduce
Stockholder's beneficial ownership of, interest in or risk relating to, any of
the Subject Securities or (iv) commit or agree to do any of the foregoing.
2.2 NO TRANSFER OF VOTING RIGHTS. Stockholder covenants and agrees that,
prior to the Expiration Date, Stockholder will not deposit any of the Subject
Securities into a voting trust or grant another proxy (except as provided
herein) or enter into a voting agreement with respect to any of the Subject
Securities.
SECTION 3. VOTING OF SUBJECT SECURITIES
3.1 PRE-TERMINATION VOTING AGREEMENT. Stockholder hereby agrees that,
prior to the Expiration Date, at any meeting of the stockholders of the Company,
however called, and in any written action by consent of the stockholders of the
Company, unless otherwise directed in writing by Parent, Stockholder shall cause
the Subject Securities to be voted:
(a) in favor of the issuance of shares of Parent Common Stock to the
Company Stockholders in the Merger, the Merger, the execution, delivery and
performance by the Company of the Merger Agreement and the adoption and approval
of the terms thereof and in favor of each of the other actions contemplated by
the Merger Agreement and any action required in furtherance hereof and thereof;
(b) against any action or agreement that would result in a breach of
any representation, warranty, covenant or obligation of the Company in the
Merger Agreement; and
(c) against the following actions (other than the Merger and the
transactions contemplated by the Merger Agreement): (A) any extraordinary
corporate transaction, such as a merger, consolidation or other business
combination involving the Company; (B) any sale, lease or transfer of
substantially all of the assets of the Company; (C) any reorganization,
recapitalization, dissolution or liquidation of the Company; (D) any change in a
majority of the board of directors of the Company; (E) any amendment to the
Company's Certificate of Incorporation or Bylaws; (F) any material change in the
capitalization of the Company or the Company's corporate structure; or (G) any
other action which is intended to, or would, impede, interfere with, delay,
postpone, discourage or adversely affect the Merger or any of the other
transactions contemplated by the Merger Agreement or this Voting Agreement.
2.
<PAGE>
3.2 Prior to the Expiration Date, Stockholder shall not enter into any
Contract with any Person to vote or give instructions in any manner inconsistent
with Sections 3.1(a), 3.1(b) or 3.1(c).
3.3 POST-TERMINATION VOTING AGREEMENT. If an Identified Termination
occurs, then, prior to the Expiration Date, at any meeting of the stockholders
of the Company, however called, and in any written action by the consent of the
stockholders of the Company, unless otherwise directed in writing by Parent,
Stockholder shall vote the Subject Securities (a) against any Acquisition
Proposal and any related transaction or agreement, and (b) against any action
which is intended, or could reasonably be expected, to facilitate the
consummation of any Acquisition Transaction. Stockholder shall not enter into
any Contract with any Person prior to the Expiration Date to vote or give
instructions in any manner inconsistent with clause "(a)" or "(b)" of the
preceding sentence.
3.4 PROXY. Contemporaneously with the execution of this Voting
Agreement, (i) Stockholder shall deliver to Parent a proxy in the form attached
hereto as Exhibit A, which shall be irrevocable to the fullest extent permitted
by law, with respect to the shares referred to therein (the "Proxy"); and (ii)
Stockholder shall deliver to Parent an additional proxy in the form attached
hereto as Exhibit A executed on behalf of the record owner of any issued and
outstanding shares of Company Common Stock and Company Preferred Stock that are
owned beneficially (but are not owned of record) by Stockholder.
SECTION 4. WAIVER OF APPRAISAL RIGHTS
Stockholder hereby waives any rights of appraisal and any dissenters'
rights that Stockholder may have in connection with the Merger.
SECTION 5. NO SOLICITATION
Stockholder covenants and agrees that, during the period commencing on the
date of this Voting Agreement and ending on the Expiration Date, Stockholder
shall not, and shall not authorize or permit any Representative of Stockholder,
to: (i) solicit, initiate or encourage the making, submission or announcement of
any Acquisition Proposal, (ii) furnish any information regarding the Company to
any Person in connection with or in response to an Acquisition Proposal, (iii)
engage in discussions or negotiations with any Person with respect to any
Acquisition Proposal, (iv) approve, endorse or recommend any Acquisition
Proposal or (v) enter into any letter of intent or other similar document or any
Contract contemplating or otherwise relating to any Acquisition Transaction;
PROVIDED, HOWEVER, that: (A) nothing herein shall prohibit the Stockholder from
disclosing, or causing the Company to disclose, to the Company's stockholders a
position with respect to a tender offer pursuant to Rules 14d-9 and 14e-2
promulgated under the Exchange Act; (B) nothing herein shall prohibit
Stockholder from making any disclosure to the Company's Stockholders if, in the
good faith judgment of the Stockholder after consultation with its outside legal
counsel, failure to so disclose would be inconsistent with applicable laws; and
(C) the Stockholder shall not be prohibited by this Section 5 from (x)
furnishing or causing to be furnished nonpublic information regarding the
Company to any Person in response to an Acquisition Proposal that is submitted
by such Person (and not withdrawn), or (y) entering into discussions with any
Person in response to a Superior Offer that
3.
<PAGE>
is submitted by such Person (and not withdrawn) if, in either such case: (1)
neither Stockholder or the Company nor any of their respective Representatives
shall have violated any of the restrictions set forth in this Section 5, (2) the
Stockholder believes in good faith, after consultation with its outside legal
counsel to the Company, that such action is required in order for the
Stockholder to comply with such Stockholder's fiduciary obligations to the
Company's other stockholders under applicable law, (3) prior to furnishing or
causing to be furnished any such nonpublic information to, or entering into
discussions with, such Person, the Stockholder gives Parent written notice of
the identity of such Person and of such Stockholder's intention to furnish or to
cause to be furnished nonpublic information to, or enter into discussions with,
such Person, and the Stockholder causes the Company to receive from such Person
an executed confidentiality agreement containing limitations no less restrictive
than the limitations imposed on Parent pursuant to that certain Mutual
Non-Disclosure Agreement dated as of January 27, 1998 between Parent and the
Company, and (4) contemporaneously with furnishing any such nonpublic
information to such Person, the Stockholder furnishes or causes to be furnished
such nonpublic information to Parent (to the extent such nonpublic information
has not been previously furnished by the Company to Parent).
SECTION 6. REPRESENTATIONS AND WARRANTIES OF STOCKHOLDER
Stockholder hereby represents and warrants to Parent as follows:
6.1 DUE AUTHORIZATION. Stockholder has all requisite power and capacity
to execute and deliver this Voting Agreement and to perform Stockholder's
obligations hereunder. This Voting Agreement has been duly executed and
delivered by Stockholder and constitutes a legal, valid and binding obligation
of Stockholder, enforceable against Stockholder in accordance with its terms,
except as enforcement thereof may be limited by bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting
enforcement of creditors' rights generally, as limited by laws relating to the
availability of specific performance, injunctive relief, or by general equitable
principles, and to the extent any indemnification or contribution provisions
thereof may be limited by applicable federal or state securities laws.
6.2 NO CONFLICTS, REQUIRED FILINGS AND CONSENTS.
(a) The execution and delivery of this Voting Agreement by
Stockholder do not, and the performance of this Voting Agreement by Stockholder
will not: (i) conflict with or violate any order, decree or judgment applicable
to Stockholder or by which Stockholder or any of Stockholder's properties are
bound or affected; or (ii) result in any breach of or constitute a default (with
notice or lapse of time, or both) under, or give to others any rights of
termination, amendment, acceleration or cancellation of, or result in the
creation of an Encumbrance on the Subject Securities pursuant to any Contract
other than this Voting Agreement to which Stockholder is a party or by which
Stockholder or any of Stockholder's properties is bound or affected.
(b) The execution and delivery of this Voting Agreement by
Stockholder do not, and the performance of this Voting Agreement by Stockholder
will not, require any Consent of any Person.
4.
<PAGE>
6.3 TITLE TO SUBJECT SECURITIES. As of the date hereof, Stockholder Owns
in the aggregate (including shares owned of record and shares owned
beneficially) the number of issued and outstanding shares of Company Common
Stock and Company Preferred Stock set forth below Stockholder's name on the
signature page hereof, and the number of options, warrants and other rights to
acquire shares of Company capital stock set forth below Stockholder's name on
the signature page hereof, and does not directly or indirectly Own, any shares
of capital stock of the Company, or any option, warrant or other right to
acquire any shares of capital stock of the Company, other than the shares,
options, warrants and other rights set forth below Stockholder's name on the
signature page hereof.
6.4 ACCURACY OF REPRESENTATIONS. The representations and warranties
contained in this Voting Agreement are accurate in all respects as of the date
of this Voting Agreement, will be accurate in all respects at all times through
the Expiration Date and will be accurate in all material respects as of the date
of the consummation of the Merger as if made on that date.
SECTION 7. COVENANTS OF STOCKHOLDER
7.1 FURTHER ASSURANCES. From time to time and without additional
consideration, Stockholder will execute and deliver, or cause to be executed and
delivered, such additional or further arrangements, proxies, consents and other
instruments as Parent may reasonably request for the purpose of effectively
carrying out and furthering the intent of this Voting Agreement.
7.2 LEGEND. Immediately after the execution of this Voting Agreement,
Stockholder shall instruct the Company to cause each certificate of Stockholder
evidencing the Subject Securities to bear a legend in the following form:
THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE SOLD,
EXCHANGED OR OTHERWISE TRANSFERRED OR DISPOSED OF EXCEPT IN COMPLIANCE
WITH THE TERMS AND CONDITIONS OF THE VOTING AGREEMENT DATED AS OF JULY
6, 1998, AS IT MAY BE AMENDED, EXECUTED BY THE REGISTERED HOLDER OF
THIS CERTIFICATE, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL
EXECUTIVE OFFICES OF THE ISSUER.
SECTION 8. MISCELLANEOUS
8.1 SURVIVAL OF REPRESENTATIONS, WARRANTIES AND AGREEMENTS. All
representations, warranties and agreements made by Stockholder in this Voting
Agreement shall survive (i) the consummation of the Merger, (ii) any termination
of the Merger Agreement, and (iii) the Expiration Date.
8.2 INDEMNIFICATION. Stockholder shall hold harmless and indemnify
Parent, and Parent's Representatives from and against any damages (regardless of
whether such damages relate to a third-party claim) suffered or incurred by
Parent or Parent's Representatives and that arise from any breach of any
representation, warranty, covenant or obligation of Stockholder contained
herein.
5.
<PAGE>
8.3 EXPENSES. All costs and expenses incurred in connection with the
transactions contemplated by this Voting Agreement shall be paid by the party
incurring such costs and expenses.
8.4 NOTICES. All notices and other communications required or permitted
to be delivered to any party pursuant to this Voting Agreement shall be in
writing and shall be deemed properly given if delivered personally, by
facsimile, sent by nationally-recognized, overnight courier or mailed by
registered or certified mail (postage prepaid, return receipt requested) to the
parties at the following addresses (or at such other address for a party as
shall be specified by like notice):
if to Stockholder:
at the address set forth below Stockholder's signature on the
signature page hereto
with a copy to:
Brobeck, Phleger & Harrison LLP
1633 Broadway, 47th Floor
New York, NY 10019
Attention: Alexander D. Lynch, Esq.
Telephone: (212) 581-1600
Fax: (212) 586-7878
if to Parent:
Gene Logic Inc.
708 Quince Orchard Road
Gaithersburg, MD 20878
Attention: President and Chief Executive Officer
Facsimile: (301) 987-1701
with a copy to:
Cooley Godward LLP
4365 Executive Drive
Suite 1100
San Diego, CA 92121-2128
Attention: Frederick T. Muto, Esq.
Facsimile: (619) 453-3555
All such notices and other communications shall be deemed to have been received
(a) in the case of personal delivery, on the date of such delivery, (b) in the
case of a facsimile, when the party receiving such facsimile shall have
confirmed receipt of the communication, (c) in the case of delivery by
nationally-recognized, overnight courier, on the Business Day following dispatch
and (d) in the case of registered or certified mail, on the fifth Business Day
following such mailing.
6.
<PAGE>
8.5 SEVERABILITY. Any term or provision of this Voting Agreement which
is invalid or unenforceable in any jurisdiction shall, as to that jurisdiction,
be ineffective to the extent of such invalidity or unenforceability without
rendering invalid or unenforceable the remaining terms and provisions of this
Voting Agreement or affecting the validity or enforceability of any of the terms
or provisions of this Voting Agreement in any other jurisdiction. If any
provision of this Voting Agreement is so broad as to be unenforceable, the
provision shall be interpreted to be only so broad as is enforceable.
8.6 ENTIRE AGREEMENT. This Voting Agreement and any documents delivered
by the parties in connection herewith constitute the entire agreement between
the parties with respect to the subject matter hereof and thereof and supersede
all prior agreements and understandings between the parties with respect
thereto. No addition to or modification of any provision of this Voting
Agreement shall be binding upon either party hereto unless made in writing and
signed by both parties hereto. The parties hereto waive their right to a trial
by jury in any action at law or suit in equity based upon, or arising out of,
this Voting Agreement or the subject matter hereof.
8.7 ASSIGNMENT, BINDING EFFECT. Except as provided herein, neither this
Voting Agreement nor any of its rights, interests or obligations shall be
assigned by Stockholder without the prior written consent of Parent. Subject to
the preceding sentence, this Voting Agreement shall be binding upon and shall
inure to the benefit of (i) Stockholder and Stockholder's heirs, successors and
assigns and (ii) Parent and its successors and assigns. Notwithstanding
anything contained in this Voting Agreement to the contrary, nothing in this
Voting Agreement, expressed or implied, is intended to confer on any Person
other than the parties hereto or their respective heirs, successors and assigns
any rights, remedies, obligations or liabilities under or by reason of this
Voting Agreement.
8.8 SPECIFIC PERFORMANCE. The parties hereto agree that irreparable
damage would occur in the event that any of the provisions of this Voting
Agreement was not performed in accordance with its specific terms or was
otherwise breached. It is accordingly agreed that Parent shall be entitled to
an injunction or injunctions to prevent breaches of this Voting Agreement and to
enforce specifically the terms and provisions hereof, this being in addition to
any other remedy to which Parent is entitled at law or in equity.
8.9 OTHER AGREEMENTS. Nothing in this Voting Agreement shall limit any
of the rights or remedies of Parent or any of the obligations of Stockholder
under any agreement between Parent and Stockholder.
8.10 GOVERNING LAW. This Voting Agreement is made under, and shall be
construed and enforced in accordance with, the laws of the State of Delaware
applicable to agreements made and to be performed solely therein, without
giving effect to principles of conflicts of law. In any action between or
among any of the parties, whether arising out of this Voting Agreement or
otherwise: (a) each of the parties irrevocably and unconditionally consents
and submits to the exclusive jurisdiction and venue of the state and federal
courts located in Maryland; (b) if any such action is commenced in a state
court, then, subject to applicable law, no party shall object to the removal
of such action to any federal court located in Montgomery County, Maryland;
(c) each of the parties irrevocably waives the right to trial by jury; and
(d) each of the parties
7.
<PAGE>
irrevocably consents to service of process by first class certified mail,
return receipt requested, postage prepaid, to the address at which such party
is to receive notice in accordance with Section 8.4.
8.11 COUNTERPARTS. This Voting Agreement may be executed by the parties
hereto in separate counterparts, each of which when so executed and delivered
shall be an original, but all such counterparts shall together constitute one
and the same instrument.
8.12 CONSTRUCTION.
(a) Headings of the Sections of this Voting Agreement are for the
convenience of the parties only, and shall be given no substantive or
interpretive effect whatsoever.
(b) For purposes of this Voting Agreement, whenever the context
requires: the singular number shall include the plural, and vice versa; the
masculine gender shall include the feminine and neuter genders; the feminine
gender shall include the masculine and neuter genders; and the neuter gender
shall include masculine and feminine genders.
(c) The parties hereto agree that any rule of construction to the
effect that ambiguities are to be resolved against the drafting party shall not
be applied in the construction or interpretation of this Voting Agreement.
(d) As used in this Voting Agreement, the words "include" and
"including," and variations thereof, shall not be deemed to be terms of
limitation, but rather shall be deemed to be followed by the words "without
limitation."
[THIS SPACE INTENTIONALLY LEFT BLANK]
8.
<PAGE>
IN WITNESS WHEREOF, Parent, Merger Sub and Stockholder have caused this
Voting Agreement to be executed as of the date first written above.
GENE LOGIC INC.
By: /s/ Michael J. Brennan
-----------------------------------------
Name: Michael J. Brennan
Title: President & CEO
GENE LOGIC ACQUISITION CORP.
By: /s/ Michael J. Brennan
-----------------------------------------
Name: Michael J. Brennan
Title: President & CEO
INCYTE PHARMACEUTICALS, INC.
/s/ Denise M. Gilbert
-----------------------------------------
Name: Denise M. Gilbert
------------------------------
Address: Incyte Pharmaceuticals, Inc.
------------------------------
3174 Porter Drive
------------------------------
Palo Alto, CA 94304
------------------------------
------------------------------
Facsimile: (650) 845-4166
------------------------------
Number of issued and outstanding shares of COMPANY COMMON STOCK Owned OF RECORD
as of the date of this Voting Agreement:
--------------
Number of additional issued and outstanding shares of COMPANY COMMON STOCK
Owned BENEFICIALLY (but not of record) as of the date of this Voting
Agreement:
--------------
Number of issued and outstanding shares of COMPANY PREFERRED STOCK Owned OF
RECORD OR BENEFICIALLY as of the date of this Voting Agreement:
--------------
Number of additional issued and outstanding shares of COMPANY PREFERRED STOCK
Owned BENEFICIALLY (but not of record) as of the date of this Voting
Agreement:
-------------
Number of options, warrants and other rights to acquire shares of Company
capital stock Owned OF RECORD as of the date of this Voting
Agreement:
--------------
Number of options, warrants and other rights to acquire shares of Company
capital stock Owned BENEFICIALLY (but not of record) as of the date of this
Voting Agreement:
--------------
[VOTING AGREEMENT]
<PAGE>
EXHIBIT A
FORM OF IRREVOCABLE PROXY
IRREVOCABLE PROXY
The undersigned stockholder of Company, Inc., a Delaware corporation
("Company"), hereby irrevocably (to the fullest extent permitted by law)
appoints and constitutes Michael J. Brennan, M.D., Ph.D. and Parent Inc., a
Delaware corporation ("Parent"), and each of them, the attorneys and proxies of
the undersigned with respect to voting (i) the shares of capital stock of
Company owned by the undersigned as of the date of this proxy, which shares are
specified on the final page of this proxy and (ii) any and all other shares of
capital stock of Company which the undersigned may acquire after the date
hereof. The shares of the capital stock of Company referred to in clauses
(i) and (ii) of the immediately preceding sentence are collectively referred to
as the "Shares." Upon the execution hereof, all prior proxies given by the
undersigned with respect to any of the Shares are hereby revoked, and no
subsequent proxies will be given with respect to any of the Shares.
This proxy is irrevocable, is coupled with an interest and is granted in
connection with the Voting Agreement, dated as of the date hereof, between
Parent and the beneficial owner of the shares of capital stock of the Company
set forth on the signature page hereof (the "Voting Agreement"), and is granted
in consideration of Parent entering into the Agreement and Plan of Merger and
Reorganization, dated as of the date hereof, among Parent, Parent Acquisition
Corp., a Delaware corporation and wholly-owned subsidiary of Parent, and the
Company (the "Merger Agreement"). Capitalized terms used but not otherwise
defined in this proxy have the meanings ascribed to such terms in the Voting
Agreement and Merger Agreement.
The attorneys and proxies named above will be empowered, and may exercise
this proxy, to vote the Shares at any time until the earlier to occur of the
termination of the Merger Agreement or the Effective Time at any meeting of the
stockholders of the Company, however called, or in any written action by consent
of stockholders of the Company:
1. in favor of the issuance of shares of Parent Common Stock to the
Company Stockholders in the Merger, the Merger, the execution, delivery and
performance by the Company of the Merger Agreement and the adoption and approval
of the terms thereof and in favor of each of the other actions contemplated by
the Merger Agreement and any action required in furtherance hereof and thereof;
2. against any action or agreement that would result in a breach of any
representation, warranty, covenant or obligation of the Company in the Merger
Agreement; and
3. against the following actions (other than the Merger and the
transactions contemplated by the Merger Agreement): (A) any extraordinary
corporate transaction, such as a merger, consolidation or other business
combination involving the Company; (B) any sale, lease or transfer of
substantially all of the assets of the Company; (C) any reorganization,
recapitalization, dissolution or liquidation of the Company; (D) any change in a
majority of the board of directors of the Company; (E) any amendment to the
Company's Certificate of Incorporation or Bylaws; (F) any material change in the
capitalization of the Company or the
1.
<PAGE>
Company's corporate structure; or (G) any other action which is intended to, or
would, impede, interfere with, delay, postpone, discourage or adversely affect
the Merger or any of the other transactions contemplated by the Merger Agreement
or this Voting Agreement.
The undersigned stockholder may vote the Shares on all other matters.
Any obligation of the undersigned hereunder shall be binding upon the
heirs, successors and assigns of the undersigned (including any transferee of
any of the Shares).
[THIS SPACE INTENTIONALLY LEFT BLANK]
2.
<PAGE>
This proxy shall terminate upon the Expiration Date.
Dated: July 6, 1998
INCYTE PHARMACEUTICALS, INC.
/s/ Denise M. Gilbert
-------------------------------------------
Print Name Denise M. Gilbert
--------------------------------
Executive Vice President and CFO
If executed by record holder on behalf of the
beneficial owner, print name of beneficial
owner:
------------------------------------------
Number of issued and outstanding shares of COMPANY COMMON STOCK Owned OF RECORD
as of the date hereof:
--------------
Number of issued and outstanding shares of COMPANY PREFERRED STOCK Owned OF
RECORD as of the date hereof:
--------------
Number of issued and outstanding shares of COMPANY COMMON STOCK Owned
BENEFICIALLY (but not of record) as of the date hereof:
--------------
Number of issued and outstanding shares of COMPANY PREFERRED STOCK Owned
BENEFICIALLY (but not of record) as of the date hereof:
--------------
1.
<PAGE>
EXECUTION COPY
July 6, 1998
Oncormed, Inc.
Attn: Dr. Timothy J. Triche
205 Perry Parkway
Gaithersburg, Maryland 20877
Re: CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT DATED FEBRUARY 27, 1998
Dear Dr. Triche:
On February 27, 1998, Oncormed, Inc., a Delaware corporation (the
"Company"), and each of Southbrook International Investments, Ltd., Westover
Investments, Ltd., Brown Simpson Strategic Growth Fund, L.P., Brown Simpson
Strategic Growth Fund, Ltd. and Incyte Pharmaceuticals, Inc. (collectively, the
"Investors") entered into that certain Convertible Preferred Stock Purchase
Agreement (as amended on March 17, 1998, the "Agreement"). In connection with
the transactions contemplated by the Agreement, among other things, (i) the
Company issued to the Investors an aggregate of 333 shares of the Company's 6%
Series A Convertible Preferred Stock, par value $.01 per share (the "Series A
Shares"); (ii) the Company and the Investors entered into that certain
registration rights agreement dated February 27, 1998 (the "Registration Rights
Agreement"); and (iii) the Company filed with the Secretary of State of the
State of Delaware that certain Certificate of Designation, Preferences and
Rights of 6% Series A Convertible Preferred Stock of Oncormed, Inc. (the
"Certificate of Designation"). Unless defined herein, all capitalized terms
used herein shall have the definition ascribed to such terms in the Agreement.
As you may know, the Company has been in discussions with Gene Logic Inc.,
a Delaware corporation ("Gene Logic"), related to the proposed acquisition of
the Company by Gene Logic in accordance with the terms and conditions of an
Agreement and Plan of Merger and Reorganization (the "Merger Agreement") to be
entered into between the Company, Gene Logic and a wholly-owned subsidiary of
Gene Logic ("Merger Sub"). Under the Merger Agreement, the Company would merge
with and into Merger Sub (together with any other structure by which the
businesses of the Company and Gene Logic may be combined, the "Merger") with
Merger Sub continuing as the surviving corporation. Each of the Investors
understands and acknowledges that, until such time as the Company announces the
Merger, any and all discussions and other information relating to the proposed
Merger is confidential and agrees not to disclose the existence or substance of
any such discussions or information to any third party. In addition, each
Investor acknowledges and agrees that this letter agreement is entered into, in
part, for the benefit of Gene Logic and Merger Sub and that each of Gene Logic
and Merger Sub are intended to be, and shall be third party beneficiaries to
this letter agreement and are entitled to all rights and remedies afforded to
them as third party beneficiaries.
In consideration of the mutual covenants contained herein, and for good and
valuable consideration the receipt and sufficiency is hereby acknowledged, each
of the Investors (severally and not jointly) hereby agrees with the Company as
follows:
1.
<PAGE>
1. WAIVER OF PURCHASE OF SERIES B SHARES. Pursuant to Section 1.3(b) of
the Agreement, subject to certain terms and conditions set forth in the
Agreement, the Investors have the right to purchase from the Company an
aggregate of 333 Series B Shares. In accordance with Section 5.4 of the
Agreement, each of the Investors hereby, subject to Section 7(e) below,
irrevocably waives its rights to purchase any Series B Shares from the
Company pursuant to Section 1.3 of the Agreement.
2. WAIVER OF REDEMPTION RIGHTS. Pursuant to Section 5(c)(vii) of the
Certificate of Designation, each of the Investors has the right, in the
event of a Change of Control Transaction (as defined in the Certificate of
Designation), to cause the Company to redeem, from funds legally available
therefor at the time of such redemption, such Investor's respective Series
A Shares in accordance with the terms of the Certificate of Designation
(the "Redemption Rights"). Each of the Investors hereby, subject to
Section 7(e) below, irrevocably waives its right to exercise Redemption
Rights with respect to the Merger.
3. DELIVERY OF HOLDER CONVERSION NOTICES. In furtherance of each
Investor's agreement and covenant contained in Section 2 hereof, and in
accordance with the Section 5(a)(i) of the Certificate of Designation, each
of the Investors covenants and agrees to convert its respective Series A
Shares (including any accrued but unpaid dividends thereon) into shares of
Common Stock as set forth herein. Prior to 5:00 P.M. (New York time) on
the Announcement Date (as defined in the Certificate of Designation) (the
"Delivery Time"), each of the Investors shall deliver to the Company
executed Holder Conversion Notices (as defined in the Certificate of
Designation) identical in both form and substance to the form attached
hereto as EXHIBIT A. For the purpose of the Holder Conversion Notices,
each of the Investors hereby agrees that the Conversion Price (as defined
in Section 5(c)(1) of the Certificate of Designation) shall be the
Conversion Price in effect on the Announcement Date; provided, however,
that if the Announcement Date is after July 9, 1998, the Investor shall
have the option to set the Conversion Price at either the Conversion Price
in effect on July 9, 1998 or the Conversion Price in effect on the
Announcement. In addition, each of the Investors agrees and covenants that
the Holder Conversion Dates (as defined in the Certificate of Designation)
with respect to the conversion of all of the Series A Shares shall not be
later than immediately prior to the Effective Time of the Merger.
Consequently, effective as immediately prior to the Effective Time of the
Merger, all of the Series A Shares then outstanding shall be automatically
converted into shares of Common Stock in accordance with the Certificate of
Designation using the Conversion Price set forth on the Holder Conversion
Notices, and the Company may provide instructions to its transfer agent to
such effect.
4. ESCROW OF HOLDER CONVERSION NOTICES. In order to ensure compliance
with Section 3 hereof, each of the Investors covenants and agrees that, by
the end of the day on which this letter agreement is executed, such
Investor will deliver its Holder Conversion Notices with respect to all of
its Series A Shares, along with irrevocable instructions to deliver the
same to the Company prior to the Delivery Time, to Robinson Silverman
Pearce Aronsohn & Berman LLP to be held in escrow until the Delivery Time.
Copies of such Holder Conversion Notices, and the irrevocable instructions
relating
2.
<PAGE>
thereto, will be provided by the end of the day on which this letter
agreement is executed to Brobeck, Phleger & Harrison LLP, counsel to the
Company.
5. VOTING OF COMPANY SECURITIES. (a) Each Investor hereby agrees, with
respect to any shares of the Company's Common Stock or Preferred Stock
beneficially owned by such Investor on the record date relating to, or at
the time of, any Company stockholder meeting called to approve the Merger,
to vote all such shares of Common Stock or Preferred Stock (i) in favor of
the Merger, (ii) in favor of any exchange of shares between the acquiring
entity in the Merger and the Company, (iii) in favor of the execution,
delivery and performance by the Company of any agreements relating to the
Merger (the "Transaction Agreements"), (iv) in favor of each of the other
actions contemplated by the Transaction Agreements, (v) in favor of any
action reasonably required in furtherance thereof, (vi) against any action
or agreement that would result in a breach of any representation, warranty,
covenant or obligation of the Company in any agreement relating to the
Merger, or (vii) against the following actions (other than the Merger and
the transactions contemplated by the Merger): (A) any extraordinary
corporate transaction, such as a merger, consolidation or other business
combination involving the Company, (B) any sale, lease or transfer of
substantially all of the assets of the Company, (C) any reorganization,
recapitalization, dissolution or liquidation of the Company, (D) any change
in a majority of the board of directors of the Company, (E) any amendment
to the Company's Certificate of Incorporation or Bylaws, (F) any material
change in the capitalization of the Company or the Company's corporate
structure, or (G) any other action which is intended to, or would, impede,
interfere with, delay, postpone, discourage or adversely affect the Merger
or any of the other transactions contemplated by the agreement governing
the Merger or this letter agreement.
(b) In furtherance of each Investor's agreement and covenant
contained in Section 5(a) hereof, each of the Investors has executed and
delivered to the Company an irrevocable proxy in the form attached hereto
as EXHIBIT B.
6. NO DISPOSITION OF COMPANY SECURITIES. Each Investor hereby agrees and
covenants that, prior to the Announcement Date, such Investor will not,
directly or indirectly, (i) offer, sell, offer to sell, sell against the
box, short sell, contract to sell, pledge, grant any option to purchase or
otherwise dispose of or transfer (or announce any offer, sale, offer of
sale, short sale, contract of sale or grant of any option to purchase or
other disposition or transfer of) any shares of the Company's Common Stock
or Preferred Stock to any person, (ii) reduce such Investor's beneficial
ownership of, interest in or risk relating to, any shares of the Company's
Common Stock or Preferred Stock except as occurs due to fluctuations in the
market price of the Common Stock, or (iii) commit or agree to do any of the
foregoing. Furthermore, each of the Investors hereby agrees and covenants
that such Investor shall not sell or otherwise transfer any Series A
Shares, including transfers to any affiliate or partner of the Investor,
unless the transferee of such shares of Preferred Stock agrees in writing
to be bound by the terms of this letter agreement. Except pursuant to
restrictions contained in this letter agreement, including, without
limitation, the restrictions in the immediately prior sentence, or in the
Certificate of Designation, after the Delivery Time there shall be no
contractual restrictions on the ability of the Investors to buy, sell or
execute other trades in the securities of the Company.
3.
<PAGE>
7. MISCELLANEOUS.
(a) ENTIRE AGREEMENT. This letter agreement together with the
Agreement, the Certificate of Designation, the Registration Rights
Agreement and the other documents and transactions contemplated by the
Agreement contains the entire understanding of the parties with
respect to the subject matter hereof and supersedes all prior
agreements and understandings, oral or written, with respect to such
matters. All other terms set forth in the Agreement, the Certificate
of Designation, the Registration Rights Agreement and the other
documents and transactions contemplated by the Agreement unless
amended or waived hereby shall remain in full force and effect.
(b) GOVERNING LAW. This letter agreement shall be governed by and
construed and enforced in accordance with the internal laws of the
State of New York without regard to the principles of conflicts of law
thereof. Each party hereby irrevocably submits to the non-exclusive
jurisdiction of the federal courts sitting in the City of New York,
borough of Manhattan, for the adjudication of any dispute hereunder or
in connection herewith or with any transaction contemplated hereby or
discussed herein, and hereby irrevocably waives, and agrees not to
assert in any suit, action or proceeding, any claim that it is not
personally subject to the jurisdiction of any such court or that such
suit, action or proceeding is improper. Each party hereby irrevocably
waives personal service of process and consents to process being
served in any such suit, action or proceeding by mailing a copy
thereof to such party at the address in effect for notices to it under
this letter agreement and agrees that such service shall constitute
good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to
serve process in any manner permitted by law.
(c) REMEDIES. In addition to being entitled to exercise all rights
provided herein or granted by law, including recovery of damages, the
parties hereto will be entitled to specific performance of the
obligations of the other parties contained herein. Each of the
Investors and the Company agree that monetary damages would not be
adequate compensation for any loss incurred by reason of any breach of
its obligations described in the foregoing sentence and hereby agrees
to waive in any action for specific performance of any such obligation
the defense that a remedy at law would be adequate.
(d) SUCCESSORS AND ASSIGNS. This letter agreement shall be binding
upon and inure to the benefit of the parties and their successors and
permitted assigns. No Investor may assign this letter agreement or
any rights or obligations hereunder without the prior written consent
of the Company.
(e) TERMINATION. This letter agreement, including all of the waivers
and the Holder Conversion Notices to be provided in connection
herewith, shall terminate and be of no further effect if the
transactions contemplated by the Merger are not consummated or
otherwise terminated on or prior to December 31, 1998. Nothing set
forth in this letter agreement shall be construed to limit the
priority status of the Series A Shares in the event of the termination
of this letter agreement.
4.
<PAGE>
(f) SIDE AGREEMENTS. The Company hereby acknowledges that it has not
entered into any side letter or similar agreement with any Investor
with respect to its investment in the Series A Shares or the matters
contained in this letter agreement.
(g) SUSPENSION OF FORM S-3. The Company agrees that, effective on
the Announcement Date, it will instruct its transfer agent to lift any
suspension of trading shares of the Company's Common Stock under the
Form S-3 Registration Statement relating to the Common Stock
underlying the Series A Shares.
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
5.
<PAGE>
Any notices relating to the issues described herein should be addressed to
each of the Investors at the addresses set forth in the Agreement (with a copy
of such notices being provided to Robinson Silverman Pearce Aronsohn & Berman
LLP). This letter agreement may be signed in two or more counterparts, all of
which when taken together shall be considered one and the same agreement and
shall become effective when counterparts have been signed by each party and
delivered to the other parties.
SOUTHBROOK INTERNATIONAL INVESTMENTS,
LTD.
BY: /s/ Kenneth C. Henderson
--------------------------------
NAME: Kenneth C. Henderson
TITLE: Attorney in Fact
WESTOVER INVESTMENTS, L.P.
BY: /s/ David C. Haley
--------------------------------
NAME: David C. Haley
TITLE: Authorized Signatory
MONTROSE INVESTMENTS, LTD.
BY: /s/ David C. Haley
--------------------------------
NAME: David C. Haley
TITLE: Authorized Signatory
BROWN SIMPSON STRATEGIC GROWTH FUND,
L.P.
BY: /s/ Evan Levine
--------------------------------
NAME: Evan Levine
TITLE:
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
6.
<PAGE>
BROWN SIMPSON STRATEGIC GROWTH FUND,
LTD.
BY: /s/ Evan Levine
--------------------------------
NAME: Evan Levine
TITLE:
INCYTE PHARMACEUTICALS, INC.
BY: /s/ Denise M. Gilbert
--------------------------------
NAME: Denise M. Gilbert
TITLE: Executive Vice President and CFO
AGREED TO AND ACCEPTED ON JULY 6, 1998:
ONCORMED, INC.
BY: /s/ Timothy J. Triche
----------------------------------------
NAME: Timothy J. Triche
TITLE: Chairman and Chief Executive Officer
7.
<PAGE>
EXHIBIT A
NOTICE OF CONVERSION
AT THE ELECTION OF HOLDER
Dated: Announcement Date
To be Executed by the Registered Holder in order to Convert Shares of Series A
Preferred:
Pursuant to the terms of a letter agreement, dated July 2, 1998, by and between
the Company and the undersigned, and subject to termination in accordance with
Section 7(e) thereof, the undersigned hereby elects to convert all of its shares
of the Company's 6% Series A Convertible Preferred Stock (the "Series A
Preferred") into shares of Common Stock, $.01 par value (the "Common Stock"), of
Oncormed, Inc. (the "Company") according to the conditions hereof, as of the
dates set forth below. If shares are to be issued in the name of a person other
than undersigned, the undersigned will pay all transfer taxes payable with
respect thereto and is delivering herewith such certificates and opinions as
reasonably requested by the Company in accordance therewith. No fee will be
charged to the Holder for any conversion, except for such transfer taxes, if
any.
Conversion calculations:
Subject to the terms of the Certificate of
Designation, as instructed in writing from
time to time by the undersigned to the
Company; provided, however, that to the
extent that any shares of Series A Preferred
held by the undersigned are outstanding as of
a date which is immediately prior to the
Effective Time of the Merger, the Company is
hereby authorized to instruct its transfer
agent to automatically convert all such
remaining shares of Series A Preferred into
shares of Common Stock in accordance with the
Certificate of Designation using the
Applicable Conversion Price set forth below.
---------------------------------------------
Dates to Effect Conversion
All shares of Series A Preferred held by the
undersigned as of July 1, 1998.
---------------------------------------------
Number of shares of Series A Preferred to be
Converted
To be determined in accordance with the
Certificate of Designation utilizing the
Applicable Conversion Price set forth below.
---------------------------------------------
Aggregate Number of Shares of Common Stock to
be Issued
For purposes of determining the Conversion
Price (as defined in Section 5(c)(1) of the
Certificate of Designation), the "date of the
applicable Conversion Notice" is the
Announcement Date; provided, however, that if
the Announcement Date is after July 9, 1998,
the Investor shall have the option to set the
Conversion Price at either the Conversion
Price in effect on July 9, 1998 or the
Conversion Price in effect on the
Announcement. On the Announcement Date,
contemporaneous with the delivery of this
Holder Conversion Notice to the Company, the
undersigned agrees to deliver a schedule
setting forth the determination of the
Conversion Price with respect to all of the
shares of Series A Preferred (and any accrued
but unpaid dividends thereon) and the
aggregate number of shares of Common Stock to
be issued upon conversion of such shares of
Series A Preferred (including accrued but
unpaid dividends thereon).
---------------------------------------------
Applicable Conversion Price
---------------------------------------------
By:
Name (include title or authorization):
Address (include name of entity):
8.
<PAGE>
EXHIBIT B
FORM OF IRREVOCABLE PROXY
IRREVOCABLE PROXY
The undersigned stockholder of Oncormed, Inc., a Delaware corporation
("Company"), hereby irrevocably (to the fullest extent permitted by law)
appoints and constitutes Michael J. Brennan, M.D., Ph.D. and Gene Logic Inc., a
Delaware corporation ("Gene Logic"), and each of them, the attorneys and proxies
of the undersigned with respect to voting (i) the shares of the Company's common
stock, $.01 par value per share (the "Common Stock"), and the shares of the
Company's 6% Series A Convertible Preferred Stock, $.01 par value per share (the
"Preferred Stock" and together with the Common Stock, the "Capital Stock"),
owned by the undersigned as of the date of this proxy, which shares are
specified on the final page of this proxy and (ii) any and all other shares of
the Capital Stock of Company which the undersigned may acquire after the date
hereof. The shares of the Capital Stock of Company referred to in clauses
(i) and (ii) of the immediately preceding sentence are collectively referred to
as the "Shares." Upon the execution hereof, all prior proxies given by the
undersigned with respect to any of the Shares are hereby revoked, and no
subsequent proxies will be given with respect to any of the Shares.
Subject to termination in accordance with the Letter Agreement, this proxy
is irrevocable, is coupled with an interest and is granted in connection with
the letter agreement, dated as of the date hereof, between the Company and the
beneficial owner of the Shares (the "Letter Agreement"), and is granted in
consideration of the execution of the Letter Agreement and the transactions
contemplated therein. Capitalized terms used herein shall have the definitions
ascribed to such terms in the Letter Agreement.
The attorneys and proxies named above will be empowered, and may exercise
this proxy, to vote the Shares at any time until the earlier to occur of the
termination of the Merger Agreement or the closing of the transactions
contemplated by the Merger Agreement at any meeting of the stockholders of the
Company, however called, or in any written action by consent of stockholders of
the Company:
1. in favor of the Merger, in favor of any exchange of shares between the
acquiring entity in the Merger and the Company, in favor of the execution,
delivery and performance by the Company of any agreements relating to the Merger
(the "Transaction Documents"), in favor of each of the other actions
contemplated by the Transaction Documents, and in favor of any action reasonably
required in furtherance thereof;
2. against any action or agreement that would result in a breach of any
representation, warranty, covenant or obligation of the Company in any agreement
relating to the Merger; and
3. against the following actions (other than the Merger and the
transactions contemplated by the Merger): (A) any extraordinary corporate
transaction, such as a merger, consolidation or other business combination
involving the Company; (B) any sale, lease or transfer of substantially all of
the assets of the Company; (C) any reorganization, recapitalization, dissolution
or liquidation of the Company; (D) any change in a majority of the
9.
<PAGE>
board of directors of the Company; (E) any amendment to the Company's
Certificate of Incorporation or Bylaws; (F) any material change in the
capitalization of the Company or the Company's corporate structure; or (G) any
other action which is intended to, or would, impede, interfere with, delay,
postpone, discourage or adversely affect the Merger or any of the other
transactions contemplated by the Merger Agreement or the Letter Agreement.
The undersigned stockholder may vote the Shares on all other matters.
Any obligation of the undersigned hereunder shall be binding upon the
heirs, successors and assigns of the undersigned (including any transferee of
any of the Shares).
[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
10.
<PAGE>
This proxy shall terminate upon the earlier of (i) the termination of the
Letter Agreement, (ii) the termination of the Merger Agreement or (iii) the
closing of the transactions contemplated by the Merger Agreement.
Dated: July 6, 1998
STOCKHOLDER
----------------------------------------
Print Name
------------------------------
If executed by record holder on behalf
of the beneficial owner, print name of
beneficial owner:
----------------------------------------
Number of issued and outstanding shares of COMPANY COMMON STOCK Owned OF RECORD
as of the date hereof:
--------------------
Number of issued and outstanding shares of COMPANY PREFERRED STOCK Owned OF
RECORD as of the date hereof:
--------------------
Number of issued and outstanding shares of COMPANY COMMON STOCK Owned
BENEFICIALLY (but not of record) as of the date hereof:
--------------------
Number of issued and outstanding shares of COMPANY PREFERRED STOCK Owned
BENEFICIALLY (but not of record) as of the date hereof:
--------------------
